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Summary
The solute carrier family 11 member 1 gene (SLC11A 1) is a divalent metal ion
transporter with various pleiotropic effects on macrophage function. This gene that
regulates iron, and is also regulated by cellular iron levels, has previously been linked
to many infectious and autoimmune diseases. In this analysis, in vitro studies using
the luciferase reporter system as well as case-control association studies were
applied to investigate the significance of SLC11A1 allelic variation in patients with
diverse disease phenotypes.
For in vitro studies, five different SLC11A 1 promoter constructs were generated,
followed by transfection into U937 and THP-1 cells. The inserted fragments included
two previously described alleles (alleles 2 and 3), two novel alleles identified in this
study (alleles 8 and 9) and a C to T point mutation at nucleotide position -237 in the
presence of allele 3. The most striking finding was the opposite effect observed for
allele 3 in the presence of the -237C~ T polymorphism, similar to that of allele 2.
Although the SLC11A 1 gene has previously been implicated in iron transport, we
have demonstrated, for the first time, that the various alleles investigated cause
differential expression of the gene upon iron loading.
Association studies were performed by investigating diseases including oesophageal
cancer (DC), inflammatory bowel disease (lBO) and hereditary haemochromatosis
(HH) (or primary iron overload). Significant associations (P<O.05) were observed with
allele 3 for all three conditions investigated only after stratification according to the
presence of the -237C~ T polymorphism. Re-assessment of the promoter alleles
according to expression profiles determined by the in vitro studies, showed
statistically significant associations for allele 3 with DC and primary iron overload,
compared with the respective population-matched control groups. Additionally,
several novel variants were identified in exon 2 (112G~A, 148deIGACCAGCCC,
157insGACCAGCCCAG) and intron 1 (IVS1-28C~T), with variant IVS1-28C~T
occurring at a significantly increased frequency in patients with DC compared with
population-matched controls (P<O.05). Investigation of the SLC11A 1 gene in
individuals presenting with iron overload in the absence of homozygosity for the HFE
C282Y mutation, provided further support for the importance of sequence variation in
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the promoter region of the SLC11A 1 gene in modified risk of iron-related disorders.
Genes related to iron homeostasis, including HFE, SLC11A3, HAMP and DCYTB,
were investigated in individuals with similar criteria and potential disease-causing
mutations were identified in 11% White and 45% Black South African patients. The
possible significance of the SLC11A3 and DCYTB genes in iron overload in the Black
South African population, and the possible involvement of the DCYTB gene in iron
overload in general, are demonstrated for the first time.
This study contributed to a better understanding of the function of the SLC11A 1 gene
in relation to iron metabolism. The involvement of SLC11A 1 in a range of disease
phenotypes including cancer and inflammatory conditions that may involve iron
dysregulation, can probably be explained by interaction with external factors such as
infectious agents that may affect cellular iron status. Our findings provide both in vivo
and in vitro evidence that iron dysregulation mediated by allelic effects of SLC11A 1
may underlie disease susceptibility to infectious and autoimmune conditions.
III
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Opsomming
Die opgeloste stof draer familie 11 deel 1 geen (SLC11 A 1) is 'n divalente metaal ioon
vervoerder met verskeie pleiotropiese effekte op makrofaagfunksie. Die geen, wat
yster reguleer en ook deur sellulêre ystervlakke gereguleer word, is voorheen verbind
met verskeie infektiewe en outo-immune siektes. In hierdie studie is in vitro analises,
deur middel van die lusiferase verklikker sisteem, asook gevalle-kontrole assosiasie
studies gebruik om die rol van SLC11A 1 alleel variasie in pasiënte met diverse
siektefenotipes te ondersoek.
Vyf verskillende SLC11A 1 promotor variante is geskep vir in vitro studies en gevolg
deur transfeksie in U937 en THP-1 sellyne. Die ingevoegde fragmente het twee
voorheen beskryfde allele (allele 2 en 3), twee nuwe allele wat in hierdie studie
geïdentifiseer is (allele 8 en 9) en In C na T puntmutasie by nukleotied posisie -237
in die teenwoordigheid van alleel 3 ingesluit. Die opvallendste bevinding was die
teenoorgestelde effek wat waargeneem is wanneer alleel 3 in die teenwoordigheid
van die -237C~ T polimorfisme voorkom, soortgelyk aan alleel 2 uitdrukking.
Alhoewel die SLC11A1 geen voorheen geïmpliseer is in yster vervoer, is daar vir die
eerste keer aangetoon dat na yster lading, die verskillende allele differensiële
uitdrukking van die geen veroorsaak.
Verskeie siektes, insluitend slukderm kanker (OC), inflammatoriese dermsiekte (lBO)
en oorerflike hemochromatose (HH) (of primêre ysteroorlading), is ondersoek deur
middel van assosiasie studies. Betekenisvolle verskille (P<O.05) is waargeneem vir
alleel 3 tussen die kontrole- en pasiëntgroepe in al drie siektes wat ondersoek is,
maar slegs na stratifikasie volgens die teenwoordigheid van die -237C~ T
polimorfisme. Na hersiening van die promotor allele volgens ekspressie profiele
verkry met in vitro studies is statisties betekenisvolle assosiasie ook verkry vir alleel 3
met OC en primêre ysteroorlading in vergelyking met die onderskeie populasie
kontrolegroepe. Verder is verskeie nuwe variante ook geïdentifiseer in ekson 2
(112G~A, 148deIGACCAGCCC, 157insGACCAGCCCAG) en intron 1 (IVS1-
28C~ T) en 'n statisties betekenisvolle verhoogde frekwensie van variant IVS1-
28C~ T is waargeneem in pasiënte met OC in vergelyking met die populasie
kontrolegroep (P<O.05). Die belangrikheid van variasie in die promotor area van die
IV
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SLC11A 1 geen as 'n modifiserende faktor in ysterverwante siektes, is verder
ondersteun deur die SLC11A 1 geen in individue met ysteroorlading in die
afwesigheid van homosigositeit vir die HFE C282Y mutasie te ondersoek. Ander
gene geassosieerd met yster homeostase, insluitend HFE, SLC11A3, HAMP and
DCYTB, is ondersoek in individue met soortgelyke seleksie kriteria en potensiële
siekte-verwante mutasies is geïdentifiseer in 11%Wit en 45% Swart Suid-Afrikaanse
pasiënte. Die moontlike belang van die SLC11A3 en DCYTB gene in ysteroorlading
in die Swart Suid-Afrikaanse populasie en die moontlike betrokkenheid van die
DCYTB geen in yster oorlading oor die algemeen, is vir die eerste keer aangetoon.
Hierdie studie dra by tot 'n beter insig in die funksie van die SLC11A 1 geen ten
opsigte van ystermetabolisme. Die betrokkenheid van SLC11A 1 in 'n reeks siekte
fenotipes, wat insluit kanker en inflammatoriese toestande wat verband kan hou met
'n yster wanbalans, kan moontlik verklaar word deur interaksie met eksterne faktore
soos infektiewe agente wat die sellulêre yster status kan beïnvloed. Ons bevindinge
verskaf beide in vivo en in vitro getuienis dat yster wanbalans, wat bemiddel word
deur alleliese effekte van SLC11A1, verantwoordelik mag wees vir vatbaarheid vir
infektiewe en outoimmune siekte toestande.
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INTRODUCTION
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1. THE SOLUTE CARRIER FAMILY 11 (PROTON-COUPLED DIVALENT METAL ION
TRANSPORTER) MEMBER 1 GENE (SLC11A1) AND DISEASE
Preface
The SLC11A 1 gene has previously been known as the natural resistance-associated
macrophage protein 1 gene (NRAMP1) and is associated with susceptibility to various
autoimmune and infectious diseases (reviewed by Blackwell et al 2001, 2003). The
results of various studies support the hypothesis that specific alleles of the SLC11A1
gene 5'-(GT)n repeat polymorphism contribute to autoimmune (allele 3) and infectious
(allele 2) disease susceptibility. However, the direct contribution of the many pleiotropic
effects of the SLC11A 1 gene on macrophage function and disease susceptibility is still
unclear.
In this study we focussed on mutational analysis of the SLC11A 1 gene implicated in iron
transport within the context of other genes that may be involved in iron homeostasis
and/or disease phenotype. We hypothesised that the involvement of SLC11A 1 in a
range of disease phenotypes may be explained by its involvement in iron metabolism.
The potential role of SLC11A1 (as a modifier locus) was investigated in patients with
different disease types, including oesophageal cancer (Oe), inflammatory bowel disease
(lBO) and hereditary haemochromatosis (HH). These diseases and other genes
implicated in their pathogenesis are discussed as an introduction to the study.
2
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1.1. LITERATURE REVIEW
1.1.1.ldentification of the SLC11A1 gene
In mice, natural resistance to infection by unrelated intracellular parasites is controlled
by the expression of a single dominant gene on mouse chromosome 1. This gene was
designated Leishmania donovani (Lsh) (Bradley 1974), Salmonella typhimurium (Ity)
(Plant and Glynn 1974) and Mycobacterium bovis (Beg) (Gros et al 1981) and affects
the capacity of macrophages to destroy ingested intracellular parasites early during
infection (Skamene et a/1982).
The murine solute carrier family 11 member 1 gene (Slc11a1) was identified as the
Bcg/lty/Lsh gene by positional cloning (Vidal et al 1993). The identification of the
SIc11a1 gene as Bcg/lty/Lsh was confirmed by using transfected macrophages in vitro
(Barton et al 1995) and gene disruption in vivo (Vidal et al 1995). The full-length cDNA
sequence of the gene was described by Barton et al (1994). S/c11a1 encodes a novel
macrophage-specific polypeptide, predicted to act as an integral membrane protein that
plays a role early in the macrophage activation pathway (Vidal et a/1993, Blackwell et al
2000). Malo et al (1994) analysed the SIc11a1 gene in inbred mice with either resistance
or susceptibility phenotypes and identified a nonconservative amino acid substitution
[glycine (resistant/dominant) to aspartic acid (susceptible/recessive) at amino acid
residue 169], within the fourth transmembrane domain of the protein, to be associated
with a susceptibility phenotype. This mutation has been predicted to affect either proper
targeting and folding of the protein in the membrane or to directly interfere with the
enzymatic activity of Slc11a1. These mice are as susceptible to Leishmania donovani,
3
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Salmonella typhimurium and Mycobacterium bovis as gene-disrupted mice (Vidal et al
1995).
Susceptibility to a range of other pathogens in mice has also been identified, including
Mycobacterium lepraemurium (Brown et a/1982, Skamene et a/1984), Mycobacterium
intracellulare (Goto et al 1989), Toxoplasma gondii (Blackwell et al 1994), Candida
albicans (puliti et al 1995) and Leishmania infantum (Leclercq et al 1996). The human
SLC11A1 gene was subsequently cloned and characterised by using eDNA clones
(Cellier et al 1994, Kishi 1994) and localised to chromosome region 2q35 by linkage
analysis (Blackwell et a/1995) as well as PCR analysis of somatic cell hybrids and YAC
cloning (Liu et a/1995).
1.1.2. Structure and protein of the SLC11A1 gene
The SLC11A1 gene comprises 15 exons (Table 1.1), and an alternatively spliced exon
encoded by an Alu element present within intron 4, spanning a region of 12 kb (Cellier et
a/1994, Blackwell et a/1995). The human SLC11A 1 gene demonstrated 92% similarity
(85% identity) to the mouse SIc11a1 gene, 73% (55% identity) to Drosophila
melanogaster, 58% (40% identity) to Oryza sativa (rice) and 46% (28% identity) to
Saccharomyces cereviviae homologues (Cellier et a/1995). The nucleotide sequence of
the 5' flanking sequence of the SLC11A 1 gene has been characterised up to position -
415 bp by Blackwell et al (1995), up to position -3456 bp by Kishi et al (1996) and up to
position -948 by Searle and Blackwell (1999). The promoter region of SLC11A 1 lacks
any conventional TATA, GC and CCAAT boxes (Blackwell et a/1995).
4
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Table 1.1. Exon/lntron boundaries of the SLC11A1 gene are tabulated with the sizes of the various exons and
introns (Blackwell et a/1995, Marquet et a/2000). The percentage amino acid (AA) identity with mouse S/c11a1 is
also indicated
Exon 5' end of exon Exon length (bp) 3' end of exon Intron length (bp) %AA Identity (Mouse
Slc11a1)
1 ATGACAG 182 TGACAGgtga 584 50
2 acagGTGACA 143 AAACCGgtgg 1140 68
3 acagGGCACC 123 TTCAAAgtaa 780 95
4 acagCTTCTC 120 CCTAAGgtga 1368 100
*4a tcagAATCCA 74 CCCAGgtac 1149 U
5 atagGTGCCC 107 TGGACGgtacc 418 91
6 tcagAATCCC 71 ACTACGgtggg 334 100
7 gtagGGCTGC 68 TATGAGgtag 167 100
8 gcagTATGTG 156 GTCAAGgtga 1915 88
9 gtagTCTCGA 159 GCTGCGgtga 1171 87
10 acagTTCAAC 90 CAGGGGgtga 88 80
11 gcagGGCGTG 120 ATGGAGgtag 1485 98
12 ccagGGCTTC 150 CTGCTGgtga 987 94
13 ccagCTCCCG 74 GGCCTgtga 438 84
14 ccagGCTGAA 154 TACCTGgtac 139 73
15 ccagGTCTGG 108 TAG 67
Exon sequences are in uppercase letters and intron sequences are in lowercase letters. *Alternatively spliced exon,
U, unknown
5
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Several regulatory elements have been identified, including a PU box [the binding site
for the transcription factor PU.1 (Klemsz et a/1990)], LPS (NF-IL6, AP-1, GMCSF) and
IFN-y (Isshiki et al 1990, Yang et al 1990) sequence motifs. A Z-DNA forming (GT)n
repeat was also identified in the promoter region (Liu et a/1995, Blackwell et a/1995). In
eukaryotes, a distinct class of binding proteins exist which interact exclusively with DNA
in the Z-conformation, and roles in both positive and negative regulatory signalling have
been attributed to this form of DNA (Rich et al 1984). The consensus sequences
identified in the promoter region are shown in Figure 1.1. Several discrepancies were
observed between the published promoter sequences of Kishi et al (1996) and Searle
and Blackwell (1999) and have been highlighted on the sequence insert (Figure 1.1).
Sequence analysis of the human SLC11A1 protein, with a calculated mass of 60 kD,
indicated that the polypeptide consists of 550-amino acids with 10 to 12 putative
transmembrane (TM) domains. Additionally, 2 protein kinase C (PKC) phosphorylation
sites within the first intracytoplasmic loop, 2 N-linked glycosylation sites within the
segment separating TM domains 5 and 6, and an evolutionary conserved consensus
transport motif within the segment separating TM domains 6 and 7 were also identified
(Figure 1.2) (Cellier et al 1994, Blackwell et al 1995). The null mutation in murine
SIc11a1 occurs in TM domain 4 (Vidal et a/1993), corresponding to TM domain 2 (exon
6) of the human SLC11A 1 gene.
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1
-1083 AATTAGCCAGGTGTGGTTGGCAGGTGCCTGT AATCCCAGCTACTCAGGAGGCTGAGGAAGAAGAA TTACTTGAA
-1009 CCCAAGAGGCAGAGGTTTCGGTGAGCCAAGGTCGCGCCA TIGCACTTCAGCCTGGGTGACAGAGCAAGACGCC
-936 ATCTCAAAGTAAATAAATAAATACATACATACATACATACAAAAAGTAGCCGGGTGTGGTGGTGCATGCCTGTAGT
1
-860 CCCAGCTACTCAGGAGGCTGAGGCAGGAGAATTGCTTAAACATGGAGGACAGAGGTIGCAGTGAGCTGAGATT
-787 ATGCCACTGCACTCCAGTCTGGGCAACAGAGTAAGACTCTGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAGGA
-712 GTTTGAGGCTGCAGTAAACTAAGATGGCACCACTGCACTTCACACCTCACTCTAGCCTGGGTGACAGAGCGAGA
~38 CCTIGTCTCTAAAAAAAAAAACAAAAAACGAAAAACCAAAAAAAAAAAAGGGTGGGGGTGGAATAGAATAAACAAC
-562 TCTGAGAAGGGACATGATCTGGTGACAATCTCAAGTGAATCAGTGGTTGAACCAGGACCAGATCCCAGTGCCCC
1~8 ATCTTCTGGGGACGTCCTGGGTCTGAATCTTCAATGCATGTCCCTTCTGCAGTGCCTTCCTCTGTGGCCCTCAAA
413 GGGAAACTGAAGCCTTTGAGGACATGAAGACTCGCATTAGGCCAACGAGGGGTCTTGGAACTCCAGATCAAAGA
-339 GAATAAGAAAGACCTGACTCTGTGTGTGTGTACGTGTGTGTGTACGTGTGTGTGTGTGTGTGTGGCAGAGGGGG
-265 GTGTGGTCATGGGGTATTGACATGAATACGCAAGGGGCAGGAAGCATCTGAAATCAGAGCTAACTTGGGAGGC
-192 ACAGAACACGGGGTGCCTGGAAGGGGAACAGATGTGTTGTGGGGCACAGGGCAGGCTGGGAGGGGAACAAAG
-120 GTCCACTCCATGGGTAACCAGACCCTTCCGCCAGGGCTGGCCACTICTGCCTTTGGAAAATGTTTCACAACGCC
+1 Transcription start site
46 CCATGTIGTGTGTGTGTGTGAATCGGCCGATGTGAACCGAATGTTGATGTAAGAGG
Figure 1.1.
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PU.1
Interferon-y (y-IRE)
[
AP1
Z-DNA forming repeat polymorphism
NF-IL6
ATTAG/AATG GMCSF
Legend to Figure 1.1.
Sequence of the promoter region of the SLC11A1 gene with 1083 bp of sequence 5' of
the transcription start site (adapted from Kishi et al 1996 and Searle and Blackwell
1999). Sequence up to position -937 and response elements are as published by Searle
and Blackwell 1999. 1Denoted only by Kishi et a/1996. Discrepancies observed: Kishi et
a/1996, transcription start site at position -27 (doubly underlined), putative TATA box
(red), additional G residues at position -127 and -148, T instead of C at position -237.
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Figure 1.2.
Legend to Figure 1.2.
Schematic representation of the putative structure of the SLC11A1 protein and its
orientation in the cell membrane (modified from Vidal et a/1995).
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The protein is localised to late endosomal and lysosomal compartments (Atkinson et al
1997, Gruenheid et a/1997, Searle et a/1998) but not to early endosomes (Gruenheid
et al 1997). More than half of the polypeptide composition (53%) consist of highly
hydrophobic amino acids such as leucine (15%), isoleucine (6%), valine (7%), alanine
(10%), phenylalanine (6%) and the apolar residue glycine (9%) (Cellier et al 1994).
Charged residues account for only 12% of the polypeptide composition with
arginine/lysine and aspartic/glutamic acid each accounting for 6%. The structure of the
SIc11a1 protein was shown to relate to that of transmembrane ion transporters (Cellier
et a/1995, Brown et a/1995, Barton et a/1995, Atkinson et a/1997, Brown et a/1997,
Gruenheid et a/1997, Searle et a/1998).
1.1.3. Polymorphisms identified in the SLC11A1 gene
No mutations were identified in the SLC11A 1 gene that were comparable to those
identified in mice although several polymorphic sites have been described (White et al
1994, Blackwell ef a/1995, Liu ef a/1995, Buu ef a/1995, Lewis ef a/1996, Searle and
Blackwell 1999, Graham ef al 2000, Kojima ef al 2001, Lee ef al 2002). These
polymorphisms included variants in i) the coding region of the gene, including one
deletion (a 9 bp deletion in exon 2), three missense mutations (A318V, V350M and
D543N) and four silent nucleotide substitutions (L39, G65, F66 and G249), ii) intronic
variants (IVS4+14G~C, IVS5-18G~A, IVS7+22G~A), and iii) variants in the
untranslated regions (UTR), including two variants in the 5'-UTR [5'-(GT)n repeat and -
236C~ Tl and one variant in the 3' UTR (1729+55deI4).
10
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Seven alleles (Table 1.2) have previously been identified for the Z-DNA-forming (GT)n
repeat polymorphism in the promoter region of the SLC11A 1 gene (Blackwell et a/1995,
Liu et al 1995, Blackwell 1996, Shaw et al 1996, 1997, Searle and Blackwell 1999,
Graham et al 2000, Kojima et al 2001) that may affect levels of SLC11A1 gene
expression (Blackwell 1996, Searle and Blackwell 1999). In vitro promoter studies of this
functional repeat polymorphism suggested a direct role of specific alleles in autoimmune
and infectious disease susceptibility (Searle and Blackwell 1999). Allele 3, the high
promoter activity sequence, is associated with susceptibility to autoimmune diseases
whereas allele 2, the low promoter activity sequence, is associated with infectious
disease susceptibility (and conversely protects against autoimmune diseases).
To investigate the significance of the 5'-(GT)n repeat, functional studies were performed
in the presence and absence of exogeneous stimuli including IFN-y and LPS (Searle
and Blackwell 1999). The 5'-(GT)n polymorphism regulated gene expression in the
absence of an exogeneous stimulus and therefore acts as an enhancer element. The
addition of IFN-y caused up regulation and LPS caused differential expression for the
various polymorphic alleles studied. Blackwell et al (2000) suggested that the allelic
association with autoimmune and infectious disease susceptibility are maintained in
human populations by some form of balancing selection.
11
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Table 1.2. Previously-documented SLC11A1 Z-DNA-forming 5'-(GT)n repeat
I h' . tpoiymorp IC varian s
Allele Repeat polymorphism *Allele Reference
frequency
Allele 1 t(gt)5ac(gt)5ac(gt)11 ggcaga(g)6 0.001 Blackwell et a/1995
Allele2 t(gt)5ac(gt)5ac(gt)1oggcaga(g)6 0.20 to 0.25 Blackwell et a/1995
Allele3 t(gt)5ac(gt)5ac(gt)gggcaga(g)6 0.75 to 0.80 Blackwell et a/1995
Allele4 t(gt)5ac(gt)gggcaga(g)6 ~ 0.001 Searle and Blackwell 1999
Allele5 t(gt)4ac(gt)5ac(gt)1oggcaga(g)6 0.02 Graham et a/2000
Allele6 t(gt)5ac(gt)5ac(gt)4at(gt)4ggcaga(g)? Unknown" Graham et a/ 2000
Allele 7 t(gt)5ac(gt)5at(gt)11ggcaga(g)6 0.045" Kojima et a/2001
* "IAllele frequencies In the general population, Identified only In the Japanese population,
"Allele frequency not denoted, $Previously identified as t(gt)5ac(gt)1oggcaga(g)6
(Blackwell et a/ 1995, Shaw et a/ 1996, 1997) and t(gt)5ac(gt)5ac(gt)4ggcaga(g)6
(Blackwell et a/1995).
A potentially functional polymorphism was also identified in exon 2 of the SLC11A 1gene
and comprises deletion of a nine-nucleotide repeat in the N-terminal proline/serine-rich
putative SH3 binding domain (Barton et a/1994, White et a/1994, Blackwell et a/ 2000).
The spacing of pralines were shown to be important in binding SH3 domains (Booker et
a/ 1993) and this polymorphic area may influence the conformation and hence function
of the protein. An additional 3-amino-acid insert in human exon 2 compared to mouse in
this area was reported by White et a/ (1994) and this was shown to be the normal allele
in humans. This deletion was observed only in a heterozygous state at a frequency of
0.02 in Brazilians and was shown to be segregating within Brazilian leprosy families, but
not with the disease (White et a/1994). A frequency of less than 0.001 was observed by
12
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Blackwell et a/ (2000) in the general population. SLC11A 1 is presumably an essential
gene and deleterious coding region mutations will therefore be rare.
1.1.4. Expression of the SLC11 A 1 gene
Expression of the SLC11A 1 gene was initially thought to be restricted to myeloid cell
lineages (Vidal et a/ 1993, Cellier et a/ 1997). However, recent evidence indicated
expression of the gene in vesicles of neurons (Evans et a/ 2001), cortical pyramidal
neurons (layers III and V), a subset of striatal neurons, cerebellar Purkinje cell bodies,
the anterior pituitary, pancreatic islets and adrenal medulla (Blackwell et a/2001).
1.1.5. The proposed function of the SLC11A1 gene
The exact function of the SLC11A 1gene is still to be elucidated but several hypotheses
have been described.
1.1.5.1. Pleiotropic effect of SLC11A1 on macrophage function
Murine S/c11a1 has been shown to have many pleiotropic effects on macrophage
activation pathways, including regulation of the CXC chemokine KC, interleukin-1j3 (IL-
113),inducible nitric oxide synthase (iNOS), major histocompatibility complex (MHC)
class II molecules, tumour necrosis factor a (TNF-a), nitric oxide (NO) release, L-
arginine flux, oxidative burst and tumoricidal as well as antimicrobial activity (Blackwell
et a/1988, Blackwell 1989, Blackwell et a/1991, Schurr et a/1991, Searle and Blackwell
1999, Blackwell et a/2000).
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SIc11a1 enhances expression of iNaS (encoded by Nos2A) and generates toxic NO in
wildtype (Slc11a1GIY169)versus mutant (Slc11a1ASP169)macrophages (Roach et a/1991,
Arias et a/1997). It was assumed that NO combines with OH- to produce the more toxic
peroxynitrite and is therefore crucial to Slc11a1-mediated resistance in vivo. Recent
evidence suggest that iNaS is not important in early Slc11a1-mediated Kupffer cell
regulation of infection but may be important later in granuloma-dependent control of the
parasite (Blackwell et a/2003). Other pleiotropic effects mediated by SLC11A1 entailed
up-regulation of various functions including class II I-A antigen expression, protein
kinase C and antigen presentation (Blackwell et al 1991). Individuals homozygous for
allele 3 of the SLC11A1 gene were shown to produce higher levels of TNF-u (Blackwell
et al 2003). However, the exact role for TNF-u, IL-1J3,chemokines or their receptors in
Slc11a1-regulated autoimmune and infectious disease phenotypes are not yet known
and needs further investigation.
1.5.1.2. SLC11A1 functions as a metal ion transporter
Several lines of evidence support the hypothesis of SLC11A 1 being a metal ion
transporter. Firstly, a consensus transport motif was identified in the third
intracellular/cytoplasmic loop of the gene (exon 11) (Vidal et a/1993). This evolutionary
conserved consensus motif, known as the "binding protein-dependent transport system
inner membrane component signature", is conserved from prokaryotes to eukaryotes
(Cellier et al 1994) and was previously identified in a series of bacterial periplasmic
transport proteins (Kerppola and Ames 1992). The motif is predicted to be localised in
cytoplasmic loops of periplasmic proteins, possibly mediating interaction of the
14
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hydrophobic membrane anchors with peripheral ATP binding subunits to energise these
transporters (Kerppola and Ames 1992).
Secondly, the polypeptide localises to intracellular vesicular membranes in resting cells,
suggesting that S/c11a1 could influence the micro-environment of the invading pathogen
within the phagolysosome by either directing the efflux or influx of some essential
substrate or toxin respectively (Atkinson and Barton 1998).
Thirdly, the S/c11a family is defined by a highly conserved hydrophobic core composed
of ten TM domains, including several invariant charged residues in these domains
(Cellier et a/1995). Helical periodicity of sequence conservation which predicts a helical
bundle within the membrane, occurring with a conserved charged interior and a semi-
conserved hydrophobic exterior, is typical of families of ion transporters and channels.
SMF1 and SMF2, the yeast homologues of S/c11a1, were shown to be involved in high
and low affinity Mn2+ uptake respectively, inhibitable by Zn2+ (Supek et al 1996).
Similarly, the SIc11a2 gene (78% identity to S/c11a1) was identified as the gene
controlling microcytic anaemia in mice (Gruenheid et al 1995), having broad specificity
as a metal ion transporter (Gunshin et a/1997). By using a Xenopus oocyte transfection
system, SIc11a2 was shown to transport Fe2+, Zn2+, Mn2+, Co2+, Cd2+, Cu2+, Ni2+ and
Pb2+. Fe2+, Zn2+ and Mn2+ are of specific interest in regulating macrophage activation as
candidate metal ions contributing to the many pleiotropic effects ascribed to ·Slc11a1
(Blackwell et al 2000). In particular, Fe2+ is of interest for its potential role in the direct
generation of toxic antimicrobial hydroxyl radicals within the phagolysosomes of infected
macrophages (Zwilling et al 1999). Zn2+ has also been shown to be important in
15
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directing endosomal fusion events (Aballay et a/1995, 1997) and Mn2+ may be important
for metalloprotease activity in the late endosomal MIIC compartment (Lang et a/1997). It
appears that removal of divalent cations from the phagosome could both restrain
pathogen growth and result in the pleiotropic effects of macrophage activation
(Buschman and Skamene 2001).
Cellier et al (1995) suggested that the SLC11A 1 polypeptides form part of a group of
transporters or channels. A 50% reduction in cellular iron content was observed in
interferon-y stimulated macrophages from SIc11a1 wildtype compared with SIc11a1
mutant mice (Zwilling et al 1999). SIc11a1 was subsequently shown to function as a
metal ion transporter that is regulated by (Atkinson et a/1997) and regulates cellular iron
levels (Atkinson and Barton 1998). Atkinson et al (1997) demonstrated that chelation of
iron with deferoxamine influences SIc11a1 protein expression in interferon-y and
lipopolysaccharide activated macrophages. Atkinson and Barton (1998) suggested that
SIc11a1 could be involved in the recycling of iron and one essential function of
phagocytes is to degrade and recycle dead or dying cells including erythrocytes. By
directing iron efflux, the gene could therefore participate in the iron salvage pathway in
the resting macrophage.
Differences in iron uptake into phagosomes isolated from SIc11a1 wildtype versus
SIc11a1 mutant macrophages was also demonstrated. Goswami et al (2001) showed,
by using Xenopus oocytes, that SIc11a1 is a divalent cation (Fe2+, Zn2+ and Mn2+)
transporter like SIc11a2 (Gunshin et a/1997). However, SIc11a2 is a symporter of H+
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and metal ions whereas SIc11a1 is an antiporter, dependent on the pH, that can flux
divalent cations in either direction against a proton gradient (Goswami et al 2001).
Divalent cations (like Mn2+ and Fe2+) are known to playa major role in the survival of
microbes within phagolysosomal vesicles since many pathogenic organisms secrete
defensive Mn- and Fe-dependent superoxide enzymes for scavenging reactive oxygen
metabolites. Iron depletion was also suggested as a mechanism by which the growth of
intracellular pathogens may be regulated. These results suggested a new model for
metal ion homeostasis in macrophages as illustrated in Figure 1.3 (adapted from
Blackwell et a/2001).
More recently, Blackwell et al (2003) investigated the role of SIc11a1 in the metabolism
of phagocytically acquired iron from phagocytosed effete red cells. They found that iron
uptake and release, following direct acquisition of transferrin (Tf)-bound iron via the Tt
receptor, were equivalent in wild type (Slc11a1GIY169) and mutant (Slc11a1ASP169)
macrophages and were not influenced by interferon-y/lipopolysaccharide activation. Iron
uptake was equivalent and up-regulated similarly with activation, following phagocytosis
of [59Fe]Tf-anti-Tf immune complexes, but intracellular distribution and release of iron
was different. In wildtype macrophages 60% of iron was in the soluble form and 12% in
the insoluble fraction with 28% ferritin (Ft)-bound. The soluble component increased to
82% with activation. In mutant macrophages 50-60% of the iron was in the soluble form,
40-50% was in the insoluble form and less than 5% was ferritin (Ft)-bound. Western
blotting confirmed these results and implied failure in the degradative process in mature
phagosomes in mutant macrophages. Nitric oxide (NO)-mediated iron release was also
17
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higher (2.4-fold) in activated wildtype macrophages compared with mutant macrophages
suggesting that iron, acquired by phagocytosis and degradation, is retained within the
phagosomal compartment in wildtype macrophages and that NO triggers iron release by
direct secretion of phagosomal contents rather than via the cytoplasm .
......;.~.
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Legend to Figure 1.3.
Schematic representation of divalent cation homeostasis in macrophages and its relationship to oxygen- and nitrogen-dependent
antimicrobial activity. S/c11a2 delivers extracellularly acquired divalent cations into the cytosol in early endosomes after recruitment
of V-ATPase and acidification of the vacuole. S/c11a1 delivers divalent cations from the cytosol to late endosomes/lysosomes (an
acidic compartment). The Fenton reaction then uses ferrous iron to generate toxic hydroxyl (OH·) radicals which may react with NO
to produce toxic peroxynitrate (adapted from Blackwell et a/2001).
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1.1.6. The role of SLC11A1 in autoimmune and infectious disease susceptibility
Susceptibility to both autoimmune and infectious diseases has been shown to be
associated with variants of the SLC11 A 1 gene. Autoimmune diseases include
rheumatoid arthritis (Shaw et al 1996, Singal et al 2000), juvenile rheumatoid arthritis
(Shaw et a/1996, 1997, Sanjeevi et a/2000), diabetes (Esposito et a/1998), sarcoidosis
(Maliarik et al 2000), Crohn's disease (Hofmeister et al 1997, Kojima et al 2001) and
multiple sclerosis (Kotze et al 2001). Infectious diseases include tuberculosis (Bellamy
et al 1998, Bellamy 1999, Cervi no et al 2000, Gao et al 2000, Greenwood et al 2000,
Ryu et a/2000), leprosy (Abel et a/1998) and human immunodeficiency virus (Marquet
et al 1999). Blackwell (2001) summarised the approach in determining susceptibility to
infectious diseases by host-pathogen interactions (Figure 1.4). The various studies
support the hypothesis that the SLC11A 1 Z-DNA forming promoter repeat polymorphism
may contribute directly to the allelic associations with infectious versus autoimmune
disease susceptibilities as shown in Table 1.3 (adapted from Blackwell et a/2003).
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Legend to Figure 1.4.
A summary for the approach in determining susceptibility to infectious diseases by host-
pathogen interactions (adapted from Blackwell 2001).
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Table 1.3. A summary of the various SLC11A1 Z-DNA-forming 5'-(GT)n repeats associated with autoimmune, infectious
disease and immune response phenotypes (adapted from Blackwell et a/2003).
Phenotype/disease Population (GT)n allele association Reference
Autoimmune disease
Rheumatoid arthritis United Kingdom Allele3 Shaw et a/1996
Rheumatoid arthritis Canada (GT)n not associated Singal et a/2000
Rheumatoid arthritis in HLA shared epitope negative patients Spain Allele2 Rodriguez et a/2002
Crohn's disease USA Not done Hofmeister et a/1997
Type 1 diabetes in sibs of RA patients United Kingdom Allele3 Esposito et a/1998
Early onset type 1 diabetes Japan Allele 2 lower in patients Bassuny et a/2002
Juvenile rheumatoid arthritis Latvia Allele3 Sanjeevi et a/2000
Primary biliary cirrhosis United Kingdom AlleleS Graham et a/2000
Sarcoidosis African Americans Allele3 Maliarik et a/ 2000
Multiple Sclerosis South Africa Alleles 3 and S Kotze et a/2001
Inflammatory bowel disease (Crohn's disease and ulcerative colitis) Japan Allele 7 Kojima et a/2001
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Table 1.3. A summary of the various SLC11A1 Z-DNA-forming 5'-(GT)n repeats associated with autoimmune, infectious
disease and immune response phenotypes (adapted from Blackwell et a/2003) (Continued).
Phenotypeldisease Population (GT)n allele association Reference
Infectious disease
Pulmonary tuberculosis Brazil Allele2 Shaw et a/1997
Pulmonary tuberculosis The Gambia Allele2 Bellamy et a/1998
Pulmonary tuberculosis Japan Allele2 Gao et al 2000
Pulmonary tuberculosis Korea Not done Ryu et a/ 2000
I
Pulmonary tuberculosis Guniea-Conakry (GT)n not associated Cervino et a/2000
Pulmonary tuberculosis Aboriginal Canadian Not done Greenwood et a/ 2000
Pulmonary tuberculosis Taiwan Not done Liaw et a/ 2002
Leprosy Vietnam Not done Abel et a/1998
Leprosy type West Africa Not done Meisner et a/2001
HIV Columbia Allele3 Marquet et a/1999
Visceral leishmaniasis Sudan Allele 3 Mohamed et a/ unpublished data
Meningcoccal meningitis United Kingdom Allele3 Hibberd et al unpublished data
-- -- --
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Table 1.3. A summary of the various SLC11A1 Z-DNA-forming 5'-(GT)n repeats associated with autoimmune, infectious
disease and immune response phenotypes (adapted from Blackwell et a/2003) (Continued).
Phenotypeldisease Population (GT)n allele association Reference
Immune response
Granulomatous mitsuda reaction to lepromin Vietnam Not done Alcais et al 2000
IL10 responses to mycobacterial PPDs Malawi (GT)n not associated Blackwell et al unpublished data
IL10 responses to LPS and LPS+IFN- Gambia Allele2 Awomoyi et al in press
- ------
"Not done" indicates that the 5'-(GT)n polymorphism was not investigated but association with other polymorph isms in the
SLC11 A1 gene was demonstrated, Allele 2, t(gt)5ac(gt)5ac(gthoggcaga(g)6, Allele 3, t(gt)5ac(gt)5ac(gt)gggcaga(g)6, Allele
5, t(gt)4ac(gt)5ac(gt)10ggcaga(g)6, Allele 7, t(gt)5ac(gt)5at(gth 199caga(g)6.
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In this study we focussed on mutation analysis of the SLC11A 1 gene implicated in both
autoimmune and infectious disease susceptibility as well as iron transport, within the
context of other genes that may be involved in iron homeostasis and/or disease
phenotype. These diseases include oesophageal cancer, inflammatory bowel disease
and hereditary haemochromatosis and are discussed briefly.
1.1.7. OESOPHAGEAL CANCER (DC)
1.1.7.1. Background
Oesophageal cancer (DC) shows marked geographic variation occurring at very high
frequencies in certain areas of China, Iran, Uruguay, France, Italy and South Africa
(Parkin ef al 1988), and displays unique epidemiological features. The disease mainly
occurs in adults (mid to late adulthood) and is rarely seen in persons younger than 25,
with mortality rates increasing steadily with age (Blot 1994). DC occurs more frequently
in males with an estimated frequency of two to four times higher in males than in
females.
Two main forms of DC, squamous cell carcinoma (SCC) and adenocarcinoma (ADC),
with different aetiological and pathological characteristics have been identified (reviewed
by Lu 2000). SCC (more prevalent in developing countries) occurs at a higher frequency
than ADC (more common in developed countries), with the highest incidence of ADC in
Northern America and in some parts of Europe, Differences have been found between
various racial backgrounds, with SCC occurring more often in Blacks and ADC being
more prevalent in Caucasians. The occurrence of DC among Blacks is higher at
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younger ages compared to Whites; with the Black/White ratio for mortality exceeding six
fold for those younger than age 55 (Blot and Fraumeni 1987).
1.1.7.2. Iron homeostasis and oe
Iron overload was previously identified as a possible risk factor in the development of
OC and evidence for the involvement of iron in cancers was demonstrated with a clear
correlation between dietary iron overload and the development of hepatocellular
carcinoma in the South African Black population (Mandishana et a/1998). Iron overload
associated with OC in the Black South African population was mainly thought to be the
result of a high consumption of home-brewed alcoholic beverages contaminated with
iron (MacPhail et a/1979, Isaacson et a/1985). It was speculated that iron loading might
be related to the enhanced absorption of iron or ironbound compounds from traditionally
brewed maize and sorghum beer (Derman et al 1980). The involvement of iron in the
development of OC had also been implicated in other populations (Amer et al 1990,
Rogers et al 1993, Hsing et al 1995). This observation was further illustrated in a rat
model where iron supplementation was indicated as a cause of developing DC
(Goldstein et a/1998, Chen et a/1999, 2000).
Normal anti-tumour activity occurs through the loss of iron from the target cell and
reduced anti-tumour activity is observed in the presence of excess iron (Green et al
1988, Huot et a/1990). Iron therefore acts as an indirect carcinogen. Excess iron also
interferes with the growth of tumouricidal-activated macrophages and leads to enhanced
tumor growth (Weiss et al 1992). The generation of oxygen free radicals due to iron
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induced mutagenesis can also contribute to the development of cancer, leading to DNA
strand damage and disruption of DNA structure (Togokuni 1996).
1.1.7.3. Factors involved in oe pathogenesis
i) Environmental involvement
Of the environmental risk factors contributing to the development of SCC, cigarette
smoking and alcoholic beverage consumption are the major determinants (International
Agency for Research on Cancer 1986, 1988, Blot 1994). The risk of developing OC is
five times higher in cigarette smokers (tenfold among heavy cigarette smokers) than
non-smokers and increased alcohol consumption among smokers further increases the
risk of developing ac in a synergistic manner. The risk of developing ac also increases
with the amount of alcohol consumed (Blot 1992), regardless of the smoking category,
with a 20 to 50-fold increase (La Vecchia and Negri 1989, Blot 1994). Diet and nutrition
may also play a major role with diets high in fresh fruit and vegetables consistently
associated with reduced risk (Van Rensburg 1981, Steinmetz and Potter 1991, Blot
1994). Other factors contributing to a lesser extent to disease pathogenesis were
occupational exposure (Selikoff et a/1979, Norell et a/1983, Gustavisson et a/1993),
ionising radiation (Smith 1984), drinking of hot beverages (Yang and Wang 1993) and
viral agents (papilloma viruses) (Hille et a/1985).
ii) Genetic involvement
Molecular studies have revealed frequent chromosomal abnormalities (Whang-Peng et
al 1990, Rosenblum-Vos et al 1993, Rao et al 1995) and gene alterations. Gene
alterations include amplification of the cellular oncogenes C-MYC (Lu et al 1988) and
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the INT-2 gene (Lu 2000), and amplification and expression of CYCLlN-D1 (CCN01)
(Liang and Lu 1991, Adelaide ef al 1995). Frequent mutations and deletions were
identified in genes such as the retinoblastome (RB1), tumor protein p53 (TP53),
adenomataus polyposis of the colon (APC), mutated in colorectal cancers (MCC) and
deleted in colorectal carcinoma (DCC) genes (reviewed by Lu 2000). Several other
genes involved in cell growth and regulatory pathways have also been found to be
altered in OC (reviewed by Klimstra 1994, Rosen 1994, Mandard ef al 2000). Rosen
(1994) stated that most tumors develop as a result of multiple mutations in genes
involved in regulating growth and differentiation. Studies involving loss of heterozygosity
(LOH) (Tarmin ef al 1994, Barrett ef al 1996, Shimada ef al 1996) and comparative
genomic hybridisation (CGH) (Moskaluk ef al 1998, Sarlomo-Rikala ef al 1998, du
Plessis ef al 1999) have also identified several chromosomal regions of potential
importance implicated in OC. These studies suggest the involvement of many
oncogenes and tumor suppressor genes in the initiation and development of OC.
1.1.8. INFLAMMATORY BOWEL DISEASE (lBO)
1.1.8.1. Background
Inflammatory bowel disease (lBO) occurs due to chronic inflammation of the intestines,
resulting in swelling, ulcerations and loss of function, and is often referred to as an
autoimmune disease. The disease is generally subdivided into two phenotypes known
as Crohn's disease (CD) and ulcerative colitis (UC) (Sanderson 1986, Griffiths 1995).
The combined prevalence of CD and UC is estimated to be 100 to 200 per 100 000 in
the Western world (Kyle 1992, Loftus ef a/1998).
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UC involves continuous inflammation of the rectum and colonic mucosal layers, without
fistulas and granulomas, with inflammation occurring rarely in the last section of the
ileum. In contrast, in CD, discontinuous inflammation occurs in any part of the
gastrointestinal tract, most frequently affecting the terminal ileum and colon, with fistulas
and granulomas. Two distinct clinical forms of CD, known as perforating and non-
perorating CD, have also been documented (Greenstein et a/1988, Gilberts et a/1994).
Nonperforating CD is the more benign form, whereas perforating CD, with the presence
of absesses and/or free perforations, is the more aggressive form. CD or UC cannot be
determined in approximately 10% of cases, referred to as indeterminate colitis, when
inflammation is confined to the rectum and colon. CD is suggested to be the outcome of
three interactive factors, including host susceptibility, enteric microflora and the mucosal
immune system (Fiocchi 1998).
Patients with lBO present with symptoms such as diarrhea, abdominal pain and rectal
bleeding (Sanderson 1986, Griffiths 1995). In some cases constipation, fever, weight
loss and dehydration also occur. Severe constipation causes perforation of the intestine
and results in toxic dilation of the colon, referred to as toxic megacolon. The presence of
CD or UC is based on clinical presentation and confirmed by radiology, or by endoscopy
and biopsy (Heikenen et a/1999). Extraintestinal inflammation of the skin, eyes or joints
can also occur and the prevelance of lBO increases when associated with other
autoimmune diseases such as ankylosing spondylitis, psoriasis, sclerosing cholangitis
and multiple sclerosis (Snook et a/ 1989, Yang and Rotter 1993). Several genetic
syndromes, such as Turner syndrome, glycogen storage disease type Ib and
28
Stellenbosch University http://scholar.sun.ac.za
Hermansky-Pudlak syndrome, have also been reported to be associated with lBO
(Shanahan et a/1988, Yang and Rotter 1993).
1.1.8.2. Iron homeostasis and lBO
Anaemia of iron deficiency, due to the inadequate intake or loss of iron, and anaemia of
chronic diseases, resulting from decreased erythropoiesis, frequently occur in lBO. Iron
homeostasis is usually altered in conditions of chronic inflammation, predominantly
resulting from chronic blood loss in the intestine (Oldenburg et a/2001). Iron deficiency
can occur due to iron malabsorption because of inflammatory activity in the small
intestine and resection or impaired dietary intake. Iron is essential for bacterial growth
and it is speculated that anaemia may result from an attempt by the host to deprive
infiltrative microorganisms of iron and thereby hindering them from growing. This is
supported by findings that high body iron leads to increase susceptibility to a variety of
bacteria (Calver et al 1979, Wright et al 1981, Van Asbeck et al 1982, Martinez et al
1990) and a low level of iron appear to protect against various pathogens (Murray and
Murray 1977, Murray et a/1980, Oppenheimer et a/1986).
However, in chronic inflammatory conditions such as rheumatoid arthritis where no
microorganisms are involved, inflammation is ascribed to the generation of reactive
oxygen species (Oldenburg et al 2001). These species give rise to the formation of OH
in the Haber-Weiss reaction (Kehrer 2000) and the availability of chelated iron is
essential for the formation of the OH radical in the Fenton reaction (Cohen 1985). A
close relationship exists between iron and immunity but the exact influence of iron
metabolism on cell-mediated immunity is not well established yet. Iron overload has
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been shown to impair intracellular killing of pathogens, through IFNy-mediated
pathways, by macrophages (Alford et al 1991). The control of iron metabolism is
interconnected with other cellular pathways, and further analysis of these aspects are
likely to provide a better understanding of pathological processes in which iron may
participate.
1.1.8.3. Factors involved in lBO pathogenesis
Research involving both cellular and molecular biology revealed the possible
involvement of several factors in the aetiology of lBO. These included both genetic and
environmental factors (Sartor 1995, Shanahan 1995, Targan 1995). By reviewing
potential animal models for CD as well as results of studies on the mechanisms of its
pathogenesis and human molecular genetics, Targan and Murphy (1995) concluded that
CD heterogeneity is at the primary genetic level and expression of genetic susceptibility
requires environmental triggers.
i) Environmental involvement
The role of environmental factors is thought to be one of the less understood and most
difficult factors to interpret in the progression of lBO, and possibly as important as
genetic factors in the risk of developing lBO (Fiocchi 1998). Potential environmental
factors include prenatal events, breastfeeding, childhood infections, microbial agents,
smoking, oral contraceptives, diet, hygiene, occupation, education, climate, pollution, .
stress, and miscellaneous components such as toothpaste, appendectomy,
tonsillectomy, blood transfusions, contact with animals, and physical activity. The most
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established association and intriguing factor is smoking, with non-smoking being
associated with UC and smoking with CD (Harries et al 1982a, 1982b, Tysk et al 1988,
Somerville et a/1994, Reif et a/1995).
ii) Genetic involvement
The involvement of genes in the pathogenesis of lBO was confirmed by familial studies
(Orhalm et a/1991, Yang et a/1993, Binder 1998), difference in concordance rates in
twin pairs (Tysk et a/1988, Binder 1998) and linkage studies (Hugat et a/1996, Satsangi
et al 1996a, Cho et al 1998, 2000, Rioux et al 2000, lBO International Geneties
Consortium 2001, Rioux et al 2001, Hugot et al 2001, Ogura et al 2001a). Linkage
studies provided evidence for linkage between lBO and loci on several chromosomes
associated with CD and/or UC (Cho et al 1998, 2000, Satsangi et a/1996a, Duerr et al
1998, Parkes et a/2000, Rioux et a/2001).
Prevalence of UC in first-degree relatives is estimated to be between 4 and 16%
(Lewkonia and McConnell 1976, Farmer et al 1980) with the frequency being higher in
CD than in UC (Satsangi et al 1994). A positive family history is more common in
patients with CD than in UC, with relatives of patients with CD developing CD or UC, but
most likely CD (Satsangi et al 1997). Satsangi et al (1996b) studied the clinical
characteristics of lBO and found statistically significant differences in the median age of
onset, being higher in the patients than in their offspring, possibly reflecting genetic
anticipation between generations. Inheritance in families did not follow simple mendelian
models and therefore lBO is considered as a complex genetic trait largely due to genetic
heterogeneity.
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Concordance rates in twin pairs provided strong evidence of genetic predisposition in
lBO, especially CD (Tysk ef a/1988, Binder 1998). A difference in concordance rate was
also identified between CD and UC in these twin studies, suggesting differences in the
genetic basis of these diseases. Genetic factors seem to be relatively more important in
CD than in UC and are considered to be related polygenic disorders (Satsangi et al
1997). Satsangi ef al (1996b) suggested that CD and UC are closely related, but distinct
polygenic disorders, sharing some susceptibility genes.
The involvement of the solute carrier family 11 member 1 gene (SLC11A 1) in lBO
pathogenesis was first investigated by Hofmeister ef al (1997). The SLC11A1 protein is
believed to regulate macrophage function and is a good candidate gene because
hyperreactive immune response toward the intestinal flora was previously implicated in
the pathogenesis of lBO (Duchmann et al 1995). Hofmeister ef al (1997) identified
significant differences in haplotype distributions in patients with CD and reported the first
association between the SLC11A1 gene and CD. However, analysis of the SLC11A1
gene polymorphisms (274C~ T and 823C~ T) in a study performed by Stokkers ef al
(1999), showed no association of the SLC11A 1 gene with lBO susceptibility. A recent
study by Kojima ef al (2001) confirmed association of a novel allele
[t(gt)sac(gt)sat(gt)11ggcaga(g)6 - Allele 7] of the SLC 11A 1 promoter repeat polymorphism
identified in the Japanese population with lBO.
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Recently, independent studies performed by Hugot et al (2001) and Ogura et al (2001a),
using positional-cloning strategies and linkage association studies, respectively,
identified disease-predisposing alleles of the caspase recruitment domain-containing
protein 15 gene (CARD15), formerly known as the NOD 2 protein gene (NOD2). The
gene is located on chromosome region 16q12 and is comprised of 12 exons (Ogura et al
2001a). This gene showed strong linkage to CD susceptibility. Thirteen sequence
variants were identified and significant association of three of these polymorph isms
(R702W, G908R and 1007fs) with CD was demonstrated. Association of the frameshift
variant with CD was confirmed in a German and British population (Hampe et al 2001).
Mutations of CARD15 were identified in 40 to 50% of CD patients (Vermeire et a/2000,
Ogura et al 2001a, Hugot et al 2001, Hampe et al 2001, Lesage et a/2002, Van Heel et
a/2002), with a causative genetic defect in about 15% of the patients. In a recent study
by Yamazaki et al (2002), significant association with CARD15 could not be confirmed in
the Japanese population. The authors suggested that the prevalent CARD15 mutations
are independent risk factors for CD in Caucasian patients.
The gene encodes a member of the Apaf-1/Ced4 superfamily of apoptosis regulators
that is expressed in monocytes. The CARD15 protein is homologous to a class of
cytosolic plant disease resistance genes. These genes recognize bacterial components
and induce appropriate pathogen specific responses (Weitzman 2001). The gene
comprises two N-terminal capase-recruitment domains (CARDs) fused. to a central
nucleotide-binding domain (NBD) and ten leucine-rich repeats (LRR) (Ogura et al
2001a).
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The variants identified are predicted to alter structure of either the LRR domain of the
protein, possibly affecting host-interactions with bacterial LPS and inducing the nuclear
factor KB (NF-KB) signaling pathway, or the adjacent region (Weitzman 2001). NF-KB is
a target of anti-inflammatory' steroids and sulfasalazine and is activated by CARD15
(Ogura et al 2001b). The function of the protein encoded by CARD15 is only partly
known and is predicted to detect bacteria in the gut and to help control inflammatory
response to them (Ogura et al 2001b). The role of the CARD15 protein in lBO
pathogenesis is speculated to: (1) regulate the induction of cytokines (via NF-KB) that
controls inflammatory response and (2) alter or change pathogen recognition patterns
due to mutations in the LRR (Weitzman 2001, Ogura et a/2001b).
1.1.9. HEREDITARY HAEMOCHROMATOSIS (HH)
1.1.9.1. Background
Hereditary haemochromatosis (HH) is generally an autosomal recessive condition
(Edwards et al 1988). Features of haemochromatosis include cirrhosis of the liver,
diabetes mellitus, athropathy, cardiomyopathy, endocrine abnormalities and
hepatocellular carcinoma, which is the result of tissue damage from the progressive
accumulation of iron (Bothwell et al 1995). Men usually present with clinical symptoms
by the fourth to fifth decade and women presenting about a decade later. Women may
be protected against iron accumulation due to menstruation and pregnancy (Bothwell
and MacPhail 1998).
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HH is characterised by the inappropriate absorption of iron from the gut, resulting in iron
overload (Bothwell et a/1995). Excessive iron absorption causes iron overload primarily
in parenchymal cells. Muir et a/ (1984) identified four groups of disease expression,
possibly indicating the involvement of other genes in iron metabolism leading to HH.
These groups include i) a classic form with elevated transferrin saturation, serum ferritin
levels and liver iron content (group I); ii) severe iron overload, accelerated disease
manifesting at an early age (group II); iii) elevated total body iron stores, normal
transferrin saturation and serum ferritin levels (group III) and iv) markedly elevated
findings on serum biochemical tests, i.e., transferrin saturation and serum ferritin, with
minimal elevation in total body iron stores (group IV).
1.1.9.3. Factors involved in HH pathogenesis
i) Environmental involvement
Non-genetic factors influencing penetrance of different HFE genotypes include
physiological and pathological blood loss, dietary intake of iron and alcohol intake
(Adams et a/2000).
ii) Genetic involvement
Type 1 haemochromatosis, also designated HFE1, is associated with mutations in the
HFE gene that maps to 6p21.3 and mutations C282Y and H63D have been identified as
the most common cause of the disorder (Feder et a/1996) [see section 1.1.9.4(i)). More
than 90% of individuals presenting with genetic haemochromatosis in the United
Kingdom will have an HFE related mutation (The UK Haemochromatosis Consortium
1997). Non-HFE related forms of HH, which are less common, have also been reported.
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The gene involved in type 2 haemochromatosis, also known as juvenile
haemochromatosis (JH) or HFE2, has been mapped to chromosome region 1q but has
not yet been characterised (Camaschella et a/1997). JH is a rare and severe disorder of
iron overload with liver and heart disease being evident by the third decade. Recently,
mutations identified in the hepcidin antimicrobial peptide gene (HAMP), that maps to
19q13, were associated with JH (Roetto et a/2003). JH linked to the unidentified gene
on chromosome region 1q has been designated HFE2A and HFE28 refers to JH
associated with mutations in HAMP. Mutations in the transferrin receptor 2 gene (TFR2),
that maps to 7q22, contribute to haemochromatosis type 3 (HFE3) (Camaschella et al
2000, Roetto et al 2001) and haemochromatosis type 4 (HFE4), associated with an
autosomal dominant form of inheritance and maps to 2q32, is associated with mutations
in the solute carrier family 11 member 3 gene (SLC11A3) (Njajou et a/2001, Montosi et
a/2001).
1.1.9.4. Genes involved in iron homeostasis
Several genes have been implicated in regulating iron homeostasis and includes the
transferrin receptor 2 gene (TFR2) (Camaschella et al 2000, Roetto et al 2001), the
solute carrier family 11 (proton-coupled divalent metal ion transporter) member 2 gene
[SLC11 A2, also known as the natural resistance-associated macrophage protein 2 gene
(NRAMP2) or divalent metal transporter 1 gene (DMT1)] (Gruenheid et a/1995, Gunshin
et al 1997), hepcidin antimicrobial peptide gene [HAMP, also known as the liver-
expressed antimicrobial peptide gene (LEAP1) or hepcidin (HEPC)] (Krause et al 2000,
Park et al 2001, Pigeon et al 2001, Nicolas et al 2001), solute carrier family 11 (proton-
coupled divalent metal ion transporter) member 3 gene [SLC11A3, also known as the
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ferroportin 1 gene (FPN1), iron-regulated transporter 1 gene (IREG1) or metal
transporter 1 gene (MTP1)] (Donovan et al 2000, McKie et al 2000, Abboud and Haile
2000), duodenal cytochrome b gene (DCYTB) (McKie et al 2001), ceruloplasmin (Cairo
et al 2001) and hephaestin (Vulpe et al 1999, Kaplan and Kushner 2000). The function
and localisation of the proteins encoding the various genes are illustrated in figure 1.5
(with permission adapted from Pointon 2001)
37
Stellenbosch University http://scholar.sun.ac.za
Macrophage
Figure 1.5.
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Legend to Figure 1.5.
A schematic representation of the movement of iron in cell types having a role in iron
metabolism. Dietary iron is absorbed by duodenal enterocytes where DCYTa reduces ferric
iron to ferrous iron at the luminal surface. Ferrous iron is transported across the apical
membrane by SLC11A2, followed by the export of iron at the basal membrane by SLC11A3.
Ferrous iron is then oxidised to ferric iron by hephaestin. In hepatocytes, iron is taken up via
either the Tf-Tf1 endocytic pathway possibly influenced by HFE or as Tf bound iron via TfR2.
Iron is stored bound to ferritin and can be exported to the circulation via SLC11A3, if required,
and reduced to ferric iron by ceruloplasmin. Iron is taken up in the red blood cell precursor by
TfR1 endocytosis and used for the synthesis of haemoglobin. Macrophages recycle iron from
phagocytosed effete red blood cells where haem iron is released by haem oxidase.
In this study, we investigated the involvement of HFE, SLC11A3, HAMP and DCYTa in
patients presenting with hereditary haemochromatosis and only these genes will be
discussed further.
39
Stellenbosch University http://scholar.sun.ac.za
i)HFE
HFE has been identified as the major gene underlying HH. The HFE gene is localised
on chromosome 6p (Simon et al 1975, Feder et al 1996). The protein consists of 343
amino acids that is homologous to the MHC class I protein, HLA-A2 and the non-
classical class I protein, HLA-G. The HFE protein consists of three extracellular
domains (a1-domain, a2-domain and a3-domain), a transmembrane domain and a
small cytoplasmic tail, and forms a heterodimer with J32-microglobulin for cell surface
expression. HFE forms a complex with transferrin receptor 1 (TfR1) (Parkkila et a/1997,
Feder et al 1998), reducing the affinity of TfR1 for transferrin (Tf) by five to ten-fold
(Feder et al 1998, Gross et al 1998, Ikuta et al 2000). Evidence of HFE being involved
in iron loading was observed in mice being deficient in Hfe (Zhou et a/1998, Fleming et
a/2001 ).
Homozygosity for a mutation in the HFE gene, causing a cysteine to tyrosine
substitution at amino acid 282 (C282Y), has been shown to be the most common cause
of HH in up to 90% of individuals from European descent (The UK Haemochromatosis
Consortium 1997). This mutation, located in the a3-domain, disrupts a disulphide bond
that is essential for the interaction with J32-microglobulinand is predicted to result in the
lack of cell surface expression of the gene (Feder et al 1996). One-third of deaths in
affected individuals being homozygous for the C282Y mutation occur due to primary
hepatocellular carcinoma
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A second missense mutation that results in a histidine to aspartic acid substitution at
amino acid 63 (H63D) is also associated with HH. Homozygosity occurs in
approximately 4.5% of HH patients (Merryweather-Clarke et a/2000) and up to 13.3% is
heterozygous for the H63D mutation (Piperno et a/ 1998). The H63D mutation is much
more common in European populations, approximately 30.4% (Merryweather-Clarke
2000), than in patients with HH. Approximately 10% of HH patients are C282Y and
H63D compound heterozygotes (Piperno et a/ 1998, Merryweather-Clarke et a/ 2000).
The H63D mutation is located in the a1-domain of the gene. Other mutations in HFE
accounts for up to 2 to 9.6% of HH individuals in different populations (Feder et a/1996,
Henz et a/1997, Douabin et a/1999, De Villiers et a/1999, Barton et a/1999a, Rochette
et a/ 1999, Wallace et a/ 1999, Worwood et a/1999, Rosmorduc et al 2000, Pointon et
a/2000, Piperno et a/2000).
ii) Solute carrier family 11 (proton-coupled divalent metal ion transporter) member
3 gene (SLC11A3)
The SLC11A3 gene, localised to chromosome 2q32 (Haile 2000), encodes a
transmembrane protein involved in releasing iron from cells (Donovan et a/2000, McKie
et a/2000, Abboud and Haile 2000). The gene was first identified by positional cloning,
in weissherbst zebrafish, as the gene responsible for hypochromic anaemia (Donovan
et a/2000). Mouse and human eDNA was subsequently isolated by RT-PCR of liver and
placenta, respectively (Donovan et a/ 2000), and by using a subtractive cloning strategy
and PCR analysis (McKie et a/2000).
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The SLC11A3 gene consists of 8 exons and spans a region of 20 kb (Njajou et a/2001).
The human SLC11A3 protein consists of 571 amino acids and contains 10
transmembrane domains (McKie et al 2000). The protein is localised to the basolateral
membrane of polarised epithelial cells. A functional iron responsive element (IRE),
predicted to form a hairpin-loop, was identified in the 5' untranslated region. The highest
level of expression of the gene in humans is in placenta, liver, spleen and kidney.
Expression of SLC11A3 in Xenopus oocytes stimulated iron efflux (McKie et al 2000).
Recently, mutations in the SLC11A3 gene have been shown to be associated with an
autosomal dominant form of haemochromatosis, also termed haemochromatosis type 4
(HFE4) (Njajou et al 2001, Montosi et al 2001, Wallace et al 2002, Devalia et al 2002,
Roetto et a/2002).
iii) Hepcidin antimicrobial peptide gene (HAMP)
Biochemical purification of blood ultrafiltrate using a cysteine alkylation assay and mass
spectrometry, followed by micropeptide sequence and RT-PCR analysis as well as 5'
and 3' RACE was used to isolate the eDNA encoding HAMP (Krause et al 2000). Park
et al (2001) also isolated the eDNA for HAMP by biochemical purification and amino
acid sequence analysis of hepcidin peaks in urine, followed by EST database searching
and 5' RACE. The human gene was mapped to chromosome region 19q13 (Krause et
al 2000, Park et al 2001, Pigeon et al 2001) and the mouse gene to chromosome 7
(Pigeon et al 2001) by genomic sequencing analysis.
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The gene consists of 3 exons with the final exon encoding the active peptide (Krause et
a/2000, Park et a/2001, Pigeon et a/2001). The protein consists of 84 amino acids that
undergo enzymatic cleavage into mature 20, 22 and 25 amino acids. The protein
contains a 24-residue N-terminal signal sequence and a pentaarginyl proteolysis site
followed by the active C-terminal 25-amino acid peptide (Krause et a/2000). The active
peptide contains a unique 17-residue stretch with 8 cysteines forming 4 disulfide bridges
that stabilize the beta-sheet structure.
By using animal models, Nicolas et al (2001) found that Hamp gene expression was
totally inhibited in mice exhibiting iron overload consequent to targeted disruption of the
upstream stimulatory factor 2 gene (Usf2), which is in close proximity to Hamp. In these
mice the development of iron overload was similar to that observed in human hereditary
haemochromatosis and in mice with knockout of the Hfe gene (Zhou et a/1998, Bahram
et al 1999, Levy et al 1999). These authors suggested that overexpression of hepcidin
might result in phenotypic traits of iron deficiency. Transgenic mice expressing hepcidin
under the control of the liver-specific transthyretin (TIR) promoter presented with
decreased body iron levels and severe microcytic hypochromic anemia. These results
support the proposed role of hepcidin as an iron-regulatory hormone. Mutations in this
gene has also been identified and associated with juvenile haemochromatosis (Roetto
et a/2003).
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iv) Duodenal Cytochrome b gene (DCYTB)
The DCYTB gene encodes a cytochrome b-like molecule and was isolated by using a
subtractive cloning strategy (McKie et a/ 2000). The gene consists of 4 exons, which
code for 286 amino acids containing six predicted transmembrane domains and four
conserved histidine residues.
DCYTB is a ferric reductase and has nucleotide sequence homology to the cytochrome
b561 family and the yeast ferrireductase Fre1 (Shatwell et a/1996). The gene is highly
expressed at the intestinal brush border and reduces ferric ions to ferrous ions in the gut
lumen for transport across the apical membrane as the first step in intestinal iron
absorption (McKie et a/ 2001). Dcytb expression, as for SIc11a2, increases when iron
absorption is stimulated and may use ascorbate as a cofactor because it lacks the
motifs for binding the more common cofactors (nicotinamide adenine dinucleotide,
nicotinamide adenine dinucleotide phosphate and flavin adenine dinucleotide) (McKie et
a/2001).
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1.2. OBJECTIVES OF THIS STUDY
i) Mutational analysis of the SLC11A 1 gene 5'-(GT)n repeat polymorphism was
performed to determine whether the effects mediated by the gene are related to its
involvement in iron homeostasis.
ii) The functional polymorph isms of the SLC11A 1 gene were analysed in patients
presenting with oesophageal cancer (DC), inflammatory bowel disease (lBO) and
hereditary haemochromatosis (HH) respectively, and association studies were
performed to investigate the SLC11A 1 gene as a potential modifier locus in these
disease phenotypes.
iii) Further investigation of the SLC11A 1 gene as a potential modifier locus was
exploited by investigating possible gene-gene interaction with the CARD15 gene, which
has been implicated in lBO susceptibility.
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CHAPTER 2
DETAILED EXPERIMENTAL PROCEDURES
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2.1. DNA EXTRACTION FROM WHOLE BLOOD
DNA was extracted from whole blood samples by a modification of the technique of
Miller et al (1988). Cold lysis buffer (40 ml) (155 mM NH4CI,10 mM KHC03. 0.1 mM
EDTA - pH 7.4) was added to each whole blood sample in a 50 ml polypropylene
tube (Falcon). The solution was kept on ice until the red blood cells had undergone
lysis and the cell suspension was then centrifuged at 250 x g for 10 minutes. After
the supernatant was removed, the pellet was washed twice with 5 ml cold PBS (27
mM KCI, 137 mM NaCl, 8 mM Na2HP04, 1.5 mM KH2P04). The intact pellet was
resuspended in 3 ml nucleic lysis buffer (0.01M Tris-HCI (pH 8.2), 0.4 M NaCl, 2 mM
EDTA - pH 8.2), 1% SDS (w/v) and 1.5 mg/ml proteinase K (Roche Diagnostics), and
incubated overnight in a water bath at 55°C.
Following overnight incubation, 1 ml of saturated 6 M NaCI was added and the
solution shaken vigorously for 1 minute, followed by centrifugation at 950 x g for 15
minutes. The supernatant containing the DNA was transferred to a clean Falcon
tube. Two times the volume ice-cold EtOH (99%-) (v/v) was added and the solution
was left at room temperature for 30 minutes. The precipitated DNAwas transferred to
a fresh 1.5 ml tube (Eppendorf) and washed twice with 1 ml 70% EtOH (v/v) to
remove any excess salt. After centrifugation at 800 x g for 15 minutes, the excess
EtOH was carefully removed and the DNA was left to air dry at room temperature.
The DNA pellet was dissolved in 500 ~I ddH20 overnight at room temperature and
the DNA stored at 4°C. DNA quality and quantity was measured by agarose gel
electrophresis or spectrophotometry (~Quant Bio-Tek Instruments)
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2.2. POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION
2.2.1. Oligonucleotide Primers
The peR primers used in this study for heteroduplex single-strand conformation
polymorphism (HEX-SSep) and denaturing high performance liquid chromatography
(dHPLe) analysis are listed in Table 2.1. Primers used for peR amplification of
products subjected to restriction fragment length polymorphism (RFLP) analysis are
listed in Table 2.2.
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Table 2.1. Oligonucleotide primers used for amplifying PCR products subjected to HEX-SSCP and dHPLC analysis
GENE EXON PRIMERS PCR ANN 1 ANN2 ANALYSIS
Forward (5'-3') *Tm Reverse (5'-3') *Tm FRAGMENT (OC) (OC)
I
(OC) (OC) SIZE (bp)
SLC11A1 a5'-UTR GGGGTCTTGGAACTCCAGAT 62 GGCAGCTCCTCAGCCTGCAC 68 467 65 60 HEX-SSCP
°2 AGGAGGGAAAGGATCAGG 56 GGATCCTGTCAATCTTGCAGGC 68 143 65 HEX-SSCP
cSLC11A3 1 CCCCGACTCGGTATAAGA 56 TTCCTCCAGAACTCGTGTAG 60 489 54 dHPLC
2 TGGATAAGCATTCTGCCCTC 60 AAAGCATGTGTACTTGGATG 56 275 54 dHPLC
3 AATGTAGCCAGGAAGTGCC 58 AGAGGTGGTGCCATCTAAG 58 416 58 dHPLC
4 GGATAAGAACAGTCTCACTG 58 TTCATCCTTTACCACTACCAG 60 243 54 dHPLC
5 TTAAACTGCCTTGTTTAGTG 54 GCCTCATTTATCACCACCG 58 279 58 dHPLC
6 TTGTGTAAATGGGCAGTCTC 58 CCTCGTCTACCAAAGCGATA 60 460 54 dHPLC
7i GCTTTTATTTCTACATGTCC 54 GCTGTGCCAATCCTGAGATC 62 435 54 dHPLC
7ii GAGCATCAGCTATAACTGG 56 TAATGGATTCTCTGAACCTAC 58 435 54 dHPLC
8i TTGAAATGTATGCCTGTAAAC 56 TTTCCATGCCTCAACATAAGG 60 567 54 dHPLC
8ii GTTTTTACCACAGCTGTGCC 60 ATACCTTAAGATCAATAGGAT 54 411 54 dHPLC
--
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Table 2.1. Oligonucleotide primers used for amplifying PCR products subjected to HEX-SSCP and dHPLC analysis (Continued)
GENE EXON PRIMERS PCR ANN 1 ANN2 ANALYSIS
Forward (5'-3') *Tm Reverse (5'-3') *Tm FRAGMENT (OC) (OC)
(OC) eC) SIZE (bp)
dDCYTB 1 AGACAGCCCCAAGAAGTC 56 TCCTCCAGCACTTCCTCAG 60 407 62.3 dHPL.,C
2 GAGGGGAGAAGCAAAAGCCAAG 56 AAGATCGCAGCACTGCACTC 62 476 63.1 dHPLC
3 GTAGTGGAACTGGAGCGAG 56 TGTCAGACTTTTTGGTCCTTC 60 496 62.1 dHPLC
4i CTGTTTTGCATGTTGCTGTATC 62 ATCTCTGCCCAGCCTCATC 60 352 58 dHPLC
4ii AGGTTCCATGCCAGCCTACTC 66 ATCTATTCTGCACAAGGCACCG 64 406 58 dHPLC
dHAMP 1 AGCAAAGGGGAGGGGGCTCAGACC 80 TCCCATCCCTGCTGCCCTGCTAAG 84 292 60 dHPLC
GA
2+3 TTGCCGGGAGCCAGTCTAGAGGTC 60 TGCAAGGCAGGGTCAGGACAAGCT 76 497 63.1 dHPLC
CA
--------- ~------ -- ---- -------- - L.....-. ---
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Table 2.1. Oligonucleotide primers used for amplifying PCR products subjected to HEX-SSCP and dHPLC analysis (Continued)
GENE EXON PRIMERS PCR ANN 1 ANN2 ANALYSIS
Forward (5'-3') *Tm Reverse (5'-3') *Tm FRAGMENT (OC) (OC)
(OC) eC) SIZE (bp)
8HFE 4 TGGCAAGGGTAAACAGATCC 60 TACCTCCTCAGGCACTCCTC 64 396 65 60 HEX-SSCP
1 GGACACTGGATCACCTAGTGTT 66 CTAGTTTCGATTTTTCCACCCC 64 355 58 dHPLC
2 ACATGGTTAAGGCCTGTTGC 60 CAGCTGTTTCCTTCAAGATGCA 64 373 54 dHPLC
3 AAATAGGGACCTATTCCTTTGGT 64 GTGCCCTGCAACCTCCTCCA 66 393 58 dHPLC
4 TGGCAAGGGTAAACAGATCC 60 CTCAGGCACTCCTCTCAACC 64 390 58 dHPLC
5 GTATGTGACTGATGAGAGCCA 62 CAGAGGTACTAAGAGACTTC 58 310 54 dHPLC
6 TAGTGCCCAGGTCTAAATTG 58 TGAGTCTCTAGTTTTGTCTCC 60 201 58 dHPLC
'CARD151 4 ACCTTCAGATCACAGCAGCC 62 GCTCCCCCATACCTGAAC 58 494 65 60 HEX-SSCP
NOD2 11 GAATGTCAGAATCAGAAGGG 58 CTCACCATTGTATCTTCTTTTC 56 230 60 55 HEX-SSCP
*Tm = 2(nA+nT) + 4(nG+nC), Abbreviations: Tm - melting temperature, Ann - annealing temperature, UTR, untranslated region
References: aKotze et a/2001, byhis study, CNjajou et a/2001, Primer sequences supplied by dDr A Merryweather-Clarke and "Prof
C Camaschella, flesage et a/2002
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Table 2.2. Oligonucleotide primers used for amplifying PCR products subjected to RFLP analysis
GENE EXONIINTRON PRIMERS PCR ANN 1 ANN 2 "ENZYME I
(Variant) Forward (5'-3') *Tm Reverse (5'-3') *Tm FRAGMENT (OC) (OC)
(OC) (OC) SIZE (bp)
aSLC11A1 5'-UTR [5'-(GT)n] GGGGTCTTGGAACTCCAGAT 62 TACCCATGACCACACCC 54 116 65 'Rsa/
DHFE 2 (S65C) TCTGTCTAATCATGAGTATT 48 CTTGCTGTGGTTGTGATTTTC 58 513 52 zHinfl
2 (IVS2+4T/C) ACATGGTTAAGGCCTGTTG 56 TGCCACTAGAGTATAGGGGC 58 870 56 'Rsa/
4 (IVS4-44T/C) TGTCTCTCCTGTAGCTTGTT 58 TTCTGTCTCCCAGGGTGCT 56 825 55 ;'Sau96/
5 (IVS5-47G/A) CCTGAACATCTGTGGTGTAG 60 TGGGACTACAGGCGTCTGC 62 1038 55 4Ban/
cCARD 15/NOD2 8 (G908R) CCCAGCTCCTCCCTCTTC 60 AAGTCTGTAATGTAAAGCCAC 58 380 65 60 "Htïe!
Tm = 2(nA+nT) + 4(nG+nC), ill'AIienzymes were incubated at 37°C, Abbreviations: Tm - melting temperature, Ann - annealing
temperature, References: aKotze et a/2001, bprimer sequences supplied by Dr J Pointon, 'Lesaqe et a/2002
/'
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Restriction endonucleases recognition sites on sense strand:
1GT+AC; Recommended buffer - NEBuffer 1 [10 mM Tris-HCI, 10 mM MgCI2, 1 mM DTT (pH 7.0)] (New England Biolabs)
2G+ANT C; Recommended buffer- Buffer B [6 mM Tris-HCI, 6 mM MgCI2, 50 mM NaCI (pH 7.5)] (Promega)
3G+GNC C; Recommended buffer- Buffer C [10 mM Tris-HCI, 10 mM MgCI2, 50 mM NaCI (pH 7.9)] (Promega)
4G+G(T/C)(AlG)C G; Recommended buffer - Buffer G [50 mM Tris-HCI, 5 mM MgCI2 (pH 8.2)] (Promega)
5G CG+C; Recommended buffer - Buffer C [10 mM Tris-HCI, 10 mM MgCI2, 50 mM NaCI (pH 7.9)] (Promega)
RFLP sizes
SLC11A 15'(GT)n repeat (most common alleles): Allele 1 (5511): 57 bp, 51 bp, 5 bp, Allele 2 (5510): 57 bp, 49 bp, 5 bp; Allele 3
(559): 57 bp, 47 bp, 5 bp, Allele 5 (4510): 55 bp, 49 bp, 5 bp
HFE S65C: S, 367bp, 72 bp, 68 bp, 6 bp; C, 435 bp, 72 bp, 6 bp
HFE IVS2+4T/C: T, 557 bp, 245 bp, 19 bp; C, 297 bp, 260 bp, 245 bp, 19 bp
HFE IVS4-44T/C: T, 523 bp, 195 bp, 108 bp; C, 305 bp, 218 bp, 195 bp, 108 bp
HFE IVS5-47G/A: G, 681 bp, 405 bp, 307 bp, 150 bp; A, 988 bp, 405 bp, 150 bp
CARD15/NOD2 G908R: G, 380 bp; R, 242 bp, 138 bp
53
Stellenbosch University http://scholar.sun.ac.za
2.2.2. DNA amplification
General peR
The DNA samples were amplified on an Applied Biosystems PCR cycler
(GeneAmp®PCR system 2700). PCR amplification of the various exons were
performed in 25 !-IIreactions. Each reaction consisted of 0.2 prnobul of each primer,
0.5 U Taq polimerase enzyme (Roche Diagnosties), 0.2 mM of each dNTP (dGTP,
dCTP, dATP, dTIP) (Promega), 1 X buffer with MgCI2 (Roche Diagnostics) and 20
ng/IJl DNA.
The PCR conditions for the exons were as follows: an initial denaturation step for 2
min at 95°C, followed by 10 cycles of denaturation at 95°C for 30 seconds, annealing
as specified for each exon in Tables 2.1 and 2.2 (Ann 1) for 45 seconds, and an
extension at 72°C for 30 seconds. This was followed by 30 cycles of the same
conditions but with an annealing temperature as specified in Tables 2.1 and 2.2 (Ann
2), followed by an extension step at 72°C for 10 minutes and a final step of 1 minute
at 25°C. The exons with only one annealing temperature (Ann 1) specified were
amplified for 35 cycles.
2.3. AGAROSE GEL ELECTROPHORESIS
Successful amplification of PCR products was tested on a 2% (w/v) horizontal
agarose gel [consisting of 2g agarose in 100 ml 1 X THE (90 mM Tris-HCI (pH 8.0),
90 mM boric acid and 1 mM EDTA)]. The PCR product (5 !-II) was mixed with an
equal volume of ficoll-orange G loading buffer [consisting of 2 mM orange G, 2 mM
ficoll and 9 mM EDTA (pH 7.0)] and loaded on the gel. The products were resolved at
150 V for 30 minutes in 1 X TBE buffer solution and 0.01 % (v/v) of ethidium bromide
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for staining purposes. The DNA was visualised by ultraviolet light transillumination
assisted by a UVP Image Store 5000 Ultra-Violet transilluminator system and
photographedwith the Sony Video Graphic Printer (UP 860 LE) system.
2.4. HETERODUPLEX SINGLE-STRAND CONFORMATION POLYMORPHISM
(HEX-SSCP) ANALYSIS
HEX-SSCP analysis (Kotze et al 1995) was performed on a 30 cm vertical gel
apparatus. These fragments were electrophoresed on a 10% polyacrylamide (PAA)
gel supplemented with urea (gel consisting of 7.5% urea (w/v), 1.5 X TBE (135 mM
Tris-CI (pH 8.0), 135 mM boric acid and 2 mM EDTA), 10% PAA (w/v) (1%C of a
40% stock [99 acrylamide (AA):1 bisacrylamide (BAA)], 0.1% APS (w/v) and 0.1%
(v/v) TEMED.
A 0.75 mm gel was cast and once polymerised, prepared for loading of the PCR
products. Gels were placed in a Hoefer electrophoresis tank filled with fresh 0.5 X
TBE buffer (45 mM Tris-CI (pH 8.0), 45 mM boric acid and 0.9 mM EDTA). The upper
buffer chamber was filled with 1.5 X TBE buffer. An equal volume of bromophenol
blue loading buffer [consisting of 95% formamide (de-ionised) (v/v), 20 mM EDTA
(disodiumsalt), 0.05% xylene cyanol (w/v) and 0.05% bromophenol blue (w/v)] was
added to the PCR products, heat denatured for 5 minutes at 95°C and then kept on
ice. Approximately 15 IJl of the denatured PCR product was loaded on the gel.
Electrophoresis of the gels was performed at 300 V at 4°C for 20 hours.
Following electrophoresis, the gels were dismantled and the DNA stained in 0.01%
(v/v) ethidium bromide for 10 min and destained in ddH20 for 3 min. The DNA
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fragments were visualised by ultraviolet light transillumination assisted by the UVP
Image Store 5000 Ultra-Violet transilluminator system and photographed with the
Sony Video Graphic Printer (UP 860 LE) system. Automated DNA sequencing was
performed on PCR products demonstrating HEX-SSCP mobility shifts (see section
2.8. for automated sequencing protocol).
2.5. DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
(dHPLC) ANALYSIS
PCR amplification was performed, in a skirted 96-well PCR plate (Southern Cross
Biotechnology) as previously described [see section 2.3.2. (i)] and an additional 0.05
U proofreading enzyme, Pwo DNA Polymerase (Roche Diagnostics), was added to
the PCR reaction prior to amplification. Following PCR amplification, heteroduplex
formation was induced by heat denaturation at 98°C for 15 minutes followed by slow
cooling (2°C/minute) and analysed by denaturing high-performance liquid
chromatography (dHPLC) on the WAVE DNA Fragment Analysis System
(Transgenomie). Five microliters of the heteroduplexed PCR products were
automatically loaded on the column and were eluted on a linear acetonitrile (Sigma-
Aldrich) gradient in a 0.1 M triethylamine acetate buffer (TEAA) (pH 7.0) with a
constant flow rate of 0.9 ml/min. The start and end points of the gradient were
adjusted according to the size of the PCR products. The denaturing run
temperatures, as predicted by the Wavemaker 4.1.44 program, are listed in Table
2.3. Data were acquired using an ultraviolet detector at 260 nm and heterozygous
profiles were identified by visual inspection of the chromatograms on the basis of the
appearance of superimposed multiple eluting peaks, followed by sequencing
analysis.
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Table 2.3. Experimental run temperatures as used for dHPLC analysis
GENE EXON TEMPERATURES
*TEMP 1 *TEMP 2 *TEMP 3
SLC11A3 1 60 (shift-2.0) 62 (shift 0.0) 66 (shift+3.0)
2 57 (shift-2.0) 59 (shift-0.5) 62 (shift+2.5)
3 57 (shift-1.5) 59 (shift-0.5) 61 (shift+1.5)
4 59 (shift-0.5) 61 (shift+2.0)
5 57 (shift-1.0) 59 (shift+1.0)
6 57 (shift-1.0) 60 (shift+1.5)
7i 59 (shift-1.0) 61 (shift+0.5)
7ii 58 (shift-0.5) 60 (shift+1.0)
8i 56 (shift-1.0) 59 (shift+1.0)
8ii 53 (shift+1.0) 56 (shift-1.0)
DCYTB 1 65 (shift-0.5)
2 59 (shift+0.5)
3 51 (shift-0.5) 55 (shift+1.5) 58 (shift+2.5)
4i 59 (shift-1.0) 61 (shift+1.0)
4ii 59 (shift+2.0)
HAMP 1 64 (shift-0.5)
2+3 60 (shift-0.5) 63 (shift+1.0)
HFE 1 59 (shift-0.5) 62 (shift+1.0) 66 (shift+3.0)
2 61 (shift 0.0)
3 61 (shift-0.5) 63 (shift+0.5)
4 63 (shift+0.5)
5 58 (shift-0.5) 60 (shift+0.5)
6 59 (shift-1.0) 62 (shift+1.0)
*Tm > oven temperature = negative shift (0.5 min/oC), Tm < oven temp = positive
shift (0.5 min/oC)
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2.6. RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) ANALYSIS
peR products subjected to RFLP analysis (as indicated in Table 2.2) were digested
overnight in 20 !-lI reactions, consisting of 10 !-lI peR product, 1 U of the relevant
enzyme and 1 X buffer, in a 37°e water bath. Following digestion, an equal volume of
bromophenol blue loading buffer was added to the peR products.
Electrophoresis of the digested peR products of SLC11A1 and CARD15/NOD2 was
performed on a 9 cm vertical (Hoefer system) PAA gel [consisting of 12% PAA (w/v)
[5%e of a 40% stock (95 acrylamide (AA):5 bisacrylamide (BAA)], 1 X TBE, 0.1%
APS (w/v) and 0.1% TEMED (v/v»). The gel was cast and once polymerised, placed
in a Hoefer electrophoresis tank filled with fresh 1 X TBE buffer. Approximately 15 !-lI
of the digested peR product with loading buffer was loaded on the gel and
electrophoresis performed at 250 V for 30 minutes at room temperature. Staining and
visualization of the gels were performed as for HEX-SSep analysis.
Electrophoresis of the digested peR products of HFE was performed on a 3% (w/v)
horizontal agarose gel [consisting of 3g agarose in 100 ml 1 X TBE (90 mM Tris-Hcl
(pH 8.0), 90 mM boric acid and 1 mM EDTA). Loading of the digested peR product,
electrophoresis and visualisation are similar as described in section 2.4.
2.7. CONSTRUCTION OF LUCIFERASE REPORTER GENE CONSTRUCTS AND
TRANSFECTION
2.7.1. Cloning and transformation
DNA samples with the various alleles of the SLC11A 1 promoter region were peR
amplified using primers 5'- agtgctagcctgcagtgccttcctctg-3' (Forward) and 5'-
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tgaagatctgccgacttcaggtactct-3' (Reverse) (Searle and Blackwell 1999). The primers
used were designed to incorporate Nhel (restriction endonuclease recognition site:
G.CTAG C) and Bg"l (restriction endonuclease recognition site: A.GATC T)
restriction sites, generating a PCR product size of 584 bp (Searle and Blackwell
1999). Following amplification, the PCR products were purified by using a PCR
purification kit (Amersham Biosciences) and dissolved in 10 ul dH20. Briefly, the GFX
column (MicroSpin™ columns pre-packed with a glass fiber matrix) was placed in a
collection tube (2 ml capless microcentrifuge tube) and 500 Jjl capture buffer
(buffered solution containing acetate and chaotrope) added to the column. The PCR
product (100 Jjl) was added to the capture buffer and mixed thoroughly by pipetting
the sample. The sample was then centrifuged at 10000 x g for 30 seconds. Following
centrifugation, the flow-through was discarded and 500 Jjl wash buffer (buffer
containing 10 mM Tris-HCI (pH 8.0), 1 mM EDTA, 80% EtOH) was added to the
column. The sample was, again, centrifuged at 10000 x g for 30 seconds and the
flow-through discarded. The GFX column was transferred to a 1.5 ml microcentrifuge
tube and 10 Jjl ddH20 added to the column. The sample was incubated at room
temperature for 1 minute and centrifuged at 10000 x g for 1 minute.
The purified PCR products and luciferase-reporter vector, the pGL2-Basic vector
(Promega) (see Figure 2.1), were digested overnight in 20 Jjl reactions with Nhel
(New England Biolabs) and BglII (Roche Diagnostics) enzymes in a 37°C water bath.
The reaction consisted of 1 U of each enzyme, 1 X buffer M [10 mM Tris-HCI (pH
7.5), 10 mM CH3COOK, 50 mM NaCI, 1 mM DTE (Roche Diagnostics)] and 10 Jjl
PCR product. A similar reaction was performed for the pGL2-Basic vector using 500
ng of the vector. After digestion, the pGL2-Basic vector was enzymatically treated by
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adding 0.3 U/~I SAP (Roche Diagnostics) (storage buffer: 25 mM Tric-HCI (pH 7.6), 1
mM MgCI2, 50% glycerol) to the reaction and incubated for 15 minutes at 37°C,
followed by incubation at 65°C for 15 minutes to inactivate the enzyme. The vector
was purified by using a PCR purification kit (Amersham Bioseiences) and dissolved
pGL2·:Baslc
Vw:r
<5596b,P)
Figure 2.1.
Legend to Figure 2.1.
Vector circle map of pGL2-Basic vector [storage buffer: 10 mM Tris-HCI (pH 7.4), 1
mM EDTA (Promega)], luc, eDNA coding firefly luciferase, SV40, DNA derived from
SV40 virus, poly(A) signal, mRNA polyadenylation signal, ori, plasmid replication
origin in Epicurian coli, Amp', gene for ampicillin resistance, f1 ori, origin of replication
derived from filamentous phage, arrow within luc, indicates direction of transcription
of the luciferase gene, arrow within f1 ori, indicates direction of ssDNA strand
synthesis.
The digested PCR products (10 1-11) was mixed with an equal volume of ficoll-orange
G loading buffer and loaded on a 1% (w/v) agarose gel. The products were resolved
at 80 V for 30 minutes in a 1 X TBE buffer and 0.01% (v/v) ethidium bromide solution
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for staining purposes. The DNA fragment was visualised by ultraviolet light
transillumination and excised from the gel with a clean, sharp scalpel.
The fragment was purified by using a GFX gel band purification kit (Amersham
Biosciences). Briefly, the gel slice was weighed in a 1.5 ml microcentrifuge tube and
10 jJl of capture buffer was added for each 10 mg of gel slice. The amount of gel slice
should not exceed 300 mg for one GFX column. The mixture was incubated at 60°C
for 10 minutes (or until the slice has completely dissolved), with vortexing every 2 to
3 minutes during the incubation. Following incubation, the sample was centrifuged
briefly to collect the sample at the bottom of the tube. To bind the DNA, the sample
was applied to the GFX column, placed in a 2 ml collection tube, incubated for 1
minute at room temperature and centrifuged at 10000 x g for 30 seconds. The flow-
through was discarded and 500 )lI wash buffer added to the column, followed by
centrifugation at 10000 x g for 30 seconds. The flow-through was discarded and the
column centrifuged at 10000 x g for 1 minute to remove residual EtOH. The GFX
column was placed into a clean 1.5 ml microcentrifuge tube and the DNA eluted by
adding 10 )lI ddH20 to the center of the membrane. The column was incubated at
room temperature for 1 minute followed by centrifugation at 10000 x g for 1 minute.
Ligation of the pGL2-Basic vector and PCR fragments, with a ratio of 1:1
(insert:plasmid), were performed by using a Rapid ligation kit (Roche Diagnostics).
Briefly, the insert DNA and vector DNA (plasmid) was dissolved in 1 X DNA dilution
buffer [20 mM Tris-HCI (pH 7.4), 1 mM EDTA, 5 mM DTE, 60 mM KCI, 50% glycerol
(v/v)] in a total volume of 10 ul. T4 DNA ligation buffer (10 ul) was added and
thoroughly mixed by pipetting. T4 DNA ligase [storage buffer: 20 mM Tris-HCI (pH
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7.4), 1 mM EDTA, 5 mM DTE, 60 mM KCI, 50% glycerol (v/v)] was added to the
mixture, thoroughly mixed and incubated for 5 minutes at room temperature. The
competent cells were transformed by adding 2 III of the ligation solution to 10 III of
XL1-Blue supercompetent cells (Stratagene's Epicurian coli competent cells) and
then incubated on ice for 30 minutes. The cells were heat-shocked at 54°C for 60
seconds and incubated on ice for 2 minutes. Following incubation, 90 III pre-warmed
SOC medium (2% tryptone (w/v), 0.5% yeast extract (w/v), 8 mM NaCI, 2.5 mM KCI,
10 mM MgS04, 0.5 mM NaOH and 0.02 M glucose) was added to the cells and
incubated for 60 min at 37°C with shaking at 250 rpm [lnnova™2100 platform shaker
(New Brunswick Scientific)). The transformed solution was plated onto a LB agar
plate [0.17 M NaCI, 1% tryptone (w/v), 0.5% yeast extract (w/v), 2% agar (w/v)),
supplemented with 50 Ilg/ml ampicillin (Roche Diagnostics), and incubated overnight
at 37°C.
After overnight incubation, colonies were picked from the plate, spread onto a master
plate (LB-agar plate with grid) and the needle placed into a 0.2 ml PCR tube
containing reagents for PCR amplification, using plasmid primers adjacent to the
insert (Forward - 5'tgtatcttatggtactgtaactg3', Reverse - 5'ctttatgtttttggcgtcttcca3').
The plates were then incubated overnight at 37°C. Successful PCR amplification was
tested on a 1% agarose gel. Colonies showing amplification was picked from the
master plate and inoculated into 50 ml LB medium [0.17 M NaCI, 1% tryptone (w/v),
0.5% yeast extract (w/v)) supplemented with 50 Ilg/ml ampicillin. This solution was
incubated overnight at 37°C with shaking at 250 rpm [Innova™2100 platform shaker
(New Brunswick Scientific)).
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Following overnight incubation and shaking, plasmid extraction was performed by
using an EndoFree plasmid maxi extraction kit (Qiagen). Briefly, the bacterial cells
were harvested by centrifugation at 6000 x g for 30 minutes at 4°C. Culture volumes
should not exceed 100 ml for high-copy plasmids and 250 ml for low-copy plasmids.
The bacterial pellet was completely resuspended in 10 ml buffer P1 (50 mM Tris-CI
pH 8.0, 10 mM EDTA, 100 ~g/ml RNase A) by vortexing. Subsequently, 10 ml buffer
P2 [200 mM NaOH, 1% SDS (w/v)] was added to the solution and mixed by
inversion, followed by incubation at room temperature for 5 minutes. A QIAfilter
cartridge was prepared by screwing the cap onto the outlet nozzle of the QIAfilter
Maxi cartridge and placed into a 50 ml Falcon tube. Following incubation of the
lysate, 10 ml chilled buffer P3 (3 M CH3COOK, pH 5.5) was added and mixed by
inverting the tube. The lysate was immediately poured into the barrel of the QIAfilter
cartridge and incubated at room temperature for 10 minutes. Following incubation,
the lysate was filtered into a 50 ml Falcon tube by removing the cap from the outlet
nozzle and the plunger gently inserted into the QIAfilter cartridge.
To the filtered lysate, 2.5 ml buffer ER (containing isopropanol and polyethylene
glycol octylphenyl ether) was added and mixed by inverting the tube. The lysate was
then incubated on ice for 30 minutes. The QIAGEN-tip 500 was equilibrated by
applying 10 ml buffer QBT [750 mM NaCI, 50 mM MOPS (pH 7.0),15% isopropanol,
0.15% Triton-X 100 (v/v)] and the column was allowed to empty by gravity flow. The
filtered lysate was added to the QIAGEN-tip and allowed to enter the resin by gravity
flow. The QIAGEN-tip was washed twice with 30 ml buffer QC [1 M NaCI, 50 mM
MOPS (pH 7.0), 15% isopropanol (v/v)] and the DNA eluted by adding 15 ml buffer
QN [1.6 M NaCI, 50 mM MOPS (pH 7.0), 15% isopropanol (v/v)]. The DNA was
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precipitated by adding 10.5 ml room temperature isopropanol, mixed by inverting the
tube and centrifuged at 5000 x g for 45 minutes at 4°C. The precipitated DNA was
washed with 70% (v/v) endotoxin-free room temperature EtOH by centrifuging at
5000 x g for 60 minutes at 4°C. The supernatant was carefully decanted and the
pellet left to air dry. The DNA was dissolved in 50 ml endotoxin-free buffer TE (10
mM Tris-CI (pH 8.0), 1 mM EDTA) and the yield determined by spectrophotometry
and/or agarose gel electrophoresis. Using the Endofree Plasmid Maxi protocol a yield
of 300 to 500 ~g for high-copy plasmids and 50 to 250 ~g for low-copy plasmids are
expected. The DNAwas concentrated at a concentration of 1 ~g/ml.
Proper orientation and insertion of the alleles were verified by automated sequencing
analysis (see section 2.8. for automated sequencing protocol), using primers Forward
- 5'tgtatcttatggtactgtaactg3', and Reverse - 5'ctttatgtttttggcgtcttcca3'.
2.7.2. Transfection
Two macrophage cell lines, THP-1 and U937, were used to investigate transcriptional
activity of the various alleles of the SLC11A1 promoter region. These cells were
cultured at 37°C in an atmosphere of 5% CO2 and 95% air in the flask, in RPMI 1640
medium (Sigma) supplemented with 10% foetal calf serum (v/v) (Sigma), 2 mM L-
glutamine (Sigma), 100 U/ml Penicillin and Streptomycin (Sigma). Transient
transfections were performed by using FUGENE 6 (Roche Diagnostics) as
transfection reagent. The various cell lines were resuspended at 2X106 cells in 2 ml
fully supplemented medium with 2 ~g of the reporter construct and 1 ~g of a control
p-galactosidase (Promega) construct. Viability of the cells were measured by staining
with a 0.4% Trypan Blue solution (v/v) (Sigma) and cells counted using a
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haemocytometer. Transfected cells were incubated at 37°G for 24 hours with or
without the addition of interferon-y [IFN-y, 0.1 1l9/1l1 (Sigma)], bacterial
lipopolysaccharide [LPS, 10 ng/ml (Sigma)], interferon-y (0.1 1l9/1l1) and bacterial
lipopolysaccharide (10 ng/ml), and ferric ammonium citrate (FAG, 200 Ilg/ml),
respectively.
Following incubation, the cells were harvested and lysed using a luciferase assay
system (Promega). Briefly, the cells were collected in a 2 ml microcentrifuge tube and
centrifuged at 200 x g for 5 minutes at room temperature. The growth medium was
removed and the cells rinsed with 1 X PBS [137 mM NaGI, 2.7 mM KGI, 4.3 mM
Na2HP04, 1.4 mM KH2P04 (pH 7.3)], followed by centrifugation at 200 x g for 5
minutes. The supernatant was removed and the cells resuspended in 1 X reporter
lysis buffer [25 mM Tris-phosphate (pH 7.8), 2 mM DIT, 2 mM 1,2-
diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol (v/v), 1% Triton X-100
(v/v)). The cells were briefly centrifuged and the supernatant transferred to a new 2
ml microcentrifuge tube. Luciferase activity was measured using a luciferase assay
reagent (Promega) where 20 III of cell lysate was added to 100 III assay lysis buffer
and relative light units (RLU) read in a luminometer (Turner Designs Luminometer
Model TO-20/20).
The j3-galactosidase assay was performed on 100 III cell lysate in 1650 III buffer
containing 20 mM Na2HP04 (pH 7.8), 2 mM KGI, 0.2 mM Mg2S04, 0.54 ml/Ij3-ME, 4
mg/ml ONPG and 285 mM Na2G03.The cell suspension was incubated at 37°G for
30 minutes followed by spectophotometry (absorbance measured at 420 nm). Protein
assays were performed with. the protein assay ESL (exact, sensitive and low
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interference) kit (Roche Diagnostics). Briefly, a series of standards were prepared to
cover an appropriate concentration range by diluting the BSA protein standard in the
same diluent as the unknown sample. Reagent A (alkaline copper tartrate solution)
(100 Ill) was added to 50 III of sample in a 1.5 ml microcentrifuge tube and mixed.
The tubes were incubated for at least 5 minutes at 15 to 25°C. Reagent B (ascorbic
acid, bathocuproine disulfonic acid solution) (1000 Ill) was subsequently added,
mixed briefly and the absorbance was measured at 485 nm after exactly 30 seconds.
The concentration was calculated against a standard calibration curve. Relative light
units of luciferase activity were normalized against the protein concentration and ~-
galactosidase readings for each construct within an experiment. These experiments
were performed three times with triplicate transfections for each construct and set of
conditions within each experiment.
2.8. AUTOMATED SEQUENCING
Automated DNA sequencing was performed using the same primers as for HEX-
SSCP, dHPLC and RFLP analysis as indicated in Tables 2.1 and 2.2. The PCR
products were purified by using a PCR purification kit (Amersham Biosciences). The
purified product (3 Ill) was added to a reaction mix consisting of 4 ill termination
ready reaction mix [BigDye® Terminator v3.1 cycle sequencing kit (Applied
Biosystems)] and 3.3 pmol primer. This was followed by cycle sequencing on a 2400
Perkin Elmer PCR cycler. The cycle program was as follows: .an initial denaturation
step at 96°C for 2 minutes, followed by 25 cycles of denaturation at 96°C for 20
seconds, annealing at 55 °C for 20 seconds and an extension at 60°C for 4 minutes.
66
Stellenbosch University http://scholar.sun.ac.za
Following cycle sequencing, the products were cleaned by spun-column
chromatography using Centri-sep columns (Applied Biosystems). After spun-column
chromatography, 2 X the volume MgCI2 (20 j.Jg/ml) and 60% EtOH (v/v) were added
to the products. The solution was left on the bench for 10 to 15 minutes, followed by
centrifugation for 15 to 20 minutes at 10000 x g. The supernatant was removed and
the pellet left to air-dry. HiDi formamide (Applied Biosystems) was added to the dry
pellet and the products were loaded on an ABI Prism 3100 genetic analyser (Applied
Biosystems) automated sequencer. Following electrophoresis, analysis of
electropherograms was performed by using sequencing analysis software supplied
by Applied Biosystems.
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T bl 2 4 AI h b ti r f II d h . I I t d th . ra e .. Ipl a e IC ISt0 genera ly use c erruca s reagen s an eir suppliers
Chemical/Reagent Supplier
AA Merck
Agar Sigma
agarose Promega
APS Promega
~-ME BDH
BAA Promega
Boric acid Promega
Bromophenol blue Sigma
Chloroform Merck
dNTPs (dATP, dDP, dCTP, dGTP) Promega
EDTA Sigma
EtOH Merck
Ficoll Sigma
Formamide (De-ionised) Merck
Glucose Merck
Isopropanol Merck
KCI BDH
KHC03 Merck
KH2P04 Merck
Mg2S04 Sigma
NaCI Sigma
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Table 2.4. Alphabetic list of generally used chemicals/reagents and their suppliers
(Continued)
Chemical/Reagent Supplier
Na2C03 Sigma
Na2HP04 SOH
NaOH Merck
NH4CI SOH
ONPG Sigma
Orange G Merck
SOS Merck
TEAA Transgenomics
TEMEO Promega
Tris-HCI Promega
tryptone Sigma
Urea Promega
Xylene cyanol Sigma
Yeast extract Sigma
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CHAPTER3
METHODS, RESULTS AND DISCUSSION
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3.1. Differential expression of allelic variants of the 5' -(GT)n repeat in the promoter
region of the SLC11A1 gene upon iron loading: Detection of an opposite allelic
effect in the presence of the -237C~ T polymorphism
3.1.1. ABSTRACT
Association of various autoimmune and infectious diseases with genetic variation in the
solute carrier family 11 member 1 (SLC11A 1) gene is in accordance with its role in iron
metabolism and immune function. In this investigation in vitro studies were performed to
determine whether allelic variants in the promoter region of the gene is affected by iron
loading, thereby leading to differential expression of SLC11A 1. Constructs containing
five different SLC11A 1 5'-(GT)n polymorphic alleles identified in the South African
population (alleles 2, 3, 5, 8 and 9) and a C to T point mutation at nucleotide position -
237, both in the absence and presence of allele 3, were cloned into the pGL2-Basic
luciferase-reporter vector and transfected into U937 and THP-1 cells. Addition of
exogenous stimuli, including interferon-y, bacterial lipopolysaccharide and ferric
ammonium citrate, demonstrated significant differences in the ability of these alleles to
regulate gene expression. Striking differences were obtained upon iron loading, with
allele 3 showing opposite effects in the presence or absence of promoter polymorphism
-237C~ T. Our findings provide direct evidence that this promoter polymorphism is
functional and support the hypothesis that iron dysregulation mediated by allelic effects
of SLC11A 1 underlies disease susceptibility linked to infectious and autoimmune
conditions.
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3.1.2. INTRODUCTION
The solute carrier family 11 member 1 gene (SLC11A1) has been linked to various
autoimmune and infectious diseases (reviewed by Blackwell et al 2003). The multiple
pleiotropic effects of SLC11A 1 associated with macrophage activation (Blackwell 1996)
are potentially important for induction and maintenance of autoimmune diseases and
crucially important in resistance to intramacrophage pathogens. The effects on
macrophage function include enhanced chemokine KC, tumour necrosis factor a,
interleukin 113, inducible nitric oxide synthase, and MHC class" expression.
Blackwell and co-workers (2000) recently speculated that regulation of iron by SLC11A 1
might underlie the allelic association with various autoimmune and infectious diseases.
Conclusive evidence has been provided that the Z-DNA forming repeat in the promoter
region of the human SLC11A 1 represents a functional polymorphism that correlates with
infectious and autoimmune disease susceptibility (Searle and Blackwell 1999). The two
most common variants designated alleles 2 [t(gt)sac(gt)sac(gt)10ggcaga(g)61 and 3
[t(gt)sac(gt)sac(gt)gggcaga(g)61, showed a similar degree of enhancement of reporter
gene expression in the presence of interferon-y (IFN), while addition of bacterial
lipopolysaccharide (LPS) caused significant reduction in expression driven by allele 2
and enhanced expression driven by allele 3. These results were in accordance with the
hypothesis that chronic hyperactivation of macrophages associated with SLC11A 1allele
3 is functionally linked to autoimmune disease susceptibility, while the poor level of allele
2 expression contributes to infectious disease susceptibility. The likelihood that allele 3
would conversely protect against infectious disease and allele 2 against autoimmune
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disease, was supported by data from Kotze et a/ (2001), who compared the allele
frequencies of the promoter variant between different age groups. SLC11A 1 alleles
considered to be detrimental in relation to autoimmune disease susceptibility appear to
be maintained in the population as a consequence of improved survival to reproductive
age following infectious disease challenge, as previously suggested by Searle and
Blackwell (1999). A single base-pair substitution has also been reported at position -236
in the promoter region of the SLC11 A 1 gene (Lewis et a/1996) but to our knowledge, in
vitro studies involving this polymorphism have thus far not been investigated.
Sequencing data obtained in our laboratory consistently identified an additional G
residue between position -167 and -169 (numbered according to the sequence
published by Lewis et a/1996) and therefore this polymorphism occurs at position -237
(du Plessis 2000).
The involvement of SLC11A1 in many clinically distinct autoimmune and infectious
diseases may suggest a mechanistic continuum of the same disease process involving
iron dysregulation. This notion was substantiated by reports on abnormalities of iron
metabolism (Weber et a/ 1988, Nielsen et a/ 1994) in arthritic conditions shown to be
associated with genetic variation in the SLC11 A 1 gene (Shaw et a/1996, Sanjeevi et a/
2000, Singal et a/ 2000, Yang et a/ 2000), which may be linked to defective iron supply
for erythropoiesis (Cazzola et a/1996).
In an attempt to demonstrate a possible direct relation of SLC11A 1 alleles with cellular
iron status, functional studies were performed in this study to test for differential
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expression of allelic variants of the Z-DNA forming promoter polymorphism upon iron
loading. The potential effect of the -237C~ T polymorphism was also investigated.
3.1.3. MATERIALS AND METHODS
The study protocol was approved by the Ethics Review Committee of the University of
Stellenbosch.
3.1.3.1. Methods
ij Plasmid construction
DNA samples of individuals harboring five different allelic variants (alleles 2, 3, 5, 8 and
9) (Table 3.1.1) of the 5'-(GT)n repeat polymorphism in the SLC11A1 gene, and an
individual with the -237C~ T polymorphism occurring in cis with allele 3, were available
for this study. These were used as templates to generate six different luciferase reporter
gene constructs cloned into the pGL2-Basic vector (Promega), using oligonucleotide
primers as previously described (Searle and Blackwell 1999). All the constructs
constitute alleles of the SLC11A1 Z-DNA forming repeat promoter polymorphism, with
plasmid construct allele 3/-237T incorporating the T-allele at nucleotide position -237 in
association with allele 3. Alleles 2, 3 and 5 have been described previously and are
designated as published (Blackwell et al 1995, Graham et al 2000), with numbering of
new variants detected in this study following consecutively. The alleles were cloned into
the vector using standard procedures and the DNA purified by using an endotoxin-free
plasmid DNA extraction kit (EndoFree Plasmid Maxi Kit - Qiagen). Proper orientation
and insertion of the various alleles were verified by sequencing analysis.
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Table 3.1.1. Variants incorporated into the pGL2-Basic vector
ALLELE VARIANTS REFERENCE
Allele2 t(gt)sac(gt)sac(gt)1oggcaga(g)6 Blackwell et a/1995
Allele3 t(gt)sac(gt)sac(gt)gggcaga(g)6 Blackwell et a/1995
Allele5 t(gt)4ac(gt)sac(gt) 1oggcaga(g)6 Graham et a/2000
Allele8 t(gt)sac(gt)sac(gt)6ggcaga(g)6 M. Zaahl, unpublished data
Allele 9 t(gt)sac(gt)sac(gt)aggcaga(g)6 M. Zaahl, unpublished data
Allele 3/-237TII' t(gt)sac(gt)sac(gt)gggcaga (g)sI-237TII' Blackwell et a/ 1995, Lewis
et a/1996
#,Previously designated -236C~ T (Lewis et a/1996)
ii) Transfection and luciferase activity
Myeloid lineage cell lines U937 and THP-1 were maintained in RPMI-1640 (Sigma)
supplemented with 10% fetal calf serum (Sigma) and 2 mmol/I L-glutamine (Gibco).
These cells were cultured at 37°C in an atmosphere of 5% CO2 and 95% air in the flask.
Transient transfections were performed by using FUGENE 6 (Roche Diagnostics) as
transfection reagent. The various cell lines were resuspended at 2X106 cells in 2 ml fully
supplemented medium with 2 j..lg of the reporter construct and 1 j..lg of a control f3-
galactosidase (Promega) construct. Viability of the cells were measured by staining with
a 0.4% Trypan Blue solution (Sigma) and cells counted using a haemocytometer.
Transfected cells were incubated at 37°C for 24 hours with or without the addition of
interferon-y (IFN-y, 0.1 j..lg/j..ll)(Sigma), bacterial lipopolysaccharide (LPS, 10 ng/ml)
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(Sigma), interferon-y (0.1 ~g/~l) and bacterial lipopolysaccharide (10 ng/ml), and ferric
ammonium citrate (FAG, 200 ~g/ml) (Sigma), respectively.
Following incubation, the cells were harvested and lysed using a reporter lysis buffer
(Promega). Luciferase activity was measured using a luciferase assay reagent
(Promega) where 20 ~I of cell lysate was added to 100 ~I of assay buffer and relative
light units (RLU) read in a luminometer. The f3-galactosidase assay was performed on
100 ~I of cell lysate in 1650 ~I of buffer containing 20 mM Na2HP04 (pH 7.8) (SOH), 2
mM KGI (SOH), 0.2 mM Mg2S04 (Sigma), 0.54 mill f3-mercaptoethanol (SOH), 4 mglml
ONPG (o-nltrophenyl-Bë galactopyranoside) (Sigma) and 285 mM Na2G03 (Sigma).
The cell suspension was incubated at 37°G for 30 minutes followed by
spectrophotometry (absorbance measured at 420 nm). Protein assays were performed
with the protein assay ESL (exact, sensitive and low interference) kit (Roche
Diagnostics). Absorbance was measured at 485 nm and the concentration calculated
against a standard calibration curve. Relative light units of luciferase activity were
normalised against the protein concentration and f3-galactosidase readings for each
construct within an experiment. These experiments were performed three times with
triplicate transfections for each construct and set of conditions within each experiment.
3.,1.3.2. Statistical analysis
Statistically significant differences between constructs and treatments were tested by
the two tailed unpaired Student's t test. A probability value smaller than 0.05 was
regarded as statistically significant.
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3.1.4. RESULTS
Various transcription factor binding sites and response elements have been identified in
the promoter region of the SLC11A 1 gene (Blackwell et al 1995) and incorrect
functioning of these elements and enhancers can result in altered gene expression. In
order to investigate the effect of the various Z-DNA forming repeats and the -237C~ T
polymorphism on promoter activity, different constructs (Table 3.1.1) were generated in
the pGL2-Basic vector. The ability of various alleles of the SLC11A 1 Z-DNA forming
promoter repeat polymorphism to drive reporter gene expression was measured with
and without the addition of exogeneous stimuli. The mean and standard error for
triplicate points obtained over three independent transfection experiments is shown in
Figure 3.1.1.
In the absence of exogeneous stimuli: Expression was observed for all of the constructs.
Higher levels of reporter gene expression were observed for allele 3 compared to the
remaining alleles. Statistically significant differences were observed for allele 3
compared to allele 2 (p<O.05). Alleles 9 (p<O.05) and 3/-237T (p<O.05) also differed
significantly compared with allele 2.
Addition of interferon-y (IFN-y): Enhanced luciferase expression with the addition of IFN-
y as an exogeneous stimulus caused an increase in gene expression for all six
constructs. No statistically significant differences were observed between constructs.
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However, increases in reporter gene activity within the constructs were significant for
alleles 2 (p<O.05) and 3/-237T (p<O.04) compared with no stimuli.
Allele 2 Allele 3 Allele 5 Allele 8 Allele 9 Allele 3/-
237T
Cl) 2::::J Ono stimuli'ii> DIFN
"C
Cl) 1.5 DIFN+LPS.!
ca .LPS
E.... .FAC0 1c:
SLe11 A 1 promoter variants
Figure 3.1.1.
Legend to Figure 3.1.1.
SLC11A 1 promoter variants transfected into U937 cells. The effect of ferric ammonium
citrate (FAC) on levels of luciferase reporter gene activity driven by three polymorphic
alleles for SLC11A1 detected, in relation to interferon-y (IFN) and bacterial
lipopolysaccharide (LPS) enhanced expression, is illustrated. The mean (SO)
normalised values obtained over three independent experiments, including triplicate
transfections for each experiment, are graphed for SLC11 A 1 constructs. Similar results
were obtained for these variants transfected into THP-1 cells.
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Addition of interferon-y (IFN-y) and bacterial lipopolysaccharide (LPS): The addition of
LPS as a second exogeneous stimulus with IFN-y results in further enhancement of
gene expression for alleles 3, 5 and 8, and causes a reduction in alleles 2, 9 and 3/-
237T allele driven response, compared to the addition of IFN-y alone. Compared to
allele 3 activity, statistically significant differences were observed for alleles 2 (p<O.03), 5
(p<O.05), 9 (p<O.02) and 3/-237T (p<O.02). Statistically significant differences were also
observed for alleles 2 (compared to no stimuli, p<O.05) and 3/-237T (compared to the
addition of IFN-y alone, p<O.04) within the constructs.
Addition of bacterial lipopolysaccharide (LPS): In the presence of LPS alone, an
increase in luciferase activity was observed for alleles 3 and 5, and a decrease for
alleles 2, 8, 9 and 3/-237T, compared to the addition of IFN-y and LPS. Compared with
allele 3, statistically significant differences were observed for alleles 2 (p<O.04), 8
(p<O.04), 9 (p<O.05) and 3/-237T (p<O.02). Within the various constructs, significant
differences were observed for alleles 3 (addition of IFN-y and LPS compared to LPS
alone, p<O.03), 9 (addition of IFN-y compared with LPS alone, p<O.04) and 3/-237T
(addition of IFN-y compared with LPS alone, p<O.05).
Addition of ferric ammonium citrate (FAC): The addition of FAC caused an increase in
luciferase activity for alleles 2, 3, 5 and 9, and a decrease in activity for allele 3/-237T,
compared to no stimuli. Activity observed for allele 8 with the addition of FAC was similar
compared to no stimuli. Significant differences were observed for all constructs
compared to allele 3 FAC activity with p<O.006 for allele 2, p<O.02 for allele 5, p<O.009
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for allele 8, p<0.02 for allele 9 and p<0.01 for allele 3/-237T. Allele 5 FAC activity was
also statistically significant compared to alleles 2 (p<0.05) and 3/-237T (p<0.05).
Significant differences within the various constructs were observed for alleles 3
(compared with no stimuli, p<0.05; compared with IFN-y activity, p<0.01), 5 (compared
with no stimuli, p<0.05), 9 (compared with LPS activity, p<0.05) and 3/-237T (compared
with IFN-y activity, p<0.02).
Compared to no stimulus, an increase for all the treatments were observed for the
various alleles except for alleles 9, with the addition of IFN-y and LPS, and LPS alone,
and 3/-237T with the addition of LPS and FAC respectively. Similar expression was
observed for alleles 8, with the addition of FAC, and 3/-237T, with the addition of IFN-y
and LPS, compared to no stimulus. Similar results were observed when transfecting the
various plasmid constructs into THP-1 cells. The results are consistent with findings
previously described for alleles 2 and 3 (Searle and Blackwell 1999). However, these
authors have not determined the effect of FAC on luciferase gene expression.
3.1.5. DISCUSSION
The various statistical comparisons performed are shown in Table 3.1.2 and 3.1.3. The
most striking observation made in this study was the opposite effects mediated by allele
3 of the SLC11 A 1 5'-(GT)n repeat in the presence or absence of the T-allele of the
polymorphism at nucleotide position -237. High expression associated with allele 3 of
the SLC11 A 1 gene in the absence of this sequence variant is in accordance with its role
in autoimmune disease susceptibility.
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Table 3.1.2. Statistical comparisons following addition of different stimuli to the various
I ·f rt tructs i r t dUCIerase repo er cons s mves Iga e
Associations within *p-value
constructs
Stimuli Allele 2 Allele 3 Allele 5 Allele 8 Allele 9 Allele 3/-237T
No stimuli vs IFN-y 0.05 0.22 0.31 0.27 0.30 0.04
No stimuli vs IFN-y+LPS 0.05 0.08 0.20 0.22 0.25 0.45
No stimuli vs LPS 0.19 0.10 0.30 0.39 0.13 0.19
No stimuli vs FAG 0.32 0.05 0.05 0.48 0.26 0.28
IFN-y vs IFN-y+LPS 0.36 0.20 0.35 0.38 0.14 0.04
IFN-y vs LPS 0.27 0.14 0.36 0.31 0.04 0.05
IFN-y vs FAG 0.12 0.01 0.13 0.29 0.36 0.02
IFN-y+LPS vs LPS 0.37 0.03 0.45 0.25 0.07 0.20
IFN-y+LPS vs FAG 0.16 0.31 0.21 0.23 0.16 0.17
FAG vs LPS 0.34 0.10 0.37 0.46 0.05 0.40
*Statlstlcal analysis performed uSing the Student's unpaired t test; statistically significant
associations are indicated in red
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Table 3.1.3. Statistical comparisons between the luciferase reporter constructs following
addition of different stimuli
Associations *p-value
between constructs
Treatment Allele 2 vs Allele 2 vs Allele 2 vs Allele 2 vs Allele 2 vs
Allele 3 Allele5 Allele 8 Allele 9 Allele 3/-
237T
No stimuli 0.05 0.28 0.29 0.05 0.05
IFN-y 0.17 0.35 0.43 0.40 0.15
IFN-y+LPS 0.03 0.36 0.28 0.25 0.37
LPS 0.04 0.35 0.39 0.26 0.28
FAC 0.006 0.05 0.42 0.12 0.05
Allele 3 vs Allele 3 vs Allele 3 vs Allele 3 vs
Allele 5 Allele 8 Allele 9 Allele 3/-
237T
No stimuli 0.19 0.20 0.37 0.25
IFN-y 0.12 0.37 0.21 0.49
IFN-y+LPS 0.05 0.41 0.02 0.02
LPS 0.20 0.04 0.05 0.02
FAC 0.02 0.009 0.02 0.01
Allele 5 vs Allele 5 vs Allele 5 vs
Allele 8 Allele 9 Allele 3/-
237T
No stimuli 0.49 0.24 0.33
IFN-y 0.36 0.27 0.10
IFN-y+LPS 0.33 0.20 0.28
LPS 0.39 0.26 0.27
FAC 0.11 0.40 0.08
Allele 8 vs Allele 8 vs
Allele 9 Allele 3/-
237T
No stimuli 0.26 0.35
IFN-y 0.47 0.38
IFN-y+LPS 0.23 0.27
LPS 0.17 0.19
FAC 0.18 0.49
Allele 9 vs
Allele 3/-
237T
No stimuli 0.33
IFN-y 0.19
IFN:y_+LPS 0.31
LPS 0.46
FAC 0.16
*Statistical analysis performed using the Student's unpaired t test; statistically significant
associations are indicated in red
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However, in the presence of the -237C~ T variant low gene expression of allele 3 is
obtained comparable to that of allele 2, known to have a protective effect against
autoimmunity while conversely predisposing to infectious diseases. Compared to allele 2
gene expression, even lower expression was observed for allele 3 in association with
the -237C~ T polymorphism for treatments with IFN-y and LPS, and LPS alone. Several
IFN-y and LPS-related response elements are in close proximity of the -237C~ T
polymorphism, suggesting that this polymorphism directly influence these response
elements. Further studies are warranted to assess the in vivo significance of this allelic
effect in relation to disease association, since occurrence of linkage disequilibrium may
lead to failure to detect a true disease association with the SLC11A 1gene.
Differential expression was observed without the addition of an exogeneous stimuli
indicating that the promoter repeat polymorphism acts as an enhancer element, as
previously suggested (Searle and Blackwell 1999). Enhanced expression for all the
constructs studied were observed with the addition of IFN-y and is consistent with the
occurrence of multiple interferon response elements both 5' and 3' of the repeat
polymorphism, therefore being important in up regulating gene expression. The addition
of LPS caused differential expression of the gene with an up regulation in gene
expression for alleles 3 and 5 and down regulation of alleles 2, 8, 9 and 3 in association
with the -237C~ T polymorphism (3/-237T), compared to the addition of IFN-y and LPS,
suggesting that the LPS related response elements (NFKB, AP-1 and NF-IL6) are
differentially affected by the various alleles. SIc11a1 expression was also shown to be
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regulated by GMCSF (Brown et a/1995), IFN-y (Brown et a/1995, Govoni et a/1'996,
Brown et a/1997) and LPS (Govoni et a/1996) in mice.
The addition of FAC caused an up-regulation in gene expression for alleles 2,3,5 and 9
and a down regulation in gene expression for allele 3 in association with the -237C~ T
polymorphism, compared with no stimulus. This is the first study demonstrating a direct
influence of iron loading on the naturally occurring alleles of the SLC11A 1 5'-(GT)n
promoter repeat polymorphism. It thus appears that the SLC11A 1 promoter is sensitive
to changes in iron levels thereby affecting expression of the SLC11 A 1 gene, but it
remains unclear whether variation in the promoter region causes the imbalance in iron
locally by altering iron recycling/homeostasis in macrophages, or whether the imbalance
of iron in the environment influences SLC11A 1 expression and therefore any associated
pleiotropic effects. No conventional iron responsive elements (IRE) were thus far
identified in the promoter region of SLC11 A 1. The effect of the -237C~ T polymorphism
on allele 3 expression raises the possibility that this sequence change affects a putative
transcription factor-binding site. Unrecognised IREs could also be in close proximity of
the -237C~ T polymorphism, thereby influencing allele 3 expression and mRNA
translation or stability.
Although the association with disease susceptibility may be related to the many
pleiotropic effects of this gene' on macrophage function (Searle and Blackwell 1999,
Marquet et a/ 1999), our data provide additional evidence that its involvement in iron
transport may contribute directly to the disease phenotype, possibly via the effect of iron
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on pathogen survival, intracellular signalling pathways and/or mRNA stability (Searle
and Blackwell 1999). Iron has to be immediately available for mounting a successful
immunological defence, but at the same time be effectively unavailable to the invading
pathogen (Weiss 2002). It therefore seems likely that the continuous battle for iron
between the host and invading pathogens known to result in cytokine-mediated
responses, could play an important role in the context of infectious and autoimmune
disease susceptibility linked to the SLC11A 1 gene. Our findings provide direct support
for the hypothesis that iron dysregulation may underlie the allelic association of the
functional SLC11A1 promoter polymorphism with infectious and autoimmune disease
susceptibility.
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3.2. Association of functional polymorphisms of SLC11A 1 with risk of
oesophageal cancer in the Coloured population of South Africa
3.2.1. ABSTRACT
Several environmental factors, including smoking and alcohol, dietary factors,
mycotoxins, nitrosamines, infection and chronic inflammation, have been implicated in
the aetiology of oesophageal cancer (OC). Excess iron also leads to enhanced tumour
growth. The purpose of this study was to assess the likelihood that variation in the
SLC11A 1 gene contributes to OC susceptibility, possibly due to its role in inflammation
and iron metabolism. The regions of the gene containing potential functional
polymorphisms, including the promoter region and exon 2, were investigated. The study
cohort included 105 OC patients with squamous cell carcinoma (SCC) and 110
population-matched controls. A significantly decreased frequency of the -237C~ T
promoter polymorphism was observed in the patient group with OC compared with the
population-matched control group (p<0.002, X2 with Yates' correction = 7.87). A
statistically significant disease association was also observed with allele 3 of the 5'-
(GT)n promoter polymorphism (p<0.0006, X2 with Yates' correction = 10.16), but only in
the absence of the T-allele at nucleotide position -237 following allelic stratification.
Several novel variants were identified in intron 1 (lVS 1-28C~ T) and exon 2 (112G~A,
148deiGACCAGCCC, 157insGACCAGCCCAG). A novel intronic polymorphism, IVS1-
28C~ T, was also significantly associated with OC (p<0.05, X2 with Yates' correction =
2.52). We demonstrate association of genetic variation in both the promoter region and
intron 1 of the SLC11A 1gene with OC susceptibility.
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3.2.2. INTRODUCTION
Oesophageal cancer (OC) occurs at high frequencies in certain areas of the world and is
more prevalent in males than in females (Blot 1994). Differences have also been
observed between racial backgrounds, with squamous cell carcinoma (SCC) occurring
more often in Blacks and adenomacarcinoma (ADC) being more prevalent in Whites.
Several risk factors contribute to the development of squamous cell carcinoma and of
these factors, cigarette smoking and alcoholic beverage consumption is the major
determinants (IARC 1986, 1988, Blot 1994). Other factors contributing to a lesser extent
includes diet and nutrition, mycotoxins, nitrosamines, infectious agents, repeated
oesophageal injury and chronic inflammation. (Selikoff et a/1979, Van Rensburg 1981,
Norell et a/1983, Hille et a/1985, Steinmetz and Potter 1991, Blot 1994, Gustavisson et
a/1993, Orlando 2002). Iron overload has previously been implicated as a possible risk
factor in the development of OC (Mandishana et a/ 1998) and evidence for the
involvement of iron in OC was illustrated in a rat model where OC developed as a
consequence of iron supplementation (Goldstein et a/1998, Chen et a/1999, 2000).
The SLC11A 1 gene is associated with susceptibility to various autoimmune and
infectious diseases (reviewed by Blackwell et a/2003) and has been shown, in mice, to
function as a metal ion transporter that is regulated by and regulates cellular iron levels
(Atkinson et a/1997, Atkinson and Barton 1998, Goswami et a/2001). A 5'-(GT)n repeat
polymorphism in the promoter region of the SLC11A 1 gene was shown to affect levels of
gene expression (Searle and Blackwell 1999). /n vitro promoter studies of this repeat
suggested direct contribution of alleles to autoimmune (allele 3) and infectious (allele 2)
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disease susceptibility (Blackwell et a/ 2000, Searle and Blackwell 1999). The 5'-(GT)n
repeat was also differentially expressed in the presence of ferric ammonium citrate and
these findings further supports the hypothesis that iron dysregulation may underlie the
allelic association of the functional SLC11A 1 promoter polymorphism with infectious and
autoimmune disease susceptibility (chapter 3.1). A potentially functional polymorphism
was also identified in exon 2 of the SLC11A 1 gene and comprises deletion of a nine-
nucleotide repeat in the N-terminal proline/serine-rich putative SH3 binding domain
(Barton et a/1994, White et a/1994, Blackwell et a/2000).
Due to the role of SLC11A 1 in iron regulation and inflammatory diseases, we examined
functional polymorphisms in the promoter region and exon 2 of the SLC11A 1gene in the
Coloured South African OC population. Association studies were performed to
investigate the likelihood that the gene, as a potential susceptibility or modifier locus,
may be involved in OC pathogenesis.
3.2.3. MATERIALS AND METHODS
The study protocol was approved by the Ethics Review Committees of the Universities
of Stellenbosch and Cape Town.
3.2.3.1. Subjects
Blood samples were 'obtained from 105 unrelated patients with squamous cell
carcinoma of the oesophagus, including 82 male and 23 female. These patients had
been referred to clinics at the Grootte Schuur and Tygerberg Hospitals in Cape Town.
Patients with OC present with symptoms such as difficulty to swallow and loss of weight.
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These patients were referred for a barium swallow followed by biopsies in the theatre to
confirm the presence of an ADC or SCC on the basis of the histology (Hermanek and
Sobin 1987). In a questionnaire completed by the individuals included in the study,
possible environmental risk factors of OC were denoted, including cigarette smoking,
alcohol drinking, family history of cancer and occupation. Blood extracted DNA samples
from 110 (43 male and 67 female) normal, unrelated population-matched individuals
were included as controls. Control individuals were recruited at the Tygerberg Hospital.
The study population included individuals from the South African "Coloured" population,
referring to individuals of mixed ancestry (Loubser et al 1999), including San, Khoi,
Madagascar, Javanese and European origin, from the Western Cape.
3.2.3.2. Experimental procedures
DNA extraction was performed on whole blood using standard techniques (Miller et al
1988). Polymerase chain reaction (PCR) amplification was performed on the promoter
region (Kotze et al 2001) and exon 2 (forward primer - 5'gtgacaagggtccccaa3'; reverse
primer - 5'atcccagacacaaaaccg3') of the SLC11A1 gene. The PCR products of the
promoter region (467-bp) and exon 2 (143-bp) were subjected to a combined
heteroduplex single-strand conformation polymorphism (HEX-SSCP) method according
to Kotze et al (1995). These PCR products were resolved on a 12% polyacrylamide gel
supplemented with 7.5% urea at 4°C (350 V) for 18 hr. In order to better discriminate
between the. different alleles of the 5'-(GT)n repeat polymorphism in the promoter region
of the gene, a 116-bp PCR product was generated (Kotze et al 2001) and subjected to
restriction fragment length polymorphism (RFLP) analysis using Rsal (Graham et al
2000). The digested PCR product was resolved on a 10% polyacrylamide gel at room
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temperature (250V) for 30 minutes. Following electrophoresis, the gels were stained
with ethidium bromide and the DNA visualised by ultraviolet light transillumination. Semi-
automated DNA sequencing was performed on PCR products demonstrating unique
mobility or conformational variants in the polyacrylamide gels, using an ABI 3100 PRISM
automated sequencer.
3.2.3.3. Statistical analysis
Allele and genotype frequencies were estimated by allele counting and statistical
differences between patient and control groups were tested for significance by the
Fisher exact test and/or chi-squared (X2) analysis with Yates' correction. A probability
value smaller than 0.05 was regarded as statistically significant. The Hardy-Weinberg
equilibrium was performed to test equilibrium for the genetic traits investigated in the
respective populations.
Allelic stratification applied in this study was based on previous findings (chapter 3.1),
demonstrating an opposite allelic effect for allele 3 (similar to that of allele 2) upon iron
loading when occurring in association with the -237C~ T polymorphism. Therefore,
when allele 3 occurred together with the T-allele of the -237C~T polymorphism, this
allelic combination was grouped with allele 2 for further statistical analysis.
3.2.4. RESULTS
Our study population included 82 (78%) males and 23 (22%) females with a mean age
of 61 years and 59 years respectively (Table 3.2.1), with the majority of patients being
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older than 50 years (63% male and 65% female). Additional data was available for only
45 (54%) male and 15 (65%) female OC patients and all of these patients were cigarette
smokers with an average of 10 cigarettes per day. Of these cigarette smokers, 9 of 60
(15%) (male: 6 of 45, 13.33%; female: 3 of 15,20%) were only smokers, 31 of 60 (52%)
(male: 27 of 45, 60%; female: 4 of 15, 26.67%) additionally consumed alcoholic
beverages (including both beer (shop-bought) and wine or spirits), 15 of 60 (25%) (male:
8 of 45, 17.78%; female: 7 of 15,46.67%) additionally consumed only beer and 5 of 60
(8%) (male: 4 of 45,8.89%; female: 1 of 15 6.67%) additionally consumed only wine or
spirits. Information concerning occupation was available for only 32 males and 15
females with the majority of the males being laborers (16 of 32,50%), farm workers (10
of 32,31%) and gardeners (6 of 32, 19%) and females being domestic workers (7 of 15,
47%) and housewifes (6 of 15, 40%). The OC patients were all from the Western Cape
and are localised within the region as shown in Figure 3.2.1.
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Table 3.2.1. Characteristics of OC patients
Patients with oe
Male (n=82) Female (n=23)
Mean Age ± *s.e. (range) 61 ± 1.41 (37-89) 59 ± 2.75(39-85)
Unknown 12 (14.6%) 3 (13%)
Alcoholic consumption
(Beer)
Weekly 18 (21.95%) 7 (30.43%)
Daily 8 (9.76%) 3 (13.04%)
Seldom 9 (10.98%) 1 (4.35%)
Never 10 (12.19%) 4 (17.39%)
Unknown 37 (45.12%) 8 (34.78%)
Alcoholic consumption
(Wine/Spirits)
Weekly 15 (18.29%) 2 (8.70%)
Daily 10 (12.20%) 2 (8.70%)
Seldom 6 (7.32%) 1 (4.35%)
Never 14 (17.07%) 10 (43.48%)
Unknown 37 (45.12%) 8 (34.78%)
Cigarette Smoking 45 (54.88%) 15 (65.22%)
Unknown 37 (45.12%) 8 (34.78%)
*s.e., standard of mean
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a.... COC8M
Figure 3.2.1.
Legend to figure 3.2.1.
Area of high incidence of OC in the Western Cape are shown (green) and possible
environmental factors contributing to OC should be considered within this region.
Mutation analysis of the promoter region of the SLC11A 1 gene using a combined HEX-
SSCP method revealed two previously-documented polymorphic residues, including -
237C~T (Lewis et al 1996) and -8G~A (Cashmore T, unpublished data). The -
237C~ T polymorphism was identified in both a heterozygous state [4 of 105 (3.81%)
OC patients and 20 of 110 (18.18%) population-matched control individuals] and
homozygous state [1 of 105 (0.95%) OC patients and 1 of 110 (0.91%) population-
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matched control individuals). The -8G~A variant was identified only in a heterozygous
state in 1 of 82 (1.22%) male OC patients and in 2 of 43 (4.65%) male control
individuals. By investigating the 5'-(GT)n promoter repeat polymorphism using RFLP
analysis, we only identified three previously described alleles, including alleles 2, 3
(Blackwell et a/1995) and 5 (Graham et a/2000) in the study population.
Mutation analysis of intron 1/exon 2 of the SLC11A 1 gene using a combined HEX-SSCP
method revealed four novel variants (112G~A, IVS1-28C~T, 148deiGACCAGCCC and
157insGACCAGCCCAG) (Figure 3.2.2). Three of these variants (112G~A [1 of 110
(0.91%)], 148deiGACCAGCCC [1 of 110 (0.91%)] and 157insGACCAGCCCAG [1 of
110 (0.91%)]) were identified only in the control individuals. The intronic variant IVS1-
28C~ T was identified in 6 of 105 (5.71%) OC patients and in 1 of 110 (0.91%) control
individuals. The polymorph isms identified in exon 2 were only present in a heterozygous
state. All the variants identified were verified by sequencing analysis. The numbering
system for variants identified in exon 2 and intron 1 is according to the sequence
published by Cellier et a/ (1994). HEX-SSCP analysis of the variants identified are
shown in Figure 3.2.3. The variants were in Hardy Weinberg equilibrium in the
population group studied.
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Nonnal: TCT CCAGCCCGACCAGCCCGACCAGCCCAG GGC
9bpdel: TCT ----CCAGCCCGA CCAGCCCAGGGC (Whiteet 8/1994)
9bp del: TCT CCAGCCCGA CCAGCCC --------AG GGC (A)
11bp ins: TCT CCAGCCCGACCAGCCCGACCA~S9~~G GGC (B)
-,- <.
A GACCAGCCCAG
B
c o
IVS1-28C~T 112G~A
Figure 3.2.2.
Legend to Figure 3.2.2.
Direct sequencing analysis of variants detected in exon 2 amplified DNA of the
SLC11A 1 gene. (A) Novel 9-bp deletion, (B) novel 11-bp insersion, (C) splice variant
(IVS1-28CIT) and (0) base pair substitution (112G/A), red, thymidine (T) blue, cytidine
(C), green, adenosine (A), black, guanosine (G), arrows indicate point of variation.
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PROMOTER VARIANTS OF THE SLC11A1 GENE
-237C~T -8G~A
N HE HO N N HE
IVS1-28C~T
VARIANTS OF INTRON 1/EXON 2 OF THE SLC11A1 GENE
148deiGACCAGCCC112G~A
N HE N HE N HE
Legend to Figure 3.2.3.
Ethidium bromide stained gel images of PCR-SSCP banding patterns of variants identified in the
promoter region and intron 1/exon 2 of the SLC11A 1 gene in 12% polyacrylamide gels
supplemented with 7.5% urea; N, banding pattern for homozygous wildtype variant; HE, banding
pattern for heterozygous variant; HO, banding pattern for homozygous mutant variant; arrows
indicate abnormal bands.
Figure 3.2.3.
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The allele and genotype frequencies of the different polymorphic SLC11A 1 variants
detected are provided in Tables 3.2.2 and 3.2.3 for the patient and population-matched
control groups. The T allele of the -237e~ T polymorphism was under represented in
the DC patient group. Statistically significant differences for the -237e~ T polymorphism
was observed when comparing allele (p<O.002, x2 with Yates correction = 7.87, df=1)
and genotype frequencies (p<O.003, x2 = 11.14, df=2) between the patient and control
groups. A significant difference was also observed when comparing male oe patients
with the respective gender control group for the -237e~ T polymorphism for both allele
(p<O.04, x2 with Yates correction = 3.11, df=1) and genotype (p<O.01, x2 = 9.83, df=2)
frequencies.
The -237C~ T polymorphism was consistently detected in the presence of allele 3
(Table 3.2.3) and none of the patient or control individuals homozygous for allele 2
presented with the -237e~ T polymorphism. Therefore, the -237e~ T polymorphism
appears to occur in cis with allele 3. No statistically significant differences were
observed when comparing the variants of the 5'-(GT)n promoter repeat polymorphism of
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Table 3.2.2. Allele frequencies of the various SLC11A 1 variants identified in the
Cid S th Af . I fooure ou ncan popu a Ion
VARIANTS aALLELE FREQUENCIES
CC OC
(2n=220) (2n=210)
Promoter variants Male Female Total Male Female Total
(2n=86) (2n=134) (2n=220) (2n=164) (2n=46) (2n=210)
Allele2 0.186 0.194 0.191 0.177 0.152 0.171
Allele 3 0.802 0.806 0.804 0.823 0.848 0.828
AlleleS 0.012 - 0.004 - - -
-8G/A 0.023 - 0.009 0.006 - 0.004
-237C~T cO.OB1 0.112 bO.10 cO.024 0.043 bO.029
Exon 2 variants
112G~A 0.012 - 0.004 - - -
IVS1-28C~T - 0.007 aO.OO4 0.030 0.022 aO.02B
148deiGACCAGCCC 0.012 - 0.004 - - -
157insGACCAGCCCAG 0.012 - 0.004 - - -
aAliele frequencies of polymorphic alleles denoted, Statistically Significant associations:
bOC vs control (p<O.004), cOC males vs control males (p<O.04), dOC vs control
(p<O.05), CC, Coloured control group, OC, oesophageal cancer patient group, Allele 2,
t(gt)5ac(gt)5ac(gt)1Qggcaga(g)6, Allele 3, t(gt)5ac(gt)5ac(gt)gggcaga(g)6, Allele 5,
t(gt)4ac(gt)5ac(gt)1Qggcaga(g)6,IVS, intervening sequence
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Table 3.2.3. Genotype frequencies of the various SLC11A 1 variants identified in the
Cid Ir f8o oure p_oQ_ua Ion 0 outh Africa
GENOTYPE FREQUENCIES
Promoter alleles CC OC
(n=110) (n=105)
Males Females Males Females
{n=43) (n=67) (n=82) (n=23)
Allele 2; Allele 2 0.05 (2) 0.01 (1) 0.05 (4) 0.09 (2)
Allele 2; Allele 3 0.28 (12) 0.36 (24) 0.26 (21) 0.13 (3)
Allele 3; Allele 3 0.65 (28) 0.63 (42) 0.70 (57) 0.78 (18)
Allele 3; Allele 5 0.02 (1) - - -
-237CC 0.84 (36) 0.79 (53) 0.97 (79) 0.91 (21)
-237CT 0.16 (7) 0.19 (13) 0.02 (2) 0.09 (2)
-237TT - 0.01 (1) 0.01 (1) -
-8GG 0.95 (41) 1.0 (67) 0.99 (81) 1.0 (23)
-8GA 0.05 (2) - 0.01 (1) -
Allele 2; Allele 3; 0.02 (1) 0.03 (2) 0.01 (1) -
-237CT
Allele 3; Allele 3; 0.14 (6) 0.16 (11) 0.01 (1) 0.09 (2)
-237CT
Allele 3; Allele 3; - 0.01 (1) 0.01 (1) -
-237TT
CC, Coloured control group, OC, oesophageal cancer patient group, number of
individuals with various genotypes are indicated in brackets, Allele 2,
t(gt)5ac(gt)5ac(gt)10ggcaga(g)s, Allele 3, t(gt)5ac(gt)5ac(gt)gggcaga(g)s, Allele 5,
t(gt)4ac(gt)5ac(gt)1oggcaga(g)s
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oe patients with the control group (data not shown), except when this was stratified
according to the presence of the -237C~ T polymorphism in association with allele 3.
Allele 3, in the absence of the T-allele, was significantly associated with oe (p<0.0006,
x2 with Yates correction = 10.16, df=1) and in particular with males (p<0.01, x2 with
Yates correction = 5.13, df=1). In cases where allele 3 was observed in association with
allele T, this genotype combination was also grouped with allele 2 for statistical analysis,
based on the finding that the genotypes including these sequence changes exert a
similar effect on transcriptional activity (chapter 3.1). Re-assessment of the 5'-(GT)n
repeat in this manner confirmed the significant association of allele 3 with oe compared
with the controls for both allele frequency (p<0.01, X2with Yates' correction = 4.54, df=1)
and genotype (p<0.005, X2 = 10.51, df=2) distribution. Statistically significant differences
for the intron 1 IVS1-28C~T polymorphism were also observed when comparing the
allele (p<0.05, X2 with Yates correction = 2.52, df=1) and genotype (p<0.05, X2 with
Yates correction = 2.56, df=1) frequencies for the oe patient and control groups.
3.2.5. DISCUSSION
Both environmental and genetic factors appear to be involved in the development of oe.
Of. the environmental factors, cigarette smoking and consuming alcoholic beverages
have been shown to be major determinants in developing oe. In our patient group the
involvement of these environmental factors were confirmed since all the patients (of
which we had data available) are cigarette smokers and/or consume large amounts of
alcoholic beverages (including both beer and wine/spirits). Occupational exposures are
also likely to playa minor role in the development of oe (reviewed by Blot 1994) and
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further investigation into this aspect would be interesting. The majority of our oe
patients are exposed to combustion products and a study performed in Sweden has
shown that a nearly three-fold excess of developing oe are observed among individuals
exposed to these products (Gustavisson et a/1993).
We assessed the likelihood that allele 3 of the 5'(GT)n promoter repeat polymorphism of
SLC11A 1, associated with autoimmune disease susceptibility, is involved in oe
susceptibility due to its role in chronic hyperactivation of macrophages and the
association of chronic inflammation with oe. A significant association was observed for
allele 3 of SLC11A1 with oe, and especially males with oe, when stratified according to
the presence of the -237e~ T polymorphism. This was done based on our findings
obtained in a previous study (chapter 3.1) where in vitro studies of SLC11A1 promoter
variants using luciferase reporter gene constructs demonstrated opposite effects on
promoter activity in relation to allele 3 in the presence and absence of the -237e~ T
polymorphism (similar to that of allele 2).
Significant association with oe was furthermore observed for the novel intronic IVS1-
28C~ T polymorphism identified in this study. A polymorphic area was previously
identified in the adjacent coding region in exon 2, located within the proline-rich SH3
binding domain consensus sequence (Barton et a/1994). The 9-bp deletion previously
identified (White et a/1994) was not similar to the 9-bp deletion identified in our study
population and an additional 11-bp insertion was identified in this area (Figure 3.2.2).
Although these variants were identified at very low frequencies, it could possibly
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influence the conformation and function of the protein. The spacing of pralines have
been shown to be important in binding SH3 domains (Booker et al 1993) and this
polymorphic area could account for susceptibility to autoimmune and/or infectious
diseases. Accurate splicing in eukaryotes are dependant on the 5' splice site, the 3'
splice site and the branch site (Cartegni et al 2002). Motifs in the intron acting as a
branch site have been identified with a conserved A residue in the branch site serving as
a branchpoint. The IVS1-28C~ T polymorphism lies within this region and could possibly
affect splicing. Functional studies needs to be performed to elucidate the role of this
variant. Alternatively, the observation of association of this polymorphism with DC could
be ascribed to linkage of this polymorphism with an unidentified mutation contributing to
DC pathogenesis. This polymorphism appears to be in linkage disequilibrium with allele
3 of the 5'-(GT)n promoter polymorphism since none of these individuals were
homozygous for allele 2, while 5 of 6 (83%) were homozygous for allele 3 and 1 of 6
(17%) presenting with alleles 2 and 3. The -237C~T polymorphism was not detected in
these six individuals.
The association of functional polymorph isms of the iron transporter SLC11A 1 with DC,
and particularly with males in our study, makes this gene a possible candidate for
explaining the higher frequency of DC in males compared to females. A previous study
involving the Black South African population also demonstrated association between
variants in the SLC11A 1 gene and DC susceptibility (du Plessis' 2000), which provides
considerable support for our findings. Direct mechanisms of iron induced mutagenesis
may occur through generation of oxygen free radicals and in turn lead to DNA strand
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damage and disruption in structure, contributing to the development of cancer (Togokuni
1996). Individuals homozygous for allele 3 of the SLC11A1 gene have also been
reported to produce higher levels of tumour necrosis factor a (TNF-a) (Blackwell et al
2003). The exact role for these pleiotrophic effects in SLC11A 1-regulated autoimmune
and infectious disease phenotypes are not yet known and needs further investigation.
Although two regions of the SLC11A1 gene has been associated with OC in our study
population, the possible influence of mutations in other genes closely linked to the
SLC11A1 gene cannot be excluded. A high frequency of loss on chromosome 2q was
indicated in a study by du Plessis et al (1999), using comparative genomic hybridisation
analysis, where various genes have been identified that could possibly be involved in
OC pathogenesis. Although association of SLC11A 1 gene variants with susceptibility to
various autoimmune and infectious diseases may be related to the many pleiotrophic
effects of the gene on macrophage function (Searle and Blackwell 1999), we conclude
that its involvement in inflammation and the generation of reactive oxygen species
possibly contributes directly to OC pathogenesis
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3.3. The -237C~T promoter polymorphism of the SLC11A1 gene exerts a
protective effect in relation to inflammatory bowel disease in the South African
population
3.3.1. ABSTRACT
The purpose of this study was to assess the likelihood that variation in the promoter
region of the solute carrier family 11 member 1 gene (SLC11A 1) contributes to
inflammatory bowel disease (IBD) susceptibility in the South African population. The
study cohort included 102 IBD patients, 47 with Crohn's disease (CD) and 55 with
ulcerative colitis (UC), and 192 population-matched controls. Mutation analysis revealed
two novel alleles for the 5'-(GT)n repeat polymorphism, t(gt)sac(gt)sac(gt)6ggcaga(g)6
(allele 8) and t(gt)sac(gt)sac(gt)sggcaga(g)6 (allele 9), and one previously-documented
point mutation -237C~ T. A significantly decreased frequency of the -237C~ T
promoter polymorphism was observed in the patient group with IBD (p<0.001) and CD
(p<0.0006) compared with the population-matched control group. These findings are in
accordance with previous in vitro studies, which demonstrated that the point mutation at
nucleotide position -237 represents a functional polymorphism that affects regulation of
the upstream 5'-(GT)n repeat polymorphism differentially upon iron loading. Our findings
raise the possibility that iron dysregulation mediated by allelic effects of SLC11A 1 may
contribute to IBD susceptibility.
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3.3.2.INTRODUCTION
Inflammatory bowel disease (lBO), generally classified as either Crohn's disease (CD) or
ulcerative colitis (UC), is characterised by chronic inflammation of the intestines
(Sanderson 1986, Griffiths 1995). It remains uncertain whether these subtypes of lBO
are distinct entities or a mechanistic continuum of the same disease process. lBO
frequently occurs in association with other autoimmune diseases, including ankylosing
spondylitis, psoriasis, sclerosing cholangitis and multiple sclerosis (Snook et a/ 1989,
Yang and Rotter 1993).
Both genetic and environmental (microbial) factors appear to be involved in the aetiology
of lBO (Sartor 1995, Shanahan 1995, Targan 1995). The frequency of affected first-
degree relatives in CD is higher than in UC (Satsangi et a/1994), and therefore genetic
factors may be relatively more important in CD (Satsangi et a/ 1997). It has been
suggested that CD might be triggered by intracellular pathogens in genetically
predisposed individuals (Targan 1995). Support for this notion was obtained by the
identification of a significant association with susceptibility alleles in the caspase
recruitment domain-containing protein 15 gene (CARD15), which appear to cause
inappropriate monocyte response to bacterial infection (Hugot et a/ 2001, Ogura et a/
2001a, Hampe et a/ 2001, Lesage et a/ 2002). However, some studies failed to
demonstrate association between mutations in the CARD15 gene and CD, possibly due
to population differences (Van Heel et a/2002). Other genes linked to lBO susceptibility
(Podolsky 2002) that are also expressed in macrophages, include the solute carrier
family 11 member 1 gene (SLC11A 1) (Hofmeister et a/1997, Kojima et a/ 2001). This
gene has been linked to various autoimmune and infectious diseases, which led to
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speculation that regulation of iron by SLC11A 1 may be of major importance in this
context (Blackwell et al 2000). This is substantiated by reports on abnormalities of iron
metabolism (Weber et al 1988, Nielsen et al 1994) in arthritic conditions shown to be
associated with genetic variation in the SLC11A 1 gene (Shaw et a/1996, Sanjeevi et al
2000, Singal et a/2000, Yang et al 2000), which may be linked to defective iron supply
for erythropoiesis (Cazzola et a/1996).
Anaemia of iron deficiency and anaemia of chronic diseases frequently occurs in lBO
(Oldenburg et al 2001). Iron deficiency in lBO patients are usually treated with oral iron
supplements but this may lead to an increased inflammatory activity by generating
reactive oxygen species. In an attempt to determine the possible role of the SLC11A1
gene in the disease process, we assessed the likelihood that variation in the promoter
region of the SLC11A1 gene contributes to IBO susceptibility in the South African
population. Previous studies of the functional Z-ONA forming repeat polymorphism in the
promoter region of the SLC11A 1gene suggested direct contribution of specific alleles to
autoimmune (allele 3) and infectious (allele 2) disease susceptibility (Searle and
Blackwell 1999, Blackwell et al 2000). These findings were considered in the current
study in relation to recent in vitro evidence, demonstrating an opposite allelic effect for
allele 3 (similar to that of allele 2) upon iron loading, in the event that allele 3 occurs in
association with the -237C~ T polymorphism (chapter 3.1).
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3.3.3. MATERIALS AND METHODS
The study protocol was approved by the Ethics Review Committees of the Universities
of Stellenbosch and Cape Town.
3.3.3.1 Subjects
Blood samples were obtained with informed consent from 102 unrelated patients
diagnosed with lBO, including 55 with UC (24 male and 31 female) and 47 with CD (18
male and 29 female). All patients attended the Gastroenterology Clinic at Grootte
Schuur Hospital. The presence of UC or CD was confirmed by radiology, or by
endoscopy and biopsy (Heikenen ef a/1999). The study population included 9 Black (9
females with UC), 77 Coloured (34 male - 18 UC and 16 CD patients, 43 female - 17
UC and 26 CD patients) and 16 Caucasian (8 male - 6 UC and 2 CD patients; 8 female
- 5 UC and 3 CD patients) South African patients diagnosed with lBO and 192 control
individuals from these respective population groups: 25 Black (12 male, 13 female), 110
Coloured (43 male, 67 female) and 57 Caucasian (33 males, 24 female). In this study
"Caucasian" refers to an individual of European descent, mainly Dutch, French, German
and British origin; "Coloured" refers to an individual of mixed ancestry, including San,
Khoi, Madagascar, Javanese and European origin; "Black" refers to South Africans of
central African descent.
3.3.3.2. Methods
DNA was extracted from whole blood using a standard method (Miller ef a/1988). The
promoter region of the SLC11A 1 gene was amplified by the polymerase chain reaction
(PCR) using oligonucleotide primers previously described (Kotze ef a/ 2001), generating
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fragments of 116-bp and 467-bp, respectively. The 467-bp PCR products were
subjected to combined heteroduplex single-strand conformation polymorphism (HEX-
SSCP) analysis (Kotze et a/1995) and resolved on a 12% PM gel supplemented with
7.5% urea at 4°C (350 V) for 18 hr. The 116-bp PCR product of the promoter region was
subjected to restriction fragment length polymorphism (RFLP) analysis (Graham et al
2000) using Rsal, which allows discrimination between the various Z-DNA forming
promoter repeat polymorphic alleles. The digested PCR products were resolved on a
10% PM gel at room temperature (250V) for 30 minutes. Following electrophoresis, the
gels were stained with ethidium bromide and the DNA visualised by ultraviolet light
transillumination. Semi-automated DNA sequencing was performed on PCR products
demonstrating mobility or conformational variants in the polyacrylamide gels, using an
ABI 3100 PRISM automated sequencer.
3.3.3.3. Statistical analysis
Allele and genotype frequencies were estimated by allele counting and statistical
differences between patient and control groups were tested for significance by the
Fisher exact test and/or chi-squared (x2) analysis with Yates' correction. The Mantel
Haenszel chi-squared test was performed to exclude the possibility of confounding
factors due to population substructures. A probability value smaller than 0.05 was
regarded as statistically significant. The Hardy-Weinberg equilibrium was performed to
test equilibrium for the gerietic traits investigated in the respective populations.
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Allelic stratification applied in this study was based on previous findings (chapter 3.1),
demonstrating an opposite allelic effect for allele 3 (similar to that of allele 2) upon iron
loading when occurring in association with the -237C~ T polymorphism. Therefore,
when allele 3 occurred together with the T-allele of the -237C~ T polymorphism, this
allelic combination was grouped with allele 2 for further statistical analysis.
3.3.4. RESULTS
Mutation analysis of the promoter region of the SLC11A1 gene was performed in South
African patients with CD and lBO, using a combined HEX-SSCP method and RFLP
analysis. This revealed several allelic variants which included the -237C~ T
polymorphism (Lewis et al 1996), and additional alleles for the 5'-(GT)n repeat
polymorphism, designated alleles 8 (t(gt)5ac(gt)5ac(gt)6ggcaga(g)6) and 9
(t(gt)5ac(gt)5ac(gt)aggcaga(g)6) (EMBL accession no. AJ535670). The variants identified
are shown in Figure 3.3.1.
The -237C~ T polymorphism was identified in both a heterozygous state (20 of 110
[18.2%] Coloured control individuals, 3 of 35 [8.57%] Coloured UC patients; 6 of 57
[10.5%] Caucasian control individuals, 2 of 11 [18.2%] Caucasian UC patients and 3 of
25 [12%] Black control individuals) and homozygous state (1 of 110 [0.91%] Coloured
control individuals and 1 of 57 [1.75%] Caucasian control individuals). Allele 9 was
identified in 2 of 42 CD patients (5%) in the Coloured population and was absent in the
control individuals. Allele 8 was identified in 1 of the 110 Coloured control individuals
(0.91%) and absent in the Black and Caucasian populations studied. All the different
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variants identified in the promoter region were verified by sequencing analysis. The
variants studied were in Hardy Weinberg equilibrium in the population group studied.
a
b
c f
d
Figure 3.3.1.
Legend to Figure 3.3.1.
Restriction enzyme (Rsa/) analysis of the 5'-(GT)n repeat of the promoter region. peR
products resolved on a 10% polyacrylamide gel and stained in 0.01% (v/v) ethidium
bromide. Different fragment sizes observed are numbered from a to f with (a) 57 base
pairs, (b) 49 base pairs (c) 47 base pairs (d) 41 base pairs (e) 45 base pairs and (f) 55
base pairs. Various genotypes observed are numbered from 1 to 8 with
lane 1: t(gt)sac(gt)sac(gthoggcaga(g)6/ t(gt)sac(gt)sac(gt)1Oggcaga(g)6
lanes 2 and 8: t(gt)sac(gt)sac(gt)gggcaga(g)6 / t(gt)sac(gt)sac(gt)gggcaga(g)6
lane 3: t(gt)sac(gt)sac(gt)gggcaga(g)6 / t(gt)sac(gt)sac(gt)6ggcaga(g)6
lane 4: t(gt)sac(gt)sac(gt)gggcaga(g)6 / t(gt)sac(gt)sac(gt)sggcaga(g)6
lanes 5 and 6: t(gt)sac(gt)sac(gt)gggcaga(g)6 / t(gt)sac(gt)sac(gt)10ggcaga(g)6
lane 7: t(gt)4ac(gt)sac(gt)1Oggcaga(g)6/ t(gt)sac(gt)sac(gt)gggcaga(g)6
110
Stellenbosch University http://scholar.sun.ac.za
The allele and genotype frequencies of the different polymorphic SLC11A 1 variants
detected for the various populations studied are presented in Tables 3.3.1 and 3.3.2.
The T allele of the -237C~ T polymorphism is under represented in the patient groups
and was not identified in any of the CD patients studied (Table 3.3.2). Statistically
significant differences were observed in the Coloured population (Table 3.3.3) but not in
the Caucasian and Black populations, most probably due to the small sample size for
these population groups. The frequency of the -237C~ T promoter polymorphism
differed significantly in Coloured patients with lBO (p<O.001) and CD (p<O.0006),
compared with the Coloured control group (Table 3.3.3). A significant difference was
also observed when comparing the lBO female group (including CD and UC patients)
and female CD Coloured patients with the respective gender Coloured control group
(p<O.005). All the variants studied were in Hardy Weinberg equilibrium for the various
population groups.
No statistically significant differences were observed when comparing the variants of the
5'-(GT)n repeat polymorphism in lBO patients with that in the control group (data not
shown), except when this was stratified according to the presence of the -237CfT
polymorphism in association with allele 3 (Table 3.3.3). Allele 3 was significantly
associated with CD in the Coloured population in the absence of this sequence variant.
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Table 3.3.1. Allele frequencies of the various SLC11A 1 promoter variants in three genetically
di tl t S th Af . I tiIS me OU ncan popu a Ions.
Promoter ALLELE FREQUENCIES
CC CCD CUC WC WCD WUC BC aBUC
alleles (2n=220) (2n=84) (2n=70) (2n=114) (2n=10) (2n=22) (2n=50) (2n=18)
Allele 1 - - - 0.009 - - - -
Allele2 0.190 0.202 0.243 0.202 0.200 0.136 0.160 0.111
Allele3 0.800 0.774 0.757 0.781 0.800 0.864 0.840 0.889
AlleleS 0.005 - - 0.009 - - - -
Allele 8 0.005 - - - - - - -
Allele 9 - 0.024 - - - - - -
-237T 0.100 - 0.043 0.070 - 0.091 0.060 -
..
"No individuals In the Black population presented with CD In this study, CC, Coloured control
group, CCD, Coloured Crohn's disease patient group; CUC, Coloured ulcerative colitis patient
group, WC, Caucasian control group, WCD, Caucasian Crohn's disease patient group, WUC,
Caucasian ulcerative patient group, BC, Black control group, BUC, Black ulcerative colitis
patient group
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Table 3.3.2. Genotype frequencies of the various SLC11 A 1 promoter variants in three genetically distinct South
African oooulaf
GENOTYPE FREQUENCIES
Promoter alleles cc CCD CUC WC WCD WUC BC aBUC
(n=110) (n=42) (n=35) (n=57) (n=5) (n=11) (n=25) (n=9)
Allele 2; Allele 2 0.03 (3) 0.05 (2) 0.03 (1) 0.02 (1) - - - -
Allele 2; Allele 3 0.33 (36) 0.31 (13) 0.43 (15) 0.37 (21) 0.40 (2) 0.27 (3) 0.32 (8) 0.22 (2)
Allele 3; Allele 3 0.63 (69) 0.60 (25) 0.54 (19) 0.58 (33) 0.60 (3) 0.73 (8) 0.68 (17) 0.78 (7)
Allele 3; Allele 5 0.009 (1) - - 0.02 (1) - - - -
Allele 3; Allele 8 0.009 (1) - - - - - - -
Allele 3; Allele 9 - 0.05 (2) - - - - - -
~Allele 1; Allele 3 - - - 0.02 (1) - - - -
-237CC 0.81 (89) 1.0 (42) 0.91 (32) 0.88 (50) 1.0 (5) 0.82 (9) 0.88 (22) 1.0 (9)
-237CT 0.18(20) - 0.09 (3) 0.10 (6) - 0.18 (2) 0.12 (3) -
-237TT 0.009 (1) - - 0.02 (1) - - - -
Allele 2; Allele 3; -237CT 0.03 (3) - - 0.04 (2) - - - -
Allele 3; Allele 3; -237CT 0.15(17) - 0.09 (3) 0.07 (4) - 0.18 (2) 0.12 (3) -
Allele 3; Allele 3; -237TT 0.009 (1) - - 0.02 (1) - - - -
"No individuals in the Black patient group presented with CD in this study, CC, Coloured control group, CCD,
Coloured Crohn's disease patient group; CUC, Coloured ulcerative colitis patient group, WC, Caucasian control
group, WCD, Caucasian Crohn's disease patient group, WUC, Caucasian ulcerative patient group, BC, Black control
group, BUC, Black ulcerative colitis patient group. The number of individuals for each genotype is indicated in
brackets.
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Table 3.3.3. Statistically significant differences of allele and genotype frequencies observed within the Coloured South
African nooulati- --- ------ - --- -- -- - - -
GENOTYPE FREQUENCIES ALLELE FREQUENCIES
Variant Association Xl. p-value df Xl.with p-value Mantel-Haenszel X;/. p- df I
tested Yates' test value
correction
-237C~T '"IBD patient group vs 9.56 0.009 2 8.17 0.001 9.09 0.003 1
control group
"IBD female patient 7.68 0.02 2 6.40 0.003 5.73 0.02 1
group vs female
control group
CD patient group vs 9.31 0.009 2 7.63 0.0006 8.35 0.005 1
control group
CD female patient 6.39 0.04 2 4.91 0.005 5.13 0.02 1
group vs female
control group
*3/3 without -237T CD patient group vs 6.49 0.004 1 6.78 0.004 7.29 0.01 1
control group
X-, chi-squared, df, degrees of freedom, p-value, probability value, *Allele 3/Allele 3 compared to Allele 3/Allele 3
associated with the -237T allele, ·180 patient group includes both CD and UC patients, refer to Table 3.3.2 for
number of individuals used for statistical analysis
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However, re-assessment of the data according to phenotypic effects determined in vitro
(chapter 3.1), demonstrating an opposite allelic effect for allele 3 (similar to that of allele
2) upon iron loading in the event that allele 3 occurs in association with the -237C~ T
polymorphism, did not show a significant association of allele 3 with lBO when
compared with the population-matched control group for the 5'-(GT)n repeat.
The likelihood that confounding factors influenced the statistical analysis was excluded
by assessment of the Mantel Haenszel chi-squared test, which demonstrated that all the
associations complied with the "rule of 5." The rare variants, alleles 5, 8 and 9, were
insufficiently represented in both the patient and control groups and were not included
for comparisons. The -237C~ T polymorphism appears to be in cis with allele 3, since
none of the patient and control groups shown to be homozygous for allele 2 presented
with the T-allele.
3.3.5. DISCUSSION
Linkage studies previously implicated the involvement of the SLC11A1 gene with CD
susceptibility (Hofmeister et a/ 1997). However, investigation of intragenic
polymorph isms (274C~ T and 823C~ T) could not confirm the association with lBO
susceptibility (Stakkers et a/1999). In a more recent study performed in the Japanese
population, a novel variant of the SLC11A1 promoter repeat polymorphism (allele 7)
was shown to be associated with lBO susceptibility (Kojima et a/2001). In this study we
performed association studies to investigate the likelihood that genetic variation in the
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promoter region of the SLC11A 1 gene is involved in the pathogenesis of IBO in the
South African population.
No disease association was detected when the allelic distribution of the 5'-(GT)n repeat
polymorphism was compared between patients and controls. However, statistically
significant differences were observed when the frequency of the downstream -237C~ T
polymorphism was compared between patients with CD and control individuals. Under
representation of the T-allele was observed and was identified in 3 of 35 UC patients
(8.57%) and in none of the 42 CD patients compared with 21 of 110 control individuals
(19.10%) in the Coloured population. Although the patient numbers were small, this
allele was not detected in Caucasian patients with CD, while present in a considerable
proportion of the population-matched control group (7 of 57, 12.28%). None of the Black
patients presented with CD in this study. The -237C~ T polymorphism was absent in
the Black UC patient group, while present in the respective control group (3 of 25,
12.0%).
Allele 3 of the SLC11A 15'-(GT)n promoter polymorphism has previously been linked to
autoimmune disease susceptibility due to its role in chronic hyperactivation of
macrophages. We therefore re-assessed the likelihood that this variant is involved in
lBO susceptibility following allelic stratification. When the potential effect of allele 3 was
considered in the absence of the -237C~ Tpolyrnorphlsrn, a significant association with
CD was observed in the Coloured population. In cases where allele 3 was observed in
association with allele T, this genotype combination was also grouped with allele 2 for
116
Stellenbosch University http://scholar.sun.ac.za
statistical analysis, based on the fact that the genotypes including these sequence
changes exert a similar effect on transcriptional activity (chapter 3.1). No statistically
significant association was observed in this analysis. This finding demonstrates the
importance of assessment of allelic interaction in case-control association studies. The
apparent protective effect of the -237C---1-T polymorphism in relation to lBO represents
the most significant finding in this study.
Several other genes, including the CARD 15 (Hugat et al 2001, Ogura et al 2001) and
TNF-a (Ruuis and Sedgwick 1999, Koss et al 2000, Sashio et al 2002, Van Heel et al
2002) genes, both expressed in macrophages, were shown to be implicated in CD
pathogenesis. According to Van Montfrans et al (2002), CARD15 mutations are
responsible for disease in about 15% of CD patients. O'Caliaghan et al (2003) have
furthermore shown that association of a TNF-a promoter variant (-857C---1-T) with lBO
was more prevalent in families with CARD15 risk alleles, suggesting that both TNF-a
and CARD15 interact with NF-KB in macrophages. Individuals homozygous for allele 3
of SLC11A1 express higher levels of TNF-a, possibly due to the pleiotropic effects of
SLC11A 1 on TNF-a. LPS-related response elements, including NF-KB, in the promoter
region of SLC11A1 were also differentially affected by the various alleles of the 5'-(GT)n
repeat. With SLC11A1, CARD15 and TNF-a all being expressed in macrophages, we
could speculate that these genes interact through a common pathway, with SLC11A1
acting as a modifier locus, to cause lBO possibly due to its role in iron metabolism.
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It should also be taken into consideration that CD activity [CD Activity Index - (COAl)]
could be influenced by an iron deficiency state due to the contribution of the haematocrit
being affected by iron deficiency, although this activity is relatively small. Unfortunately
iron status was not available for the patients included in this study. In conditions of
chronic inflammation such as lBO, iron homeostasis is usually altered mainly due to
chronic blood loss in the intestine (Oldenburg et al 2001). Iron deficiency can occur due
to iron malabsorption because of inflammatory activity in the small intestine and
resection or impaired dietary intake.
The significant decreased frequency of the -237C~ T promoter polymorphism observed
in this study in patients with Crohn's disease compared with population-matched
controls confirm the role of the SLC11A 1 gene in lBO. It is clear that interaction between
various genes and environmental factors contribute to the disease phenotype and future
studies to assess the impact of SLC11A 1 promoter alleles on subsequent expression of
disease activity and characterisation may prove valuable in patient management.
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3.4. CARD15 gene mutations in South African patients with inflammatory bowel
disease patients: interaction with SLC11A 1gene variants
3.4.1. ABSTRACT
The caspase recruitment domain gene (CARD15) was recently identified as an
important susceptibility gene for Crohn's disease (CD). The purpose of this study was to
determine whether the three most common CARD15 mutations, R702W, G908R and
1007fs, contribute to inflammatory bowel disease (lBO) susceptibility in three genetically
distinct South African populations. The study cohort included 101 lBO patients, 46 with
CD and 55 with ulcerative colitis (UC), and 183 population-matched controls. Mutations
R702W, G908R and 1007fs were present at relatively low frequencies «20%) in our
predominantly non-Caucasian study population. No statistically significant differences
were observed in the mutation frequencies in UC and CD patients or when these groups
were compared with healthy control individuals within each population group. Two
additional mutations were identified, one novel (A661 P) and one previously described
(A725G), with the latter being identified mainly in the Coloured UC patients (4 of 35,
11%). In this population, statistically significant differences were obtained between UC
and control individuals when comparing both allele (p<0.004, l with Yates' correction =
8.01) and genotype frequencies (p<0.004, 'X: with Yates' correction = 8.14) for the
A725G mutation, suggesting a possible role for this variant in disease expression. Since
the same study 'population has previously been investigated for allelic association with
the SLC11A 1 gene, possible combined allelic effects of both genes were finally
considered in an attempt to explain our findings.
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3.4.2.INTRODUCTION
Inflammatory bowel disease (lBO) is a disease of chronic inflammation in the intestines,
and is often referred to as an autoimmune disease. The disease is generally subdivided
into two phenotypes known as Crohn's disease (CD) and ulcerative colitis (UC)
(Sanderson 1986, Griffiths 1995). Both genetic and environmental factors have been
implicated in the development of lBO (Sartor 1995, Shanahan 1995, Targan 1995).
A susceptibility locus on chromosome 16 was first identified by Hugot et al (1996) and
subsequently by other groups (reviewed in the lBO International Genetics Consortium
2001, Zouali et al 2001). However, several authors failed to replicate these findings
(Rioux et al 1998, Vermeire et al 2000, Paavola et al 2001). Independent studies
performed by Hugot et al (2001) and Ogura et al (2001a) identified disease-predisposing
alleles of the caspase recruitment domain-containing protein 15 gene (CARD15).
Several mutations and polymorphisms of the CARD15 gene have been identified to date
in lBO patients demonstrating significant association with three of these mutations
(R702W, G908R and 1007fs), mainly with CD in the Caucasian population (Hugat et al
2001, Ogura et al 2001a, Hampe et al 2001, Lesage et al 2002). Mutations of CARD15
are considered to be the causative genetic defect in about 15% of CD patients (van
Montfrans et al 2002), altering either the structure of the LRR domain of the protein
(Ogura et a/2001 a) or the adjacent region (Weitzman 2001).
In this study we investigated the presence of mutations R702W, G908R and 1007fs in
the CARD15 gene in three genetically distinct South African populations and performed
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case-control association studies to assess the significance of this gene in the
pathogenesis of lBO in the South African population. The same study population has
recently been subjected to analysis of the SLC11A 1 gene (chapter 3.3) and therefore
mutation frequencies were also considered within the context of the SLC11A 1 genetic
I background and allelic effects of promoter variants. We specifically investigated the
likelihood that the apparent protective effect associated with the SLC11A 1 -237C~ T
polymorphism in relation to lBO susceptibility has influenced our data. Similar to
CARD15, the SLC11A1 gene is also expressed in macrophages and gene variation is
associated with various autoimmune and infectious diseases, including susceptibility to
lBO (Hofmeister et a/1997, Kojima et a/2001, Podolsky 2002).
3.4.3. MATERIALS AND METHODS
The study was approved by the Ethics Review Committees of the Universities of
Stellenbosch and Cape Town.
3.4.3.1. Subjects
. Blood samples were obtained with informed consent from 101 unrelated patients
diagnosed with lBO, including 55 with UC (23 male and 32 female) and 46 with CD (17
male and 29 female). All patients attended the Gastroenterology Clinic at Grootte
Schuur Hospital. The presence of UC or CD was confirmed by radiology, or by
endoscopy and biopsy (Heikenen et al 1999). The study population included 9 Black (9
females with UC), 76 Coloured (31 male - 16 UC and 15 CD patients, 45 female - 19
UC and 26 CD patients) and 16 Caucasian (9 male - 7 UC and 2 CD patients; 7 female
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- 4~HC and 3 CD patients) South African patients diagnosed with lBO and 183 control
individuals from these respective population groups: 25 Black (12 male, 13 female), 100
Coloured (39 male, 61 female) and 58 Caucasian (34 males, 24 female). In this study
"Caucasian" refers to an individual of European descent, mainly Dutch, French, German
and British origin; "Coloured" refers to an individual of mixed ancestry (Loubser et al
1999), including San, Khoi, Madagascar, Javanese and European origin; "Black" refers
to South Africans of central African descent.
3.4.3.2. Methods
DNA was extracted from whole blood using a standard method (Miller et a/1988). Prior
to inclusion in this study, all individuals have been genotyped for the 5'-(GT)n repeat
polymorphism of the SLC11A1 gene (chapter 3.3). Exons 4,8 and 11 of the CARD15
gene were amplified by polymerase chain reaction (PCR) amplification using
oligonucleotide primers previously described (Lesage et al 2002). The PCR products of
exons 4 (494 bp) and 11 (230 bp), incorporating polymorph isms R702W and 1007fs
respectively, were subjected to a combined heteroduplex single-strand conformation
polymorphism (HEX-SSCP) analysis (Kotze et a/1995) method and resolved on a 12%
PM gel supplemented with 7.5% urea at 4°C (350 V) for 18 hr. The PCR product of
exon 8 (380 bp), incorporating polymorphism G908R, was subjected to restriction
fragment length polymorphism (RFLP) analysis using Hhal (Promega). The digested
PCR products were resolved on a 10% polyacrylamide gel at room temperature (250V)
for 30 minutes. Following electrophoresis, the gels were stained with ethidium bromide
and the DNA visualised by ultraviolet light transillumination. Semi-automated DNA
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sequencing was performed on PCR products demonstrating mobility or conformational
variants in the polyacrylamide gels, using an ABI 3100 PRISM automated sequencer.
3.4.3.3. Statistical analysis
Allele and genotype frequencies were estimated by allele counting and statistical
I,
differences betJeen patient and control groups were tested for significance by the
Fisher exact test and/or chi-squared (x2) analysis with Yates' correction. The total carrier
frequency, including heterozygotes and homozygotes, was counted to estimate the
prevalence of gene variants. The prevalence of combined mutation carriers in patient
and control subjects were compared to elucidate possible gene-gene interaction,
according to Butt et al (2003). A probability value smaller than 0.05 was regarded as
statistically significant. The Hardy-Weinberg equilibrium was performed to test
equilibrium for the genetic traits investigated in the respective populations.
Allelic stratification applied in this study was based on previous findings (chapter 3.1),
demonstrating an opposite allelic effect for allele 3 (similar to that of allele 2) upon iron
loading when occurring in association with the -237C~ T polymorphjsm. Therefore,
when allele 3 occurred together with the T-allele of the -237C~ T polymorphism, this
allelic combination was grouped with allele 2 for further statistical analysis.
3.4.4. RESULTS
The three most common CARD15 mutations implicated in Crohn's disease were
screened for by using a combined HEX-SSCP method (R702W and 1007fs) and RFLP
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analysis (G908R). Mutations R702W and 1007fs were observed in both the
heterozygous and homozygous state, whereas the G908R mutation was identified only
in a heterozygous state (Table 3.4.1). A single previously described mutation (A725G)
(Lesage et al 2002) and one novel variant (A661P) were also identified in exon 4 of the
CARD15 gene. Figure 3.4.1A and B shows the direct sequencing analysis of the five
different variants detected in the CARD15 gene.
The A661 P variant caused a G to C transversion, changing alanine to proline, and was
identified in a heterozygous state in 1 of 100 (0.01%) Coloured control individuals.
Variant A725G caused a C to G transversion, changing alanine to glycine and was
previously detected at a frequency of 0.3% in CD patients and was absent in the
controls (Lesage et al 2002). These mutations would probably not have a major effect
"-,
on the properties of the protein as both amino acids represent neutral hydrophobic
amino acids. Mutation A725G was identified in 4 of 35 (11%) ulcerative colitis individuals
of the Coloured population in our study and was observed only in a heterozygous state.
The A725G variant was absent in the Coloured CD patient group and population-
matched control group as well as in both the Black and Caucasian patient (including CD
and UC) and control groups. One UC patient with the A725G variant was also
heterozygous for the R702W mutation. Unfortunately, additional family members of this
individual was not available for genotype-phenotype association studies.
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Table 3.4.1. Allele and genotype frequencies of the variants identified in the CARD15 gene in three genetically distinct
South African populations
\
Phenotype R702W G908R 1007fs A725G
Genotype Allele Genotype Allele Genotype Allele Genotype Allele
CC CT TT C T GG GC cc G C CC InsC InsC C insC cc CG GG C G
(he) (ho)
CCD (n-41) 0.88 0.12 - 0.94 0.06 1.0 - - 1.0 - 0.98 0.02 - 0.99 0.01 1.0 - - 1.0 -
(36) (5) (41) (40) .(1) (41)
CUC (n=35) 0.97 0.03 - 0.99 0.01 1.0 - - 1.0 - 0.91 0.09 - 0.96 0.04 0.89 aO.11 - 0.94 '0.06
(34) (1) (35) (32) (3) (31) (4)
CC (n=100) 0.95 0.05 - 0.97 0.03 0.99 0.01 - 0.995 0.005 0.93 0.07 - 0.96 0.04 1.0 - - 1.0 -
(95) (5) (99) (1) (93) (7) (100)
WCO(n=5) 0.80 0.20 - 0.90 0.10 1.0 - - 1.0 - 0.80 - 0.20 0.80 0.20 1.0 - - 1.0 -
(4) (1) (5) (4) (1) (5)
WUC (n=11) 0.82 0.09 0.09 0.86 0.14 1.0 - - 1.0 - 1.0 - - 1.0 - 1.0 - - 1.0 -
(9) (1) (1) (11) (11) (11 )
WC(n=58) 0.90 0.08 0.02 0.94 0.06 1.0 - - 1.0 - 0.90 0.07 0.03 0.93 0.07 1.0 - - 1.0 -
(52) (5) (1) (58) (52) (4) (2) (58)
BUC (n=9) 0.89 0.11 - 0.94 0.06 1.0 - - 1.0 - 0.89 0.11 - 0.94 0.06 1.0 - - 1.0 -
(8) (1) (9) (8) (1) (9)
BC (n-25) 0.92 0.08 - 0.96 0.04 1.0 - - 1.0 - 1.0 - - 1.0 - 1.0 - - 1.0 -
(23) (2) (25) (25) (25)
CCD, Coloured Crohn's disease patients; CUC, Coloured ulcerative colitis patients, CC, Coloured control individuals,
WCD, Caucasian Crohn's disease patients; WUC, Caucasian ulcerative colitis patients, WC, Caucasian control
individuals, BUC, Black ulcerative colitis patients, BC, Black control individuals, he, heterozygote; ho, homozygote, aCUC
vs CC (allele frequency and genotype frequencies: p<O.004). The number of individuals for each genotype is indicated in
brackets.
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AII
III
Figure 3.4.1.A
Legend to Figure 3.4.1.A
Direct sequence analysis of the three common CARD15 gene mutations with i) sense
strand of the R702W (2104 C~ T) mutation, ii) sense strand of the G908R (2722 G~C)
mutation and iii) sense strand of the 1007fs (3020insC) mutation (homozygous
insertion); red, thymidine (T) blue, cytidine (C), green, adenosine (A), black, guanosine
(G), arrows indicate point of variation.
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II
B
Figure 3.4.1.8
Legend to Figure 3.4.1.8
Direct sequence analysis of the two additional variants identified in exon 4 of the
CARD15 gene, with i) sense strand of variant A725G (2174 C~G) and ii) sense strand
of variant A661 P (1981 G~C), red, thymidine (T) blue, cytidine (C), green, adenosine
(A), black, guanosine (G), arrows indicate point of variation.
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The allele and genotype frequencies of the variants studied are provided in Table 3.4.1
for the different population groups. Mutations R702W, G908R and 1007fs were
observed in 13%, 0% and 4% CD patients, 5%, 0% and 7% UC patients, and 7%, 0.5%
and 7% of the control group, respectively. No statistically significant differences were
observed for any of the common mutations (data not shown). However, when
performing statistical analysis for the A725G variant, highly significant association was
observed for both allele and genotype frequencies in the Coloured UC patient group
compared with controls (allele frequency: p<0.004, x2 with Yates' correction = 8.02;
genotype frequency: p<0.004, x2 with Yates' correction = 8.14). All the mutations
studied were in Hardy Weinberg equilibrium in all the population groups, except for
the 1007fs mutation in the healthy Caucasian control group (p<0.002). Explanations
for this finding are not clear since the control group was not selected for or against a
particular genotype.
Observed and theoretical prevalence of combined mutation carriers in the patient
and control groups are shown in Table 3.4.2. Analysis of the CARD15 mutations was
also investigated in combination with SLC11A 1 promoter variant genotypes (Table
3.4.3) as genetic background. No statistically significant associations were observed
when possible combined effects of the SLC11A 1 promoter variants and three common
CARD15 mutations were investigated. A similar analysis was not performed for variant
A725G since this mutation did not occur in the control population.
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Assessment of the frequency of the -237C---+T polymorphism in the patient group
compared with controls having one or more of the three common mutations (R702W,
G908R and 1007fs) or the A725G did not show any co-existence of these CAR01S and
SLC11A 1 variants in either the patient or control groups.
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Table 3.4.2. Theoretical and observed prevalence for combined carriers of various mutations identified in the CARD15
gene and SLC11A 1 promoter variants identified in three genetically distinct South African populations
Phenotype Observed prevalence for combined genotype frequencies (%) Theoretical prevalence for combined carriers
CARD15 SLC11A1 (Observed prevalence for combined carriers)
R702W G908R 1007fs A725G *Allele 2 *Allele 3 R702WI R702WI G908R1 G908R1 1007fsl 1007fsl A725GI A725GI
Allele2 Allele3 Allele2 Allele3 Allele2 Allele3 Allele 2 Allele3
CCD (n-41) 12% 0% 2% 0% 37% 95% 4.4% 11.4% 0% 0% 0.7% 1.9% 0% 0%
(4.9%) (12.2%) (0%) (0%) (0%) (2.4%) (0%) (0%)
CUC (n=35) 3% 0% 9% 11% 54% 97% 1.6% 2.9% 0% 0% 4.9% 8.7% 5.9% 10.7%
(2.9%) (2.9%) (0%) (0%) (2.9%) (8.6%) (5.7%) (11.4%)
CC (n=100) 5% 1% 7% 0% 52% 92% 2.6% 4.6% 0.51% 0.91% 3.6% 6.4% 0% 0%
(1.0%) (5.0%) (1.0%) (1.0%) (2.0%) (7.0%) (0%) (0%)
WeD (n=5) 20% 0% 20% 0% 40% 100% 8.0% 20.0% 0% 0% 8.0% 20.0% 0% 0%
(20.0%) (20.0%) (0%) (0%) (0%) (20.0%) (0%) (0%)
wue (n=11) 18% 0% 0% 0% 54% 100% 9.7% 18.0% 0% 0% 0% 0% 0% 0%
(9.1%) (18.2%) (0%) (0%) (0%) (0%) (0%) (0%)
WC(n=58) 10% 0% 10% 0% 47% 90% 4.7% 9.0 0% 0% 4.7% 9.0% 0% 0%
(1.7%) (10.3%) (0%) (0%) (6.9%) (10.3%) (0%) (0%)
BUe (n-9) 11% 0% 11% 0% 22% 100% 2.4% 11.0% 0% 0% 2.4% 11.0% 0% 0%
(0%) (11.1%) (0%) (0%) (11.1%) (11.1%) (0%) (0%)
Be (n=25) 8% 0% 0% 0% 44% 100% 3.5% 8.0% 0% 0% 0% 0% 0% 0%
(4.0%) (8.0%) (0%) (0%) (0%) (0%) (0%) (0%)
*T-allele of the -237C~ T polymorphism in the presence of allele 3 was grouped with allele 2 based on in vitro allelic
effect (chapter 3.1), CCD, Coloured Crohn's disease patients; CUC, Coloured ulcerative colitis patients, CC, Coloured
control individuals, WCD, Caucasian Crohn's disease patients; WUC, Caucasian ulcerative colitis patients, WC,
Caucasian control individuals, BUC, Black ulcerative colitis patients, BC, Black control individuals,
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Table 3.4.3. Genotype frequencies of the various SLC11A 1 promoter variants in three genetically distinct South African
I .,
..r_-____E_------------
GENOTYPE FREQUENCIES
Promoter alleles CC CCD CUC WC WCD WUC BC *BUC
(n=100) (n=41) (n=35) (n=58) (n=5) (n=11 ) (n=25) (n=9)
Allele 2; Allele 2 0.03 (3) 0.05 (2) 0.03(1) 0.02 (1) - - - -
Allele 2; Allele 3 0.34 (34) 0.32 (13) 0.43 (15) 0.36 (21) 0.4 (2) 0.36 (4) 0.32 (8) 0.22 (2)
Allele 3; Allele 3 0.62 (62) 0.63 (26) 0.54(19) 0.58 (34) 0.6 (3) 0.64 (7) 0.68 (17) 0.78 (7)
Allele 1; Allele 3 - - - 0.02 (1) - - - -
Allele 5; Allele 3 0.01 (1) - - 0.02 (1) - - - -
-237CC 0.82 (82) 1.0(41) 0.91 (32) 0.88 (51) 1.0 (5) 0.82 (9) 0.96 (22) 1.0 (9)
-237CT 0.17 (17) - 0.09 (3) 0.10 (6) - 0.18 (2) 0.04 (3) -
-237TT 0.01 (1) - - 0.02 (1) - - - -
Allele 2; Allele 3; - 0.03 (3) - - 0.03 (2) - - - -
237CIT
Allele 3; Allele 3; - 0.14 (14) - 0.09 (3) 0.07 (4) - 0.18 (2) 0.04 (3) -
237CIT
Allele 3; Allele 3; - 0.01 (1) - - 0.02 (1) - - - -
237TIT
*No individuals in the black patient group presented with CD in this study, CC, coloured control group, CCD, coloured
Crohn's disease patient group; CUC, coloured ulcerative colitis patient group, WC, Caucasian control group, WCD,
Caucasian Crohn's disease patient group, WUC, Caucasian ulcerative patient group, BC, black control group, BUC, black
ulcerative colitis patient group. The number of individuals for each genotype is indicated in brackets.
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Table 3.4.4. Assessment of the various SLC11A1 variants in relation to the common CARD15 mutations
"SLC11A1 Promoter CARD151NOD2 GENOTYPE FREQUENCIES
Ialleles mutation
1007fs CC CCD CUC WC WCD WUC BC "BUC
j_n=100) (n=41) (n=35) (n=58) (n=5) (n=11) (n=25) (n=9)
Allele 2;Allele 3 C 0.43(43) 0.32(13) 0.49(17) 0.33(19) 0.40(2) 0.55(6) 0.44(11) 0.11(1)
jnsC (he) 0.02(2) - 0.03(1) 0.05(3) - - - 0.11(1)
jnsC (ho) - - 0.02(1) - - - -
Allele 3;Allele 3 C 0.42(42) 0.61(25) 0.40(14) 0.47(27) 0.40(2) 0.45(5) 0.56(14) 0.78(7)
jnsC (he) 0.05(5) 0.02(1) 0.06(2) 0.02(1) - - - -
jnsC (ho) - - 0.02(1) 0.20(1) - - -
G908R
Allele 2;Allele 3 GG 0.44(44) 0.32(13) 0.51(18) I 0.40(23) 0.40(2) 0.55(6) I 0.44(11) 0.22(2)
GC 0.01(1) - - I - - - I - -
R702W
Allele 2;Allele 3 CC 0.44(44) 0.27(11) 0.49(17) 0.38(22) 0.20(1) 0.45(5) 0.40(10) 0.22(2)
CT 0.01(1) 0.05(2) 0.03(1) 0.02(1) 0.20(1) - 0.04(1} -
TI - - - - - 0.09(1) - -
Allele 3;Allele 3 CC 0.43(43) 0.56(23) 0.46(16) 0.41(24) 0.60(3) 0.36(4) 0.52(13) 0.67(6)
CT 0.04(4) 0.07(3) - 0.05(3) - 0.09(1) 0.04(1) 0.11(1)
TI - - - 0.02(1) - - - -
Allele 3;Allele 5 CC 0.01(1) - - - - - - -
CT - - - 0.02(1) - - - -
A725G
Allele 2;Allele 3 CC 0.45(4S) 0.32(13) 0.46(16) 0.40(23) 0.40(2) 0.55(6) 0.44(11) 0.22(2)
CG - - 0.06(2) - - - - -
GG - - - - - - - -
Allele 3;Allele 3 CC 0.47(47) 0.63(26) 0.40114) 0.50(29) 0.60(3) 0.45(5) 0.56(14) 0.78(7)
CG - - 0.06(2) - - - - -
GG - - - - - - - -
*Only genotypes in association with the CARD15 variants are denoted and T-allele of the -237C~ T polymorphism in the
presence of allele 3 was grouped with allele 2 based on in vitro allelic effect, #No individuals in the Black patient group
presented with CD in this study, CC, Coloured control group, CCD, Coloured Crohn's disease patient group; CUC,
Coloured ulcerative colitis patient group, WC, Caucasian control group, WCD, Caucasian Crohn's disease patient group,
WUC, Caucasian ulcerative patient group, BC, Black control group, BUC, Black ulcerative colitis patient group. The
number of individuals for each genotype is indicated in brackets. Allele 2, t(gt)sac(gt)sac(gthoggcaga(g)6, Allele 3,
t(gt)sac(gt)sac(gt)9ggcaga(g)6, Allele 5, t(gt)4ac(gt)sac(gt)10ggcaga(g)6
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3.4.5. DISCUSSION
Association of the CARD15 gene with CD susceptibility has previously been identified in
several studies. By investigating the gene regions spanning the three most common
CARD15 mutations in the diverse South African population, we additionally identified
one novel variant (A661 P) and a previously described variant (A725G) (Lesage et al
2002). The common mutations were identified at low frequencies in our study cohort
and was present in only 14.9% of the patient group [8 of 46 (17.4%) CD patients and 7
of 55 (12.7%) UC patients]. No statistically significant differences were observed for
these mutations between patient and control groups. In a previous study, Yamazaki et
al (2002) investigated the three common mutations in Japanese CD patients and also
found no association with these mutations. A recent study also failed to demonstrate an
association between these variants and CD susceptibility in the Dutch population
(Stokkers et a/2003).
Yamazaki et al (2002) suggested that the prevalent CARD15 mutations are independent
risk factors for CD in Caucasian patients. The Caucasian contribution to the South
African Coloured population is only approximately 33% (Loubser et al 1999), and
therefore the incidence of mutations in this population is expected to be a third of the
incidence estimated in the South African Caucasian population. Although no significant
associations were achieved for the R702W, G908R and 1007fs mutations in our study
cohort, with the majority of individuals from the Coloured population, association cannot
be confirmed or excluded for the Caucasian and Black populations because of a small
sample group. We would, however, expect these mutations to contribute to CD in the
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Caucasian population but possibly not in the Black population. In future studies, these
population groups need to be expanded to elucidate the involvement of the CARD15
gene in CD susceptibility in the general South African population, within the context of
the other candidate genes such as SLC11A 1 (Kojima et a/2002, chapter 3.3) and TNF-
a (Ruuis and Sedgwick 1999).
The previously described variant, A725G, was observed mainly in the Coloured UC
patients. In a previous study, this variant was identified in only 3 of 906 (0.3%) CD
patients from European descent and was absent in 318 UC patients and 206 controls
(Lesage et al 2002). In our study, the A725G variant was identified in 4 of 35 UC
patients of the Coloured population and statistically significant differences were
achieved (p<0.004, x2 with Yates' correction = 8.02). The likelihood that this variant may
be in linkage disequilibrium with a functional mutation in the CARD15 gene or other
. disease-causing loci should be considered, as this mutation was considered to be a
benign polymorphism.
Although no linkage with the CARD15 gene and UC has previously been reported, the
involvement of this gene with UC remains a possibility. In a recent study by Van Heel et
al (2002), linkage could not be confirmed by microsatellite linkage and linkage
disequilibrium mapping to the CARD15 gene with CD susceptibility even though
association was observed with the disease-causing alleles of the gene in the population
studied. These authors and others highlighted the difficulties inherited in fine-mapping
disease genes for complex traits (Risch and Merikangas 1996, Lernmark and Ott 1998)
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and this should be considered before excluding CARD15 as a susceptibility gene for
UC. Here we found significant association of the gene with UC susceptibility although
no linkage could be confirmed for UC and CARD15 in previous studies. It is, however,
possible that unique precipitating factors present in the Coloured population of South
Africa converts the disease state from a genetic predisposition for CD to UC, but the
nature of this proposed mechanism is unknown. In light of the multifactorial nature of
CD, it seems likely that the CARD15 gene plays a less important role in relation to other
genetic and environmental factors (e.g. smoking, infectious agents), which may be
required to express the disease in South African patients.
The difficulty of identifying genes involved in complex conditions has also been
highlighted in the earlier study of the SLC11A 1 gene performed in the same study
population (chapter 3.3). We have shown that variation in the promoter region of the
SLC11A 1 gene may modify risk of lBO, despite the fact that no linkage to this
chromosomal region on 2q has previously been found in genome-wide screens.
Although no significant associations were observed when possible combined effects of
the SLC11A1 promoter variants and mutations of CARD15 were investigated, marginal
significant associations were observed for combined carriers of H702W and allele 2 of
SLC11A1 (p<O.08) and combined carriers of R702W and allele 3 (p<O.08) for CD in the
Coloured population. Because of the low frequency observed for the three common
CARD15 mutations, the study population needs to be expanded to further
investigate/confirm the possible interaction between SLC11A 1 and CARD15 implicated
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by this analysis. Sub classification of our study population for disease type/behaviour
(including fistulising, stricturing and inflammation) and location of disease (including
colonic, enterocolonic and small bowel) could also give a better understanding of the
contribution of these genes to CD susceptibility. A recent study has shown that variant
1007fs is associated with stricturing, G908R with inflammation and R702W with
fistulising (Sambuelli et a/2003).
The CARD15 gene needs to be screened for other variants that may also be involved in
lBO susceptibility because linkage to chromosome 16 is not completely explained by the
three disease-associated mutations (Van Heel et a/ 2001, Lesage et a/ 2002). Linkage
has also been found with other regions of chromosome 16 as demonstrated by Hampe
et a/ (2002). These authors confirmed the importance of the CARD15 locus in CD and
identified another susceptible lBO locus on the proximal region of 16p. Different areas of
linkage were also previously detected on chromosome 16 (Hugot et a/1996, Curran et
a/1998, Brant et a/1998, Annese et a/1999, Cavanaugh 2001, Cavanaugh et a/1998,
Cho et a/1998), suggesting association of other genes on chromosome 16.
The unexpected association of a CARD15 mutation (A725G) with UC, that we have
demonstrated, further contributes to the contradictory results obtained over various
studies and highlights the complexity of lBO. One common denominator recurs in all
these studies, i.e. that multiple genes interact with environmental factors to contribute to
the lBO phenotype.
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3.5. Analysis of genes implicated in iron regulation in individuals presenting with
primary iron overload
3.5.1. ABSTRACT
Extensive investigation into the molecular basis of iron overload disorders have provided
new insight into the complexity of iron metabolism, known to be interconnected with
various cellular pathways. The possible involvement of genes related to iron
homeostasis, including HFE, SLC11A1, SLC11A3, HAMP and DCYTB, were
investigated in individuals who were referred for confirmation or exclusion of a molecular
diagnosis of haemochromatosis, but who tested negative or were heterozygous for the
most frequent HFE mutation, C282Y. Denaturing high performance liquid
chromatography (dHPLC) analysis of the HFE, SLC11A3, HAMP and DCYTB genes
revealed a unique spectrum of mutations in the South African study population, including
67 unrelated South African patients and 50 population-matched controls. A case-control
study performed in 81 unrelated patient referrals and 91 control individuals from the
United Kingdom furthermore confirmed the significance of sequence variation in the
promoter region of the SLC11A 1gene in iron-related disorders. Two novel DCYTB gene
mutations, R226H and IVS1-4C--)oG, not detected in the control population, could
possibly explain the non-HFE iron overload in 11% of South African Caucasian patient
referrals. In Africans with iron overload not related to the HFE gene, the possible
involvement of the SLC11A3 and DCYTB genes were demonstrated for the first time.
This study confirms the genetic heterogeneity of haemochromatosis and highlights the
significance of DCYTB mutations in relation to iron overload.
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3.5.2. INTRODUCTION
Hereditary haemochromatosis (HH) is generally an autosomal recessive condition and is
characterised by iron overload, primarily in parenchymal cells (Bothwell et a/1995). Iron
accumulation usually results in tissue damage and causes cirrhosis of the liver, diabetes
mellitus, athropathy, cardiomyopathy, endocrine abnormalities and hepatocellular
carcinoma which is associated with HH (Powell et a/1994, Bothwell et a/1995).
Mutations in the HFE gene, with homozygosity for the C282Y mutation being the most
common disease genotype, have been identified as the cause of HH in over 80% of
individuals of European descent with this disorder (Feder et al 1996, Worwood et al
1997). Other mutations in the HFE gene account for the disease phenotype in
approximately 2-10% of cases (reviewed by Painton et a/2000). Non-HFE related forms
of HH are less common but have also been reported and include mutations in the TFR2
(Camaschella et a/2000, Roetto et a/2001), SLC11A3 (Njajou et a/2001, Montosi et al
2001) and HAMP (Roetto et al 2003) genes. A complex spectrum of phenotypic
expression has been observed for individuals with HH (Adams et al 1997, Rhodes et al
1997, de Villiers et al 1999, Milani and Kotze 1999, Sachot et al 2001) and a recent
study showed that only 1% of individuals present with clinical expression of the disease
(Beutler 2003), which raised the possibility of other modifier genes contributing to the
clinical variability observed in HH.
In this study genes involved in iron overload, including HFE and HAMP, and genes
involved in iron storage and transport, including SLC11A3 and DCYTB, were analysed
in patients referred for a molecular diagnosis of HH in the South African population.
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Possible involvement of the SLC11A 1gene involved in iron transport was investigated in
patients with similar criteria from the United Kingdom. These individuals comprised a
subpopulation of individuals who either tested negative for the HFE mutation C282Y, or
who were heterozygous for this common mutation underlying HH.
3.5.3. MATERIALS AND METHODS
3.5.3.1. Subjects
The South African study population initially included 161 apparently unrelated patients
who were referred for HH mutation screening based on abnormal iron parameters
(Bacon and Sadiq 1997) in the absence of secondary causes for elevated ferritin and
transferrin saturation levels. After exclusion of all C282Y homozygous patients, a
subpopulation including 58 (86.6%) individuals without mutation C282Y and 9 (13.4%)
C282Y heterozygotes were selected for further analysis. The patients and controls were
from the South African Black (11 patients and 20 control individuals) and Caucasian (56
patients and 50 control individuals) populations, with "Caucasian" referring to an
individual of European descent, mainly Dutch, French, German and British origin and
"Black" referring to South Africans of central African descent.
Blood samples were additionally obtained from 81 unrelated patients from the United
Kingdom with elevated serum iron and/or characteristics of organ damage compatible
with HH. These included 59 (73%) males and 22 (27%) females that were C282Y
negative [61 of 81 (75.3%)] or C282Y heterozygous [20 of 81 (24.7%)], who were
referred to the MRC Molecular Haematology Unit in the United Kingdom for genetic
testing. DNA samples of 91 unrelated population-matched control individuals, including
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41 (45%) males and 50 (55%) females were available for comparative analysis. Iron
status was unknown in these healthy control individuals.
3.5.3.2. Methods
i) dHPLC analysis of the HFE, SLC11A3, HAMP and DCYTB genes
DNA was extracted from whole blood using a standard method (Miller et a/1988). The
various exons of SLC11A3 (Njajou et a/ 2001), HFE, HAMP and DCYTB (A
Merryweather-Clarke, unpublished data) genes were amplified by polymerase chain
reaction (PCR) amplification using intronic oligonucleotide primers. The samples were
heteroduplexed by heating at 95°C followed by cooling at 2°C per minute and analysed
by denaturing high-performance liquid chromatography (dHPLC) on the WAVE DNA
Fragment Analysis System (Transgenomic). Semi-automated DNA sequencing was
performed on PCR products demonstrating variation on the chromatograms using an
ABI 3100 PRISM automated sequencer.
ii) Mutation analysis of the promoter region of the SLC11A 1gene
PCR amplification was performed using oligonucleotide primers spanning the 5'-(GT)n
repeat polymorphism and a point mutation at base -237 in the promoter region of the
SLC11A 1 gene, generating fragments of 116-bp and 467-bp, respectively (Kotze et a/
2001). The 467-bp PCR product of the promoter region was subjected to a combined
heteroduplex single-strand conformation polymorphism (HEX-SSCP) method (Kotze et
a/ 1995) for mutation detection. These PCR products were resolved on a 12%
polyacrylamide gel supplemented with 7.5% urea at 4°C (350 V) for 18 hr. The 116-bp
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peR product of the promoter region was subjected to restriction fragment length
polymorphism (RFLP) analysis (Graham ef al 2000). These products were digested with
Rsal to discriminate between the various Z-DNA forming promoter repeat polymorphic
alleles. The digested peR product was resolved on a 10% polyacrylamide gel at room
temperature (250V) for 30 minutes. Following electrophoresis, the gels were stained
with ethidium bromide and the DNA visualised by ultraviolet light transillumination.
3.5.3.3. Statistical analysis
Allele and genotype frequencies were estimated by allele counting and statistical
differences between patient and control groups were tested for significance by the
Fisher exact test and/or chi-squared (x.2) analysis with Yates' correction. A probability
value smaller than 0.05 was regarded as statistically significant. The Hardy-Weinberg
equilibrium was performed to test equilibrium for the genetic traits investigated in the
respective populations.
3.5.4. RESULTS
Five genes previously implicated in iron homeostasis (HFE and HAMP) or iron transport
and storage (SLC11A1, SLC11A3 and DCYTB) were investigated in patients presenting
with primary iron overload that could not be ascribed to homozygosity for the common
HFE e282Y mutation. Mutation analysis of HFE, SLC11A3, HAMP and DCYTB, in the
South African population revealed several mutations, including promoter, exonic and
intronic variants. Chromatograms and sequencing analysis of the novel variants
identified are shown in Figures 3.5.1, 3.5.2 and 3.5.3.
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Chromatograms Sequence
IVS2+21T~C
IVS3+111A~G
Figure 3.5.1.(A)
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Chromatograms
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Sequence
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IVS6-2A~T
Figure 3.5.1.(8)
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Direct sequencing analysis of the (CGG)n repeat
(CGG)7
(CGG)s
(CGG)g* *
Figure 3.5.1.(C)
Legend to Figure 3.5.1.
A and B: Chromatograms and sequencing analysis of the novel variants
identified in the SLC11A3 gene, arrows indicate points of variation C:
Sequencing analysis of the (CGG)n repeat in the promoter region of the
SLC11A3 gene, *Artefacts due to mobility shifts, red, thymidine (T) blue, cytidine
(C), green, adenosine (A), black, guanosine (G).
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Chromatograms Sequence
3' -UTR+131 c~ T
Figure 3.5.2
Legend to Figure 3.5.2.
Chromatograms and sequencing analysis of the novel variant identified in the HAMP gene.
Arrow indicates point of variation, red, thymidine (T) blue, cytidine (C), green, adenosine (A),
black, guanosine (G).
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Chromatograms Sequence
lIlS I~
'lit
co
=
IVS2+8T~C
R226H
Figure 3.5.3.
Legend to Figure 3.5.3.
Chromatograms and sequencing analysis of the novel variants identified in the
DCYTB gene. Arrows indicates points of variation, red, thymidine (T) blue,
cytidine (C), green, adenosine (A), black, guanosine (G).
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The variants identified in both the patient and control groups are shown in Table 3.5.1,
together with their allele frequencies. Statistically significant differences detected
between patient and control populations are indicated in the table. The Hardy-Weinberg
equilibrium was determined within each patient subpopulation versus the respective
control groups to assess possible effects of the selection criteria (exclusion of C282Y
homozygotes) from the study population. The results obtained demonstrated that all the
groups complied with the Hardy Weinberg equilibrium, except for the DCYTB IVS2+8T/C
polymorphism (p<0.02) in the Caucasian patient group. This may be due to the fact that
a subpopulation was studied, after exclusion of C282Y homozygotes.
HFE gene
Mutation analysis of the HFE gene revealed only previously described variants
(Rochette ef a/1999, Hohler ef al 1999, de Villiers ef al 1999, Beutler and West 1997)
(Table 3.5.1). Heterozygosity for the C282Y mutation was identified in 9 of 56 (16.1%)
Caucasian patients and 6 (10.7%) of these patients also had the H63D mutation. The ~
S65C mutation was present in 3 of 56 (5.4%) Caucasian patients and was absent in the
respective control group. One individual with the S65C mutation also had the H63D
mutation.
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Table 3.5.1. Allele f ,fth ts identified in the South Af .tnean population.
GENE EXONI VARIANT *ALLELE FREQUENCIES P *ALLELE FREQUENCIES P
INTRON
WHH WC BHH BC
(2n=112) (2n=100) (2n=22) (2n=40)
HFE 2 aIVS2+4T~C 0.39 0.31 ns 0.18 0.43 eO.05
2 DH63D 0.17 0.15 ns - - ns
4 a1VS4-44T~C 0.10 0.06 ns 0.18 0.03 "0.04
4 aIVS4-50A~G 0.06 0.15 ns 0.14 1.00 8<0.0001
5 a1VS5-47G~A 0.50 0.46 ns 0.45 0.65 ns
SLC11A3 5'-UTR iI(CGG)S 0.65 0.78 ns 0.23 0.10 0.08
5'-UTR "(CGG)g - - - 0.27 0.12 0.07
5'-UTR a-23A~G - - - 0.36 0.03 DO.0007
5'-UTR D-8C~G 0.15 0.15 ns - 0.08 ns
5'-UTR D-98G~C 0.20 0.15 ns - 0.08 ns
1 aIVS1-24G~C 0.84 0.88 ns 0.82 0.28 "<0.0001
2 D,cIVS2+21T ~C - - - 0.04 - ns
3 D, c1VS3+111A~G - - - 0.04 - ns
4 DI109 0.008 - ns - 0.03 ns
4 DL129 - - - 0.23 0.05 "0.04
6 ~221 0.21 0.08 "0.03 0.14 - "0.04
--_._-----
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Table 3.5.1. Allele frequencies of the variants identified in the South African population Continued).
GENE EXONI VARIANT *ALLELE FREQUENCIES P *ALLELE FREQUENCIES P
INTRON
WHH wc BHH BC
(2n=112) (2n=100) (2n=22) (2n=40)
DCYTS 2 aIVS2+8T~C 0.67 0.64 ns 0.77 0.88 ns
4 aS266N 0.76 0.86 ns 0.77 0.88 ns
Allele frequency of polymorphic allele denoted, "ldentified in both a heterozygous and homozygous state, "ldentified only
in a heterozygous state, cRare variants, dStatistically significant over representation of the polymorphic allele in the patient
compared to the control groups, eStatisticaily significant under representation of the polymorphic allele in the patient
compared to the control groups, WHH, Caucasian haemochromatosis patient group, WC, Caucasian control group, BHH,
Black haemochromatosis patient group, BC, Black control group, P, probability value, ns, not significant.
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The C282Y, H63D and S65C mutations were absent in the Black population and only
previously described polymorph isms were identified in this population group (Table
3.5.1). Statistically significant associations were, however, observed for various
polymorph isms in the Black patient group compared with the population-matched
control group. These associations were observed when comparing allele frequencies for
IVS2+4T ~C (p<0.05, X2 with Yates' correction = 2.59), and IVS4-44T ~C (p<0.04, X2
with Yates' correction = 2.83). A statistically significant association was observed with
IVS4-50A~G for both allele (p<0.0001, X2 with Yates' correction = 43.35) and genotype
(p<0.0001, X2 with Yates' correction = 30.00) frequencies. The variants IVS2+4T~C
and IVS4-50A~G were under represented and variant IVS4-44T ~C was over
represented in the Black patient group compared with the population-matched control
group. This finding may be indicative of linkage disequilibrium with functional
polymorph isms in the gene affecting expression of the HFE gene.
SLC11A3 gene
Several previously described polymorphisms were identified and are presented in Table
3.5.1. Seven novel variants were also identified: 1) an A to G substitution at position -23
in the 5'-UTR region of the gene, 2) nine CGG repeats [(CGG)gJ in the 5'-UTR region of
the gene, 3) a T to C transition within the second intron (IVS2+21), 4) an A to G
transition within the third intron (IVS3+111), 5) a C to T substitution at nucleotide
position 327, involving amino acid 109 (1109), 6) a C to T substitution at nucleotide
position 387, involving amino acid 129 (L129) and 7) a splice variant involving an A to T
transversion within the sixth intron (IVS6-2). No clear correlation could be made
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between the CGG repeat in the promoter region and chromatograms and it was decided
to perform direct sequencing analysis for the patient and control groups on this region.
The majority of these variants were identified only in the Black South African population,
including (CGG)9, -23A~G, IVS2+21T ~C, IVS3+111A~G, L129 and IVS6-2A~T. The
intronic variants IVS2+21T ~C and IVS3+111A~G occurred together in a Black patient
and were absent in the control population. The base changes are not expected to alter
gene splicing and were not investigated further. The potential disease-causing splice
variant IVS6-2A~ T identified in only one patient was absent in the control population.
Statistical analysis was performed for the various polymorph isms identified and the only
significant association achieved in the Caucasian population was for the polymorphism
within exon 6 (V221) (allele frequency: p<0.03, x2 with Yates' correction = 3.14;
genotype frequency: p<0.02, x2 with Yates' correction = 3.98) when comparing the
patient group with the population-matched control group.
Several statistically significant associations were observed for the polymorph isms
identified in the Black population when comparing the patient group with the population-
matched control group. These associations included the following variants: -23A~G
(allele frequency: p<0.0007, x2 with Yates' correction = 10.53; genotype frequency:
p<0.001, x2 = 12.82), IVS1-24G/C (allele frequency: p<0.0001, x2 with Yates' correction
= 14.71; genotype frequency: p<0.001, x2 = 13.09), L129 (allele frequency: p<0.04, x2
with Yates' correction = 2.86; genotype frequency: p<0.02, x2 = 5.10) and V221 (allele
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frequency: p<O.04, x2 with Yates' correction = 3.15; genotype frequency: p<O.03, x2 with
Yates' correction = 3.32).
HAMPgene
Mutation analysis of the HAMP gene revealed a novel variant identified in the 3'-UTR
region of the gene, causing a C to T substitution (3'-UTR+131). This variant was present
in an individual who was also heterozygous for both the C282Y and H63D mutations of
the HFE gene.
DCYTBgene
The previously described polymorphism S266N within exon 4 of DCYTB was identified
at a high frequency in our study population, at similar frequencies in the respective
Caucasian and Black populations (Table 3.5.1). Additionally, we identified a new
polymorphism within intron 2, causing a T to C transition (IVS2+8), which was also
common in our study population. Three novel mutations were identified only in the
patient group: 1) a C to G transversion within intron 1 (IVS1-4), 2) a G to A substitution
at amino acid 226 resulting in an arginine to histidine substitution (R226H), and 3) a G
to C transversion within intron 3 (IVS3-32). The IVS1-4C--+G variant was identified in 4
of 56 (7.1%) and mutation R226H was identified in 1 of 56 Caucasian patient referrals.
Variant IVS3-32G--+C was identified in 4 of 11 (36.4%) Black HH patients and was
absent in the population-matched control group. A poly T region within intron 2 showed
high variability in our study population and ranged from 12 to 21 Ts in this region. No
statistically significant associations were observed for the polymorphisms identified in
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the DCYTB gene, although it is highly likely that the mutations only identified in patients
and not controls might contribute to the disease phenotype.
SLC11A1 gene
Mutation analysis of the promoter region by HEX-SSCP identified the -237C~ T
polymorphism (Lewis et al 1996) in the heterozygous state in a single UK patient (1 of
81, 1.23%), while detected in 10 of 91 (10.99%) population-matched control individuals.
Only one of the control individuals was homozygous (1 of 91, 1.10%) for the
polymorphism. RFLP analysis revealed only previously described alleles of the 5'-(GT)n
repeat in the UK study cohort, including alleles 1, 2, 3 (Blackwell et al 1995) and 5
(Graham et a/2000).
The allele and genotype frequencies for SLC11A 1 promoter variants are shown in
Tables 3.5.2 and 3.5.3. Statistically significant under representation was observed for
both allele (p<0.002, x2 with Yates' correction = 7.75, df=1) and genotype (p<0.01, x2 =
8.79, df=2) frequencies for the -237C~ T polymorphism in the patient group compared
with the controls. This association was particularly evident in males for both allele
(p<0.002, x2 with Yates' correction = 6.98, df=1) and genotype (p<0.01, x2 = 7.84, df=2)
frequencies compared with the respective gender control group. No statistically
significant differences were observed for the variants of the 5'-(GT)n repeat
polymorphism (data not shown). However, when stratified according to the presence of
the -237C~ T polymorphism, significance was achieved for allele 3 compared with the
controls (p<O.005, x2 with Yates' correction = 7.67) and especially in males,
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representing a larger sample size, when compared with the respective gender control
group (p<O.01, X2 with Yates' correction = 6.65). Re-assessment of the promoter alleles
according to expression profiles upon iron loading previously determined for allele 3
(chapter 3.1), demonstrated a significant association between allele 3 and iron overload
in patients without two copies of the C282Y mutation (p<O.01, X2 with Yates' correction
= 6.66, df=1). When investigating the respective gender groups, significant association
was observed for males (p<O.03, X2 with Yates' correction = 4.84, df=1) compared with
the respective gender control group for allele 3 (in the absence of the -237C~ T
polymorphism).
Table 3.5.2. Allele frequencies of the various SLC11A 1 polymorph isms identified in
individ I f th U 't d K' dI uas rom e me mg10m
VARIANTS aALLELE FREQUENCIES
Control Iron overload
(2n=182) patients
(20=162)
Promoter alleles Male Female Male Female
(2n=82) (2n=100) (2n=118) (20=44)
Allele 1 - 0.020 -
Allele2 0.354 0.270 0.246 0.295
Allele3 0.646 0.700 0.754 0.659
AlleleS - 0.010 - 0.045
-237C~T 0.085 0.060 0.008 -
aAilele frequencies of polymorphic alleles denoted, Control, population-matched control
group, Allele 1, t(gt)5ac(gt)5ac(gt)11ggcaga(g)6, Allele 2, t(gt)5ac(gt)5ac(gt)1Oggcaga(g)6,
Allele 3, t(gt)5ac(gt)5ac(gt)gggcaga(g)6, Allele 5, t(gt)4ac(gt)5ac(gt)10ggcaga(g)6
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Table 3.5.3. Genotype frequencies of the various SLC11A1polymorph isms identified in
th I r f th U . d K' de popu a Ion rom e nite Ing~om
GENOTYPE FREQUENCIES
Promoter alleles Control Iron overload patients
(n=91) (n=81)
Males Females Males Females
(n=41) (n=50) (n=59) (n=22)
Allele 2; Allele 2 0.15 (6) 0.02 (1) 0.03 (2) 0.14 (3)
Allele 2; Allele 3 0.41 (17) 0.50 (25) 0.42 (25) 0.32 (7)
Allele 3; Allele 3 0.44 (18) 0.42 (21) 0.54 (32) 0.45 (10)
Allele 3; Allele 5 - 0.02 (1) - 0.09 (2)
Allele 3; Allele 1 - 0.04 (2) - -
-237CC 0.85 (35) 0.88 (44) 0.98 (58) 1.00 (22)
-237CT 0.12 (5) 0.12 (6) 0.02 (1) -
-237TT 0.02 (1) - -
Allele 2; Allele 3; - 0.02 (1) 0.02 (1) - -
237Crr
Allele 3; Allele 3; - 0.10 (4) 0.10 (5) 0.02 (1) -
237Crr
Allele 3; Allele 3; - 0.02 (1) - - -
237Trr
Control, population-matched control group, Allele 1, t(gt)sac(gt)sac(gt)11ggcaga(g)6,
Allele 2, t(gt)sac(gt)sac(gt)1oggcaga(g)6, Allele 3, t(gt)sac(gt)sac(gt)gggcaga(g)6, Allele 5,
t(gt)4ac(gt)sac(gt)10ggcaga(g)s.The number of individuals for each genotype is indicated
in brackets.
3.5.5. DISCUSSION
Polymorph isms are sequence variations that are present in the general population with
no obvious deleterious effect on protein function. However, several studies have
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recently demonstrated the involvement of low-penetrance polymorph isms in the clinical
expression of complex diseases (Borrego et a/ 1999, Cambien et a/ 1999, Cargill et a/
1999, Fitze et a/1999, Yang et a/2001, Rosenberg et a/2002). In this study, statistically
significant associations were observed for many of the polymorphisms identified,
especially in the Black South African population. Because of small sample size, these
observations could be due to chance although the possibility of low penetrance
mutations contributing to the disease phenotype cannot be ruled out. The likelihood that
the polymorph isms identified may be in linkage disequilibrium with other disease-
causing loci should also be considered. Functional studies need to be performed to
elucidate the role of these polymorph isms, potentially contributing to the
haemochromatosis phenotype in the Black South African population.
A likely candidate for contributing to iron overload, in the Black South African
population, is the (CGG)n microsatellite identified in the promoter region of the
SLC11A3 gene. Previously, seven [(CGG)?l and eight [(CGG)sl repeats were identified
in this region. Here we identified nine [(CGG)gl repeats in the Black South African
population and a marginal significant association was observed for this polymorphism.
Of particular interest is the -23A-~G polymorphism, identified in 8 of 11 Black HH
patients and 1 of 20 controls in the same population, which appears to be in cis with the
(CGG)? allele. It would be interesting to determine if an allelic effect similar to that
recently observed for the -237CIT polymorphism in the SLC11A 1 gene applies, where
expression of allele 3 of the promoter (GT)n repeat is reverted in the presence of this
variant, resulting in expression profiles similar to that of allele 2 (chapter 3.1).
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Possible non-HFE disease-causing mutations, not detected in the control population,
were identified in 11 of 67 (16%) patients investigated using dHPLC analysis. These
included 6 of 56 (11%) in the Caucasian population [HAMP: 3'-UTR+131 C~ T (1 of 56,
2%); DCYTB: IVS1-4C~G (4 of 56, 7%), R226H (1 of 56,2%)] and 5 of 11 (45%) in the
Black population [SLC11A3: IVS6-2A~ T (1 of 11, 9%); DCYTB: IVS3-32G~C (4 of 11,
36%)].
Intronic mutations identified in the SLC11A3 (IVS6-2A~T) and DCYTB (IVS1-4C~G,
IVS3-32G~C) genes may cause splice defects resulting in abolishment or at least a
reduction in the amount of mature mRNA generated. It was estimated that 15% of all
point mutations in an intron result in a mRNA splicing defect, causing human disease
(Krawczak et al 1992). Efficient splicing is dependent on accurate cleavage and
rejoining which appears to be determined by the GT and AG dinucleotide present at the
5' and 3' exon/intron boundaries, respectively. However, these sequence motifs are not
the only determinants of accurate splicing (Breathnach and Chambon 1981, Mount
1982, Padgett et al 1986). A branch site 5' from the exon (estimated to be between
base pairs 20 and 40 in the intron), with a conserved A residue serving as a branch
point, and a polypyrimidine tract preceding the 3' AG dinucleotide have also been
identified to affect splicing. The DCYTB IVS3-32G~C variant could affect splicing since
it is included within the branch site area. The IVS1-4C~G variant identified in DCYTB
precedes an exon encoding for a region of b561 that is thought to be related to
substrate binding or recognition and variant IVS3-32G~C precedes the exon encoding
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the sixth transmembrane domain. Splicing defects are a common cause of human
disease resulting in an exon not being recognised (exon skipping) and thereby excluded
from the mature mRNA transcript. Variant IVS6-2A~T of the SLC11A3 gene precedes
an exon encoding the second intracellular loop between transmembrane domains four
and five.
Alternative splicing of many pre-mRNAs is also affected by the intracellular
concentrations of antagonistic splicing factors of the SR family and hnRNAPA 1 (Zahler
et a/1993, Caceres et a/1994, Muro et a/1999). Predictive results for the effect of the
R226H variant, located at the C-terminal of the DCYTB gene, on these factors were
generated by using the ESEfinder (ESE - Exonic Splice Element) program
(http://exon.cshl.edu/ESE/). A SF2/ASF and SC35 binding site was abolished in the
presence of the mutated allele (A) which might result in generating aberrant mRNAs
that are either unstable or code for defective or deleterious protein isofarms. Functional
studies needs to be performed to elucidate the role of all the mutations identified and to
confirm results obtained using the ESEfinder program. DCYTB is responsible for the
duodenal ferric reductase activity with protein and mRNA levels increasing in iron
deficiency conditions and reduces upon iron loading, therefore regulating iron status
(McKie et a/ 2001, 2002). The mutations identified in DCYTB could possibly disrupt the
gene product, resulting in an inability of the gene to regulate intracellular iron levels.
The patient with the 3'UTR+ 131C~ T variant, a 23 year old Caucasian male, presented
with high serum ferritin levels [226.8 ng/ml (reference range 20-100 ng/ml)] and was
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found to be heterozygous for both the C282Y and H63D mutations that are rarely «1 %
of cases) associated with iron overload. Subsequent analysis showed that his father
and younger brother were H63D heterozygotes and his mother and other brother were
heterozygous for both the C282Y and H63D mutations. The 3'UTR+131 C~ T mutation
was also present in the proband's father who presented with normal iron status. The
other family members' iron status profiles were not available and were not available for
testing of HAMP. It seems likely that this variant is in linkage disequilibrium with an
unknown mutation contributed to the elevated iron levels in the HFE compound
heterozygote due to digenic inheritance (Merryweather-Clarke ef a/2003).
Several iron response elements (IREs) have been shown to be located in the 3'UTR
region of genes, regulating iron metabolism. We speculate that the mutation identified in
HAMP in the 3'-UTR of the gene (3'UTR+131C~T), could possibly disrupt an
unidentified iron response element resulting in mRNA degradation. The patient with this
mutation, a 23 year old Caucasian male, presented with high serum ferritin levels [226.8
ng/I (reference range 20-100 ng/I)] and was found to be heterozygous for both the
C282Y and H63D mutations that are rarely «1 % of cases) associated with iron
overload. Subsequent analysis showed that his father and younger brother were H63D
heterozygotes and his mother and other brother was heterozygous for both the C282Y
and H63D mutations. The 3'UTR+131C~T mutation was also present in the proband's
father who presented with normal iron status. The other family members' 'iron status
profiles were not available and were not available for testing of HAMP. It seems likely
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that this mutation contributed to the elevated iron levels in the HFE compound
heterozygote due to digenic inheritance (A Merryweather-Clarke, in press).
The SLC11A1 gene is implicated in iron transport and influences intracellular iron levels
(Barton et al 1999b, Biggs et al 2001). High expression of the SLC11A 1 gene in
macrophages is associated with an increase in iron efflux and results in low intracellular
iron levels. Similarly, elevated intracellular iron levels were observed with low SLC11A1
activity. The SLC11A 1gene was investigated by Lee et al (2002) in haemochromatosis
patients homozygous for the HFE C282Y mutation. Their results concerning the 5'-
(GT)n repeat polymophism were inconclusive and no other associations were observed.
The likelihood that SLC11A 1 could contribute, as a possible modifier locus, to the
clinical variability observed in HH penetrance therefore needs to be investigated further
taking our in vitro observations (chapter 3.1) into consideration. Our data in patients with
primary iron overload in the absence of C282Y homozygosity, indicated statistically
significant differences compared with population-matched controls for the 5'(GT)n
promoter repeat polymorphism. Association of allele 3 of the SLC11A1 gene with iron
overload can be explained by the fact that allele 3, driving high expression of the gene,
is associated with low intracellular iron levels and higher levels of iron in macrophages,
limited by the host iron-witholding mechanism. Barton et al (199gb) showed that higher
influx of iron into the cytosol was obtained in unstimulated SIc11a1 expressing cells
compared to non-expressing cells, therefore contributing to regulation of iron balance or
metabolism. A feature of haemochromatosis is that macrophages fail to regulate iron
release (Brock 2000) and this could possibly be a direct result of SLC11A1 allele 3 gene
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expression on macrophage function. Similar studies are underway in a South African
population to investigate whether the association observed can be replicated in another
population.
Follow-up studies need to be performed to elucidate the mode of inheritance, by
including family members of these individuals, and correlate iron parameters with
mutations identified in affected individuals. It is well known that autosomal recessive
inheritance is associated with HFE mutations (Feder et al 1996) while mutations in the
SLC11A3 gene are associated with an autosomal dominant form of inheritance (Njajou
et a/ 2001; Montosi et al 2001, Wallace et al 2002, Devalia et al 2002, Roetto et al
2002). DCYTB mainly causes microcytic anaemia in mice and no association with
mutations in patients presenting with iron overload has previously been reported in
relation to this gene. Identification of two novel variants in this gene, R226H and IVS1-
4C~G, therefore represents an important finding in the Caucasian population. These
two mutations are likely to explain the non-HFE iron overload in up to 11% of South
African Caucasians due to their potential role in exon/intron splicing.
Iron overload in African patients could not be ascribed to the common HFE mutations,
but possible mutations in the HFE promoter region, affecting regulation of the gene, and
the possible involvement of SLC11A3 and DCYTB warrants further investigation in this
context. The data presented are in accordance with .various other studies,
demonstrating the significance of multiple genes in iron regulation.
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CHAPTER4
CONCLUSIONS AND FUTURE PROSPECTS
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4.1. IN CONCLUSION
Our increasing understanding of the molecular basis of genetic disorders of iron
metabolism in mammalian species is providing new insight into genes involved in
mediating intestinal iron absorption. All organisms are dependant on iron for survival and
it is essential for functions such as the production of cellular iron, oxygen transport, DNA
synthesis and various enzymatic reactions. It has become clear that the control of iron
metabolism is interconnected with other cellular pathways and further analysis of these
aspects are likely to provide a better understanding of pathological processes in which
iron may participate. This study focused on mutational analysis of the iron transporter
solute carrier family 11 member 1 gene (SLC11A 1) known to have various pleiotropic
effects on macrophage function, within the context of various disease phenotypes where
iron may be involved.
4.1.1./n vitro expression of the SLC11A1 gene 5'-(GT)n promoter alleles
In vitro studies, using luciferase reporter gene constructs, showed that the naturally
occurring alleles of the SLC11 A 1 gene differed in their ability to drive gene expression
upon iron loading. This was the first study to investigate the effect of iron loading on
expression of the naturally occurring alleles of the SLC11A1 5'-(GT)n promoter repeat
polymorphism. High gene expression was observed for allele 3, which is in accordance
with its role in autoimmune disease susceptibility and low gene expression, associated
with infectious disease susceptibility, was observed for allele 2. The most striking finding
was the opposite effect observed for allele 3 in the presence of the -237C~ T
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polymorphism. An inverse in allele 3 gene expression was observed in the presence of
the -237C~ T polymorphism, which is similar to that observed for allele 2 known to be
associated with infectious disease susceptibility. Even lower expression was observed
for allele 3 in association with the -237C~ T polymorphism compared with allele 2.
These observations also demonstrated that the -237C~ T polymorphism is functional
and should be included in future association studies for assessment of the SLC11A 1
gene 5'-(GT)n alleles in relation with autoimmune and infectious disease susceptibility.
The effect observed for allele 3 in association with the -237C~ T polymorphism on gene
expression could explain the discrepancies observed for various autoimmune and
infectious disease association studies. Several studies have not shown association with
the 5'-(GT)n repeat (Cervino et al 2000, Singal ef al 2000) and re-investigation of these
alleles in context of expression profiles observed with the -237C~ T polymorphism may
be very informative. Also, the opposite effect mediated by the -237C~ T polymorphism
in association of allele 3, suggests that the -237C~ T polymorphism could possibly
affect an iron response element (IRE). No conventional IREs have thus far been
identified in the promoter region of SLC11 A 1, but this observation raise the possibility of
unidentified IREs in this region. Another possibility could be that novel/unknown
consensus sequences for IREs are present in the promoter region of SLC11A 1 and is in
close proximity of the -237C~ T polymorphism.
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4.1.2. The SLC11A1 gene 'and the diseases investigated
The use of genetic association studies are well recognised for identifying genetic
variants that alter susceptibility to complex diseases (Risch and Merikangas 1996,
Campbell and Rudan 2002). Several studies have also demonstrated the involvement of
low-penetrance polymorphisms in the clinical expression of complex diseases (Borrego
et al 1999, Cambien et al 1999, Cargill et al 1999, Fitze et a/ 1999, Yang et a/ 2001,
Rosenberg et a/2002).
The possible involvement of the SLC11A 1 gene as a modifier locus was investigated in
diseases including oesophageal cancer (DC), inflammatory bowel disease (lBO) and
hereditary haemochromatosis (HH), due to its role in inflammation and iron transport.
The -237C~ T polymorphism was under represented in the respective patient groups
studied compared with population-matched controls. A significant association was
achieved for allele 3 of the SLC11A 1 gene 5'-(GT)n polymorphism only when stratified
according to the presence of the -237C~ T polymorphism for all diseases investigated.
Re-assessment of the promoter alleles according to expression profiles previously
demonstrated, showed a statistically significant association for allele 3 with DC and non-
HFE iron overload compared with the respective population-matched controls. The 5'-
(GT)n alleles were however not associated with lBO when allele 3 occurring together
with the -237 T-allele, was combined with allele 2 based on similar expression profiles,
but this may be due to the small sample size.
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i) Oesophageal cancer (OC)
An increasing number of individuals in the Coloured South African population are
currently developing OC. Patients with OC present with symptoms such as difficulty to
swallow and loss of weight and, at the time of diagnosis, have deficient diets. It is
therefore difficult to assess iron parameters accurately in these patients because iron
deficiencies observed could be due to dietary restrictions. Two polymorphic alleles of the
SLC11A1 gene (IVS1-28C~T and allele 3) were shown to be associated with OC in our
study population. Association with allele 3, driving high SLC11A1 gene expression and
being associated with autoimmune diseases, suggests the involvement of inflammation
and generation of reactive oxygen species in the development of OC in our study
population. Association with the variant in intron 1, IVS1-28C~ T, found to be in linkage
disequilibrium with allele 3, could also be associated with an unidentified functional
mutation within another gene in close proximity of the SLC11A 1 gene. However, after
extensive bioinformatic analysis (results not shown), no obvious candidate genes were
found in close proximity of the SLC11A 1 gene. Several genes with unknown function
were detected and therefore association of these genes with OC susceptibility cannot be
excluded.
Exposure to cytotoxic agents released during inflammation, such as tumour necrosis
factor-a (TNF-a), can lead to the development of cancer (Ruuis and Sedgwick 1999). In
this respect, the involvement of the SLC11A 1 gene in OC is further highlighted because
individuals homozygous for allele 3 produce higher levels of TNF-a., a proinflammatory
cytokine (Blackwell et al 2003). It therefore seems possible that the predominance of
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allele 3 observed in oe patients may be related to cancer development via a
mechanism involving TNF-a inflammatory response.
ii) Inflammatory bowel disease (lSD)
Frequent co-existence of lBO with other autoimmune conditions such as multiple
sclerosis (Minuk and Lewkonia 1986, Agranof and Schon 1995) where iron
dysregulation appears to be involved (Kotze et al 2001, Kotze et al 2003), raises the
possibility that common features shared by these two conditions (Lossos et al 1995)
could be explained by a related autoimmune process mediated, at least in part, by the
SLC11A1 gene. The role of this gene in many clinically distinct autoimmune and
infectious diseases may suggest a mechanistic continuum of the same disease process
involving iron dysregulation.
Linkage demonstrated between the SLC11A 1 gene and lBO susceptibility (Hofmeister et
a/1997, Kojima et a/2001) is in general agreement with our findings, demonstrating the
significance of the -237C~ T polymorphism as a modifying factor, and to a lesser extent
the possible involvement of allele 3 of the 5'-(GT)n polymorphism. Although this may be
related to the many pleiotropic effects of this gene on macrophage function (Searle and
Blackwell 1999, Marquet et al 1999), the in vitro studies performed in this analysis
further highlight the crucial role iron plays in the disease process underlying clinical
, expression of CD and possibly also UC. Unfortunately iron status was not available for
the patients included in this study.
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Again, association with allele 3 of SLC11A1 in this group was only demonstrated when
stratified according to the presence of the -237C~ T polymorphism. This is in
accordance with its role in autoimmune disease susceptibility. Several other genes have
also been implicated in CD pathogenesis, including the CARD15 gene. Wild-type
CARD15 enhances NF-KB expression in macrophages, which initiates immune-cell
apoptosis (Hugot et al 2001, Ogura et al 2001 b). Low frequencies of the common
CARD15 mutations were identified in our study population and an unexpected
association of a previously described variant, A725G, was demonstrated with UC. The
common CARD15 mutations probably playa less important role in the development of
lBO in non-Caucasian South African populations and other genes implicated in lBO
susceptibility should be considered. However, the possibility of other variants in the
CARD15 gene contributing to lBO in the South African population cannot be excluded
and should also be investigated.
Involvement of the TNF-a gene in lBO susceptibility is also well documented (Ruuis and
Sedgwick 1999, Koss et al 2000, Sashio et al 2002) and it is clear that interaction
between various genes and environmental factors contribute to this disease phenotype.
An association with TNF-a, using linkage studies in an Australian population, has
recently been observed in families with both CD and UC (O'Caliaghan et al 2003).
These authors have shown that association of a TNF-a promoter variant (-857C~ T)
with lBO was more prevalent in families with CARD15 risk alleles (p<0.0001)
segregating with the disease, suggesting that both TNF-a and CARD15 interact with NF-
KB in macrophages. As previously mentioned, individuals homozygous for allele 3 of
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SLC11 A 1 express higher levels of TNF-a, possibly due to the pleiotropic effects of
SLC11 A 1 on TNF-a as a contributing factor of the disease phenotype. We have shown
for the first time that presence of the -237C~ T polymorphism is likely to protect against
lBO and should be considered as a potential modifying factor in disease expression.
Signal transduction pathways such as NF-KB shows rapid and sustained translocation to
the nucleus in SIc11a1 wildtype compared to mutant macrophages after stimulation of
the macrophage with LPS, mediated by oxygen free radicals. Results from a previous
study (Searle and Blackwell 1999) and our current results of the luciferase reporter gene
constructs (Chapter 3.1), demonstrated differential expression of the SLC11 A 1 gene
upon stimulation of macrophages with LPS. These results suggested differential
expression of LPS-related response elements (NF-KB, AP-1 and NF-IL6) by the various
alleles of the 5'-(GT)n repeat promoter polymorphism of SLC11 A 1. The gene could
therefore act as a modifier locus together with CARD15 and TNF-a expression all being
expressed in macrophages, thereby interacting through a common pathway to cause
lBO. In turn, the effects mediated by SLC11 A 1 on TNF-a could possibly directly alter
CARD15 gene expression or vise versa.
iii) Hereditary haemochromatosis (HH)
We hypothesised that the involvement of the SLC11 A 1 gene in iron transport could
contribute to the variability observed in HH phenotypes. By investigating individuals from
the United Kingdom presenting with primary iron overload in the absence of
homozygosity for the HFE C282Y mutation, under representation of the -237C~ T
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variant in the promoter region of the SLC11A1 gene was demonstrated. Iron-overload
observed in patients with haemochromatosis can affect the immune system by exposing
the system to higher levels of iron, leading to altered function of the immune system or
by facilitating the availability of iron to micro-organisms (Brock 2000). A feature of
haemochromatosis is that macrophages fail to regulate iron release and this could
possibly be a direct result of SLC11A 1 allele 3 gene expression on macrophage
function.
Upon investigating other genes involved in regulation and transport of iron, including
HFE, HAMP, SLC11A3 and DCYTB, potential disease-causing mutations were identified
in 16% of our study population. These mutations could possibly explain the iron overload
in 11% White and 45% Black South African patients studied. The common HFE C282Y
mutation is not associated with African iron overload and we demonstrated possible
involvement for the SLC11A3 and DCYTB genes in Black patients with primary iron
overload for the first time. The possible involvement of the DCYTB gene in iron overload
is also documented for the first time and further highlights the heterogeneity of HH.
Delineation of effects of the mutations identified on the protein structure could broaden
our understanding of the biological role of these genes in iron homeostasis. The
identification of mutations in patients with primary iron overload in the genes
investigated would in future lead to improved and accurate counselling of patients and
their families, and ultimately contributing to optimal therapy targeted at the cause of the
disease. Following further studies, these results could lead to formulating a
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comprehensive DNA diagnostic test for individuals presenting with primary iron overload
in the South African population.
4.1.3. The SLC11A1 gene
Although association of SLC11 A 1 with susceptibility to various autoimmune and
infectious diseases may be related to the many pleiotropic effects of the SLC11 A 1gene
on macrophage function, it is highly likely that its involvement in iron transport may
contribute directly to most of these disease phenotypes. This is based on previous
findings (Atkinson et al 1997, Atkinson and Barton 1998, 1999, Barton et al 1999b,
Goswami et al 2001, Mulero et al 2002) and the results obtained in our study
demonstrating differential expression of SLC11 A 1 alleles in the presence of ferric
ammonium citrate. The functional significance of the SLC11 A 1 promoter repeat
polymorphism in infectious and autoimmune disease susceptibility therefore seems to
be directly linked to iron regulation. A significant inflammatory process also interferes in
iron delivery for heme synthesis, resulting in altered iron levels. Haemoproteins are
involved in various biological functions including oxygen binding (haemoglobins), oxygen
metabolism (oxidases, peroxidases, catalases and hydroxylases) and electron transfer
(cytochromes).
The primary function of the SLC11 A 1gene is to transport divalent cations (such as Fe2+,
Zn2+ and Mn2+). The secondary function of these metal ions should not be excluded,
since these may contribute to the pleiotropic effects observed. The S/c11 a 1 gene also
functions as a pH-dependent manganese transporter at the phagsomal membrane and
Jabado et al (2000) suggested that by transporting Mn2+ from the phagosomal lumen to
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the cytoplasm deprives ingested pathogens of Mn2+, an essential co-factor of superoxide
dismutase. Similar arguments can be proposed for the transport of Fe2+ or Zn2+ across
the phagosomal membrane which together may be essential for pathogen survival or
expression of virulence determinants responsible for inhibition of phagolysosome
maturation (Clemens and Horwitz 1995, Strugill-Koszycki et a/1996, Jabado et a/2000).
Low expression of the SIc11a1 gene in mice, similar to allele 2 of SLC11A1 in humans,
is associated with iron influx, resulting in high intracellular iron levels and high transferrin
saturation. Higher expression of the gene in mice, similar to allele 3 of SLC11 A 1 in
humans, is associated with efflux of iron and therefore low intracellular iron levels.
Based on these results, we could speculate that individuals heterozygous for alleles 2
and 3 of human SLC11A1 can regulate iron influx/efflux depending on the need for iron
in either direction. A built-up of iron in and around macraphages is also associated with
inflammation and can lead to anaemia of chronic disease. This could be as a
consequence of invading pathogens resulting in a blockage of iron release (iron-
withholding mechanism). Barton et al (1999b) have shown, by using the fluorescent iron
sensor calcein (Breuer et a/1995), that higher influx of iron into the cytosol was obtained
in unstimulated SIc11a1 expressing cells compared to non-expressing cells. In this
respect, iron can be stored in ferritin and exported to the circulation via SLC11 A3, if
required. Higher levels of iron in the cytosol can also lead to disruption of the heme
biosynthesis pathway and :cause the various pleiotropic effects on macrophage
activation. Elucidation of the influence of genes affecting iron stores may therefore
provide a route to understanding genetic differences in susceptibility to a range of
common diseases.
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The importance of the various pleiotropic effects of SLC11A 1 in disease susceptibility
has not yet been fully elucidated. In mice, these pleiotropic effects mediated by the
SIc11a1 gene, includes up-regulation of class II I-A antigen expression, nitric oxide,
protein kinase C and antigen presentation (Blackwell et al 1991, Buschman et al 1995,
Zwilling and Hilburger 1994). Several of these pleiotropic effects are speculated to be
the result of mRNA stability, where high cellular iron levels cause low mRNA stability
and vise versa (Blackwell and Searle 1999). In the presence of an inflammatory
stimulus, an increase in S/c11a1 expression has been observed (Govoni et al 1997),
suggesting that SIc11a1 expression is modified in the presence or absence of an
inflammatory signal. It can also be suggested that the source/origin of the pathogen
mediating an inflammatory response can differentially affect expression of the SLC11A 1
gene, thereby contributing to the many pleiotropic effects observed.
Although it seems likely that iron transport regulated by SLC11A 1 causes the pleiotropic
effects associated with macrophage activation, the direct influence of these pleiotropic
effects should not be excluded in contributing to susceptibility of inflammatory and
infectious diseases. It is clear that the complexity of several genes involved in regulating
iron homeostasis complicates disease association studies. A better understanding of
these aspects is likely to be obtained by using microarray analysis. Microarrays offer the
advantage to simultaneously investigate the pattern of expression of thousands of
genes. This pattern of expression is biologically informative and provides clues to the
function of the gene. Proteins interact directly with each other, with more than one
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member of a subunit complex required for disease expression, and may operate in
distinct but complementary pathways. A dysfunction in one pathway may be rescued by
an alternative route, which also could be compromised by the occurrence of disruptive
mutations.
Based on the data obtained in this study we conclude that the naturally occurring alleles
of the repeat promoter polymorphism of the SLC11A 1 gene most likely acts as a
modifying factor in diseases involving iron homeostasis, especially in genetically
predisposed individuals. It is clear that both environmental factors and the influence of
other genes affect expression of the SLC11A 1 gene. In order to determine how
susceptibility alleles contributing to the various diseases implicated may interact and
give rise to a multifactorial phenotype, it is important to understand the mode of action of
the SLC11A 1 gene as a potential modifier gene. Our results have contributed to
unraveling the mechanisms underlying SLC11A 1 gene regulation. This study has led to
a better understanding of the molecular basis of autoimmune and infectious disease
susceptibility and may eventually contribute to the elucidation of disease mechanisms
related to defective macrophage function.
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4.2. FUTURE PROSPECTS
4.2.1. Oesophageal cancer (OC)
To further investigate the involvement of OC in the genetically distinct populations of
South Africa, our study population needs to be extended to include individuals of the
White and Black South African populations. A previous study including the Black South
African population confirmed association of variants of the SLC11A 1 gene with OC
susceptibility (du Plessis 2000). The possible effect of the IVS1-28C~T polymorphism,
as a branch point mutation that may affect splicing, will be investigated by using the
minigene system (Cartegni et al 2002).
Human papillomavirus infections have been implicated as a risk factor for the
development of squamous cell carcinomas that may possibly increase the risk of OC
development (Chang et al 1993, Cooper 1995). An intriguing possibility that requires
further investigation is whether allele 2 of the SLC11A 1 5'-(GT) repeat polymorphism
shown to be associated with infectious diseases, would predispose individuals to human
papillomavirus infection.
4.2.2. Inflammatory bowel disease (lBO)
The lBO patient groups will be extended by including more patients from the different
ethnic groups in the South African population, to further investigate the involvement of
the SLC11A1 gene. Mutation analysis of the CARD15 and TNF-a genes will be
performed to identify possible mutations contributing to lBO in the South African
population and gene-gene interaction will be investigated for these genes and SLC11A1.
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The clinical data obtained for our study population was very limited and a challenge for
the future would be to obtain well-characterised patient and control groups. As shown in
a previous study, disease type/behaviour (including fistulising, stricturing and
inflammation) and location of the disease (including colonic, enterocolonic and small
bowel) may be preferentially associated with one of the three common CARD15
mutations (Sambuelli et al 2003). A well-characterised patient group could shed more
light on the low frequency obtained in our study population for the three common
CARD15 mutations.
4.2.3. Hereditary haemochromatosis (HH)
Our study involving the SLC11A 1 gene analysed in patients with apparent non-HFE iron
overload (although some individuals included for analysis were C282Y heterozygotes)
will be extended by screening individuals from the South African population with primary
iron overload. The South African study population to be recruited for further study would
also include C282Y homozygotes with variable clinical expression, ranging from organ
damage at a relatively young age to non-expression in advanced age. Association of
allele 3 in these groups could establish an association of SLC11A 1 with primary iron
overload. Functional studies need to be performed to elucidate the role of potential
disease-causing mutations identified in the SLC11A3, HAMP and DCYTB genes.
Promoter variants identified in the SLC11A3 gene will be investigated for functionality by
using luciferase reporter gene constructs. In addition, the results obtained using the ESE
finder program to identify potential splice variants will be investigated by using the
minigene system. Further investigation of a well-characterised study population could
shed more light on the function of these genes. Extensive screening of these genes in
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individuals with iron overload in especially the Black South African population will be
performed in future to elucidate the involvement of these genes in this population group.
We neglected to investigate the promoter regions of HFE, HAMP and DCYTB but the
intension is to include these gene regions for mutational analysis in future studies.
Despite the many limitations of the study, such as small sample size, lack of extensive
clinical information on age-related disease expression, and the fact that iron status was
not determined, this investigation represents a significant contribution to current
knowledge on the role of iron or iron-related genes in health and disease.
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Poster presentation at:
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ABSTRACT 1
Transcriptional activity of variants of the Z-DNA forming NRAMP1 promoter repeat
polymorphism
Zaahl MG1,2, Warnich L2, Kotze MJ3, Robson KJH4
'Division of Human Genetics, Faculty of Health Sciences, University of Stellenbosch, Tygerberg,
2Department of Geneties, University of Stellenbosch, Stellenbosch, 3Genecare Molecular Geneties,
Christiaan Barnard Annexe, Cape Town, SOUTH AFRICA and 4MRC Molecular Haematology Unit,
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UNITED KINGDOM.
Background: NRAMP1 is thought to be involved in iron homeostasis. Previous studies
indicated that allele 2 [t(gt)s(gt)s(gt)1Q]of a Z-DNA forming repeat polymorphism in the
promoter region is associated with infectious disease susceptibility and allele 3
[t(gt)s(gt)s(gt)g] with autoimmune disease susceptibility
Aim: To determine the effect of the various repeat polymorphism alleles on NRAMP1
expression.
Materials and methods: The variants were cloned in a luciferase-reporter vector
(pGL2) and transfected into U937 and THP-1 cell lines using FUGENE 6. Cells were
incubated in the absence and presence of exogenous stimuli, including interferon-y,
bacterial lipopolysaccharide, bacterial lipopolysaccharide plus interferon-y, and ferric
ammonium citrate. Luciferase activity in harvested cells was determined
luminometrically.
Results and Discussion: Six promoter variants were studied, including four previously
described variants [alleles 2 and 3, allele 4 (t{gt)s{gt)S{gt)4)and allele 5 (t{gt)4{gt)S{gt)1Q)]
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and two novel variants [allele 6 (t(gt)5(gt)5(gt)6) and allele 7 (t(gt)5(gt)5(gt)S)], and one
previously described base pair substitution (-237CIT). Ferric ammonium citrate caused a
five-fold enhancement of luciferase reporter gene expression for allele 3 with U937 cells.
Interferon-y and bacterial lipopolysaccharide caused a ten-fold enhancement of gene
expression for allele 5 and a five fold-enhancement for the addition of interferon-y for the
-237CIT polymorphism in THP-1 cells.
Conclusion
The alleles differ in their ability to drive gene expression between constructs and cell
lines. These results support the hypothesis that this functional repeat polymorphism
could contribute directly to the association of variants with infectious or autoimmune
disease.
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ABSTRACT 2
Analysis of the SLC11A1 gene in South African patients with inflammatory bowel
disease
M. G. Zaahl1, A.V. Peeters 1, L. Warnich 1, T. Winte.-2, K.J.H. Robsorr', M. J. Kotze 4
'Department of Geneties, University of Stellenbosch, Stellenbosch, 2Gastrointestinal Clinic, Groote Schuur
Hospital, Cape Town, South Africa, 3MRC Molecular Haematology Unit, Weatherall Institute of Molecular
Medicine, John Radcliffe Hospital, Oxford, United Kingdom and 4Genecare Molecular Genetics, Christiaan
Barnard Memorial Hospital, Cape Town, South Africa.
Background: Inflammatory bowel disease (lBO) is subdivided into Crohn disease (CD)
and Ulcerative colitis (UC) and occurs due to chronic inflammation of the intestines. The
aetiology of lBO remains unknown but it has been suggested that genetic, infectious and
environmental factors contribute to the disease phenotype. The solute carrier family 11
member 1 (SLC11A 1) gene, previously known as the natural resistance associated
macrophage protein 1 (NRAMP1) gene, has previously been implicated in Crohn
disease, but this association could not be confirmed in all the populations studied.
Aim: To investigate the likelihood that variation in the SLC11A1 gene may underlie
susceptibility to lBO in South African patients and to determine the effect of the various
repeat polymorphism alleles on gene expression.
Materials and Methods: DNA extraction was performed on blood samples of 77 lBO
patients, including 42 CD and 35 UC patients, and 110 control individuals. PCR
amplification was performed on the promoter region and exon 2 of SLC11A 1 followed by
heteroduplex single-strand conformation polymorphism (HEX-SSCP) and/or restriction
fragment length polymorphism (RFLP) analysis using Rsa/. SLC11A 1 promoter region
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variants were cloned in a luciferase-reporter vector (pGL2) and transfected into U937
and THP-1 cell lines using FUGENE 6. Cells were incubated in the absence and
presence of exogenous stimuli, including interferon-y (IFN), bacterial lipopolysaccharide
(LPS) and ferric ammonium citrate (FAC). Luciferase activity in harvested cells was
determined luminometrically.
Results and Discussion: HEX-SSCP and RFLP analysis revealed several novel
variants in the promoter region (-8G/A; t(gt)sac(gt)sac(gt)sggcaga(g)s;
t(gt)sac(gt)sac(gt)aggcaga(g)s) and exon 2 (112G/A; IVS1-28CIT; 147deIGACCAGCCC;
156insGACCAGCCCAG). Statistically significant differences were obtained for the total
lBO patient group (p<0.0007) and CD (p<0.002) and UC (p<0.05) patients groups,
respectively, compared with the control group for the -237CIT promoter polymorphism.
Six promoter variants were cloned. FAC caused a five-fold enhancement of luciferase
reporter gene expression for allele 3 compared to the various constructs. This was
statistically significant for all constructs (p<0.05).
Conclusion: The alleles differ in their ability to drive gene expression upon iron loading.
This finding provides direct support for the hypothesis that iron dysregulation may
underlie the allelic association of the functional SLC11A 1 promoter polymorphism with
infectious and autoimmune diseases.
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ABSTRACT 3
Microarray analysis and microsatellite genotyping in South African patients with
multiple sclerosis: Identification of a significant association with the gene
encoding monocyte chemotactic protein-3
Zaahl MG1,2, Merryweather-Clarke AT3, de Villiers JNP1,4, Pointon JJ3, Smith LS,
Freeman T6, Williams 06, Pritchard CS,Warnich L2, Robson KJH3, Kotze MJ4
'Division of Human Genetics, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South
Africa, 20epartment of Geneties, University of Stellenbosch, Stellenbosch, South Africa, 3MRC Molecular
Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK,
4Genecare Molecular Genetics, Christiaan Barnard Memorial Hospital, Cape Town, South Africa, 5MRC
Mammalian Genetics Unit, Harwell, Oidcot, UK, and 6UK MRC HGMP Resource Centre, Hinxton,
Cambridge, UK.
Multiple genes and environmental factors are believed to contribute to the aetiology of
multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system. In
this study microarray technology, which makes it possible to simultaneously study the
expression of thousands of genes in a single experiment, has been applied to identify
genes underlying susceptibility to MS in the genetically homogeneous Afrikaner
population of South Africa. RNA was extracted from cultured human fibroblasts, and
f1uorescently labelled single stranded cDNA was generated using either reverse
transcriptase incorporation of Cy-3 or Cy-5 dCTP into first strand cDNA, or Klenow
labelling following a cDNA amplification step. The fluorescently labelled cDNAs of the
panent-and control samples were hybridised to the immobilised DNAs on the array using
an automated slide processor. Following hybridisation, the DNA microarrays were
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scanned to monitor the fluorescence of each target that was successfully hybridised to
the immobilised probe. Data were interpreted using the Applied Biosystems Quantarray
package, and further data analysis was performed in Genespring (Silicon Genetics) and
Microsoft Excel. The resulting gene expression ratios indicated significant under- and
over-expression of various genes involved in regulating macrophage function in the MS
compared with the control samples. Over-expression of monocyte chemotactic protein-3
(MCP-3), known to attract immune cells to the site of inflammation, represented the most
significant finding (p<O.002). The results were confirmed with quantitative methods,
including real-time polymerase chain reaction (PCR) and northern blot analysis.
Subsequent analysis of the CA/GA microsatellite polymorphism in the promoter-
enhancer region of the MCP-3 gene revealed a significant difference in allelic
distribution between 117 South African MS patients and 73 population-matched controls
(p<0.05, 3df, x2=9.14). Sequencing of the coding region of three MS patients showing
over-expression of MCP-3 did not reveal any sequence changes, which is in accordance
with involvement of the promoter region in MCP-3 over-expression. Since the data
presented in this study confirm previous findings of a significant association between MS
and the MCP-3 gene, a comprehensive genetic test based on these and related findings
will be developed for diagnostic purposes.
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ABSTRACT4
HFE, DCYTB, IREG1 and HAMP mutations in primary iron overload patients in the
South African population
Zaahl MG1,2,Merryweather-Clarke AT3, Pointon JJ3, van der Merwe 54, Warnich L2,
Kotze MJ5, Robson KJH3
'Division of Human Genetics, Faculty of Health Sciences, University of Stellenbosch, Tygerberg,
2Department of Geneties, University of Stellenbosch, Stellenbosch, SOUTH AFRICA. 3MRC Molecular
Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UNITED
KINGDOM, "Department of Internal Medicine, University of Pretoria, Pretoria and 5Genecare Molecular
Genetics (Pty) Ltd, Christiaan Barnard Memorial Hospital, Cape Town, SOUTH AFRICA
Background: Our increasing understanding of the molecular basis of genetic disorders
of iron metabolism in mammalian species is providing new insight into genes involved in
mediating intestinal iron absorption. It has become clear that the control of iron
metabolism is interconnected with other cellular pathways and further analysis of these
aspects are likely to provide a better understanding of pathological processes in which
iron may participate.
Aim: To identify the possible involvement of genes involved in primary iron overload
including DCYTB, HAMP, IREG1 and HFE in patients referred for a diagnosis of
hemochromatosis who tested negative for the most frequent HFE mutation e282Y.
Materials and methods: The study population consists of 72 patients with primary iron
overload and 50 population-matched control individuals. Polymerase chain reaction
(peR) amplification of genomic DNA was performed on the coding and promoter regions
of DCYTB, HAMP, IREG1 and HFE using intronic primers. The peR products were
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subjected to denaturing high performance liquid chromatography (dHPLC) analysis and
those with variation in wave patterns were subjected to sequencing analysis. Statistically
significant differences were determined by the Fisher exact test and/or chi-squared (X2)
analysis with Yates' correction. A P value smaller than 0.05 was regarded as statistically
significant.
Results and Discussion: Mutation analysis of the various genes revealed several
variations with 6 novel mutations in IREG1, 2 in HAMP, 2 in DCYTB and 2 in HFE as
well as novel polymorph isms in all the genes investigated. Several previously described
polymorphisms were also detected, including 7 HFE and 4 IREG1 polymorph isms.
Statistically significant differences were observed when comparing the patient and
population-matched control groups for a polymorphism identified in the promoter region
of IREG1 (p<0.003, X2 = 8.51, 1df).
Conclusion: The identification of several mutations in the investigated genes in 17% of
the patient group indicates the involvement of these genes in iron homeostasis.
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ABSTRACT 5
Heterozygosity for novel hepcidin mutations may modify the phenotype of HFE
C282Y heterozygotes
Alison T Merryweather-Clarke1, Monique G Zaahl2,3, Estelle Cadet\ Vip
Vlprakaslt'", Schalk van der Merwe6, Dominique capron", Adrian Bomford",
Jennifer J Pointon 1, Victoria LC Wimhurst1, Louise Warnich3, Voravarn
Tanphalchltr'', Maritha J Kotze9, Jacques Rochette", Kathryn JH Robson",
1MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Headley Way, Oxford OX3
90S, UK; 20ivision of Human Genetics, Faculty of Health Sciences, University of Stellenbosch, Tygerberg,
South Africa (SA); 30epartment of Geneties, University of Stellenbosch, Stellenbosch, SA; 4Génétique
Médicale, Faculté de Médicine, Université Jules Verne de Picardie, Amiens, France; 50epartment of
Paediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 60epartment of
Internal Medicine, University of Pretoria, SA; 7Hépato-gastro-entérologie, Faculté de Médicine, Université
Jules Verne de Picardie, Amiens, France; 81nstitute of Liver Studies, Kings College Hospital, London, UK;
9Genecare Molecular Genetics, Christiaan Barnard Memorial Hospital, Cape Town, SA.
Hepcidin antimicrobial peptide (HAMP) is secreted by the liver in response to increased
iron stores, resulting in decreased absorption of dietary iron. Juvenile
haemochromatosis patients have been described who are homozygous for mutations in
the hepcidin gene (Roetto et al, 2003). We report here a spectrum of hepcidin mutations
found in patients with varying severity of iron loading, some of whom are heterozygous
for the HFE C282Y mutation, and suggest that the phenotype of HFE heterozygotes
may be modulated by HAMP mutations.
The first patient, BS, is a 65 year old British male who had a triple angioplasty at age 55.
He had a serum ferritin (sF) of 1000J.l9/1, and is heterozygous for HFE C282Y. DHPLC
analysis of HAMP exons 2 & 3 revealed a novel heteroduplex pattern. Sequencing
revealed that BS is heterozygous for a missense mutation in exon 3 of HAMP. BS also
has two children who are C282Y homozygotes, both undergoing venesection, a 35 year
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old son whose serum ferritin on diagnosis was 1000Jl9/1 and who lacks the HAMP
mutation, and a 39 year old daughter with rheumatoid arthritis who is heterozygous for
the HAMP mutation.
The second patient is from Picardy, MP, aged 46 years, who is also a HFE C282Y
heterozygote. At age 27 he was found to have congestive heart failure, with general
fatigue and dyspnoea as the main symptoms. He also presented with
hypogonadotrophic hypogonadism, type diabetes, skin pigmentation and
hepatomegaly. Transferrin saturation (TSat) was 92%, sF 1645JlglI, serum glucose
10JlM. Fibrosis was detected on liver biopsy, when hepatic iron concentration was 481
J.lM/g dry liver and HII=17.8. Removal of 27g of iron over 4 years restored his TSat to
30% and sF to 40Jl9/1. A total of about 80g iron has been removed over during 19 years
of inconsistent attendance for phlebotomy. Unless at least 0.5g of iron is removed per
month, his TSat goes up to >80% in about 3 months. DHPLC and sequencing analysis
of HAMP revealed heterozygosity for a deletion in exon 2 which also involves a splice
site. The resulting transcript is likely to be extended to 179 codons due to a frameshift,
completely disrupting the active peptide. MP's mother is aged 86 years with no major
clinical problems. She lacks HFE C282Y but is heterozygous for HFE H63D, and also
heterozygous for the HAMP mutation. Her transferrin saturation is 35%, ferritin 52Jlg/l,
normal transaminases, serum glucose 6JlM, red cells 4.25x1 012/1, Hb13g/dl, MCV 82fl.
Two further pairs of related patients with iron overload from South Africa, three of whom
are HFE C282Y and H63D compound heterozygotes and the other a HFE H63D
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heterozygote, were found to be heterozygotes for two different pairs of HAMP mutations
and polymorph isms following DHPLC and sequencing.
Finally, a young Thai haemoglobin E patient who has never been transfused, with an sF
of 461 !lg/I, was found to be heterozygous for a polymorphism in HAMP intron 1.
We propose that the phenotype of C282Y heterozygotes may be modified by
heterozygosity for mutations which disrupt the function of hepcidin in iron homeostasis,
with the severity of iron overload corresponding to the severity of the HAMP mutation.
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